var title_f16_18_16672="Surgical knots";
var content_f16_18_16672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surgical knots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Square knot and surgeon's knot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16672=[""].join("\n");
var outline_f16_18_16672=null;
var title_f16_18_16673="Calculator: Urinary protein excretion estimation";
var content_f16_18_16673=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"UrinaryProteinExcretion_form\" name=\"UrinaryProteinExcretion_form\" onkeydown=\"clrResults();\" onkeyup=\"UrinaryProteinExcretion_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Urinary protein excretion estimation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          UrineProteinToCreatinineRatio = SpotUrineProtein / SpotUrineCreatinine",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Spot Urine Protein",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Spot_Urine_Protein_param\" onblur=\"UrinaryProteinExcretion_fx(); minMaxCheck();\" onchange=\"UrinaryProteinExcretion_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"100\">",
"             <select class=\"medCalcFontSelect\" name=\"Spot_Urine_Protein_unit\" onchange=\"UrinaryProteinExcretion_fx();\" style=\"width:90px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Spot Urine Creatinine",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Spot_Urine_Creatinine_param\" onblur=\"UrinaryProteinExcretion_fx(); minMaxCheck();\" onchange=\"UrinaryProteinExcretion_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"100\">",
"             <select class=\"medCalcFontSelect\" name=\"Spot_Urine_Creatinine_unit\" onchange=\"UrinaryProteinExcretion_fx();\" style=\"width:90px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Cr\">",
"               mg/dL",
"              </option>",
"              <option value=\"1|0|mg%_Cr\">",
"               mg%",
"              </option>",
"              <option value=\"100|0|mg/mL_Cr\">",
"               mg/mL",
"              </option>",
"              <option value=\"1000|0|gm/dL_Cr\">",
"               gm/dL",
"              </option>",
"              <option value=\"100|0|gm/L_Cr\">",
"               gm/L",
"              </option>",
"              <option value=\"0.0113122171945701|0|mcmol/L_Cr\">",
"               mcmol/L",
"              </option>",
"              <option value=\"11.3122171945701|0|mmol/L_Cr\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Protein To Creatinine Ratio",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Urine_Protein_To_Creatinine_Ratio_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                mg/mg",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"UrinaryProteinExcretion_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The normal",
"       <b>",
"        Urine Protein To Creatinine Ratio",
"       </b>",
"       is less than 0.2 mg/mg.",
"      </li>",
"      <li>",
"       Ratios greater than 3.5 mg/mg are in the nephrotic range for proteinuria.",
"      </li>",
"      <li>",
"       Daily protein excretion (ratio equivalent to grams protein per day per 1.73 m",
"       <sup>",
"        2",
"       </sup>",
"       body surface) can be  estimated from the",
"       <b>",
"        Urine Protein To Creatinine Ratio",
"       </b>",
"       of a random urine specimen.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples.",
"        <i>",
"         Arch Intern Med",
"        </i>",
"        . 1987 May;147(5):943-4.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 1983 Dec 22;309(25):1543-6.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Houser M. Assessment of proteinuria using random urine samples.",
"        <i>",
"         J Pediatr",
"        </i>",
"        . 1984 Jun;104(6):845-8.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16673=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function UrinaryProteinExcretion_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.UrinaryProteinExcretion_form){",
"",
"",
"doCalc = true;",
"if (Spot_Urine_Protein_param.value.indexOf(',') >= 0){ Spot_Urine_Protein_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Spot_Urine_Protein_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Spot_Urine_Protein_unit.options[Spot_Urine_Protein_unit.selectedIndex].value.split('|');",
"Spot_Urine_Protein = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Spot_Urine_Creatinine_param.value.indexOf(',') >= 0){ Spot_Urine_Creatinine_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Spot_Urine_Creatinine_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Spot_Urine_Creatinine_unit.options[Spot_Urine_Creatinine_unit.selectedIndex].value.split('|');",
"Spot_Urine_Creatinine = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Urine_Protein_To_Creatinine_Ratio =  Spot_Urine_Protein / Spot_Urine_Creatinine;",
"",
"if (doCalc) Urine_Protein_To_Creatinine_Ratio_param.value = fixDP(Urine_Protein_To_Creatinine_Ratio, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.UrinaryProteinExcretion_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.UrinaryProteinExcretion_form){",
"",
"Urine_Protein_To_Creatinine_Ratio_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f16_18_16673=null;
var title_f16_18_16674="Patient information: Rinsing out your nose with salt water (The Basics)";
var content_f16_18_16674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86630\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/40/655\">",
"         Using a neti pot",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/38/37474\">",
"         Patient information: Seasonal allergies in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/53/17234\">",
"         Patient information: Sinusitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/13/37073\">",
"         Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/8/41092\">",
"         Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/58/42915\">",
"         Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rinsing out your nose with salt water (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H86691160\">",
"      <span class=\"h1\">",
"       Why should I rinse my nose with salt water?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rinsing out your nose with salt water can wash dirt and mucus from your nose. It also helps wash away things that trigger allergies, such as pollen, mold spores, and dust.",
"     </p>",
"     <p>",
"      Rinsing out your nose with salt water is also called &ldquo;nasal irrigation.&rdquo;",
"     </p>",
"     <p>",
"      Your doctor might recommend that you rinse out your nose with salt water when you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A stuffy or runny nose from a cold or allergies",
"       </li>",
"       <li>",
"        Post-nasal drip &ndash; This happens when mucus from your nose drips down the back of your throat.",
"       </li>",
"       <li>",
"        Sinusitis &ndash; This condition causes mucus, a stuffy nose, and pain in the face.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86691175\">",
"      <span class=\"h1\">",
"       How do I make the salt water?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To make the salt water solution, follow these steps:",
"     </p>",
"     <p>",
"      1) Find a clean, 1-quart glass jar with a lid. Fill it with distilled water or tap water that has been boiled and cooled. This is important because a few people have gotten serious infections from using tap water that was not clean. These infections are very rare, but it&rsquo;s better to be absolutely safe.",
"     </p>",
"     <p>",
"      2) You can buy premixed packets for making the solution at a drug store or you can make your own. To make your own, use 1 teaspoon of baking soda and 1 to 1.5 teaspoons of salt. Use pickling or canning salt, which is very pure so it dissolves easily. Do not use regular table salt because it contains other chemicals besides salt.",
"     </p>",
"     <p>",
"      3) Mix and store at room temperature for up to 1 week. Throw out any salt water that you don&rsquo;t use within a week.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86691190\">",
"      <span class=\"h1\">",
"       How do I get the solution inside my nose?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are several products you can use to squirt the solution into your nose. These are made for this purpose. Some examples include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A squeeze bottle (sample brand name: Neil Med Sinus Rinse)",
"       </li>",
"       <li>",
"        A neti pot (sample brand name: Neil Med NasaFlo Neti Pot) &ndash; This is a small pot with a long spout, similar to a teapot (",
"        <a class=\"graphic graphic_picture graphicRef86789 \" href=\"UTD.htm?0/40/655\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A nasal irrigation syringe (sample brand name: Nasaline) &ndash; Use a 60 cc (2 ounce) syringe, not a bulb syringe for a baby.",
"       </li>",
"       <li>",
"        A pulsating irrigation device (sample brand names: Grossan HydroPulse, Waterpik Sinusense Water Pulsator) &ndash; These are battery-powered devices that send a gentle pulse of water into the nose. Make sure to get 1 with an irrigation tip.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you are using a syringe, pour the amount of fluid you plan to use into a clean bowl, or pour it directly into the squeeze bottle or neti pot. DO NOT put your used syringe back into the storage container. If you like, you can warm the solution slightly in the microwave. This might make the rinsing process more comfortable. But be sure that the solution is NOT HOT.",
"     </p>",
"     <p>",
"      Bend over the sink with your head turned slightly to 1 side and squirt the solution into the nostril that is higher. You can also do this in the shower. Aim the stream toward the back of your head, NOT the top of your head. Keep your mouth open. The solution should flow into 1 nostril and out the other. It&rsquo;s fine if you swallow a small amount. You might feel a little burning sensation the first few times you rinse out your nose. This usually goes away after you get used to it.",
"     </p>",
"     <p>",
"      Once all the solution has run out of your nose, blow your nose gently. Some salt water might drain out of your nose over the next few minutes if you bend over.",
"     </p>",
"     <p>",
"      Clean your device after each use, either with boiling water or as instructed by the makers of the device. Let it air-dry or dry it with a clean towel.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86691239\">",
"      <span class=\"h1\">",
"       How often should I rinse out my nose with salt water?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people rinse out their nose every day. Others rinse only when they have symptoms. You can safely rinse out your nose a few times per day.",
"     </p>",
"     <p>",
"      Doctors recommend daily rinsing for people with sinusitis that lasts more than 3 months (called &ldquo;chronic sinusitis&rdquo;.)",
"     </p>",
"     <p>",
"      If you use nasal sprays to treat your symptoms, use them after your rinse out your nose.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86691256\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/53/17234?source=see_link\">",
"       Patient information: Sinusitis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/38/37474?source=see_link\">",
"       Patient information: Seasonal allergies in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/13/37073?source=see_link\">",
"       Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=see_link\">",
"       Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"       Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/18/16674?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86630 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-E85F879F22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16674=[""].join("\n");
var outline_f16_18_16674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86691160\">",
"      Why should I rinse my nose with salt water?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86691175\">",
"      How do I make the salt water?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86691190\">",
"      How do I get the solution inside my nose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86691239\">",
"      How often should I rinse out my nose with salt water?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86691256\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/40/655\">",
"      Using a neti pot",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/13/37073?source=related_link\">",
"      Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=related_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=related_link\">",
"      Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/38/37474?source=related_link\">",
"      Patient information: Seasonal allergies in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/53/17234?source=related_link\">",
"      Patient information: Sinusitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_18_16675="Canker sore PI";
var content_f16_18_16675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Canker sores",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDvgxQoAgbuKHfMvORj+L1puAQ2HAwPlX1p25WIPJCjkf4VwnvDRlWy/HzdTT3lYAO4I3dCfSm72ePaq7QvJBomJbYRj6etIQ8lXIfDFznIqGRmL73ySealUujcqcE9hUcuNsvXcBke1KQIj3qr84dicgYo5CuhG1xwBUcBJjL7iSvyg+9IgZpieSpGOfX1qUMsSuOMdAOT709k3Mrluo5FN2DYUjG8DkmhcJFlgcselWkK5JHJ+7zxkmkdQCCCcUyUFtu3gD0oZiU69BVLYZKkvI44qCd9rZ96gMmF4PNVJ7jrk8YoLjHUlkuSrtg1nyXpYkEjIqpeTFsmMnIrPlk3Akde9B2wpq2poPJuJOaoXdwQ3J6VC0pGOcVFMfMjbB+lFjZabj5brcoJNUri7GMg1QaUh2TJ9KrTyEKVOc1Lk7GiSRqRXO85J6U43Jzxmsa0nIVkJOaQ3GGxu5FF7IV1c6aGcbDzUcsvUlwcnIHpXNfb2VvlbipTfqyfeyaOcLdTaaYYwCMVl3GVfcCapm/A6NVe4v8A5eCCB1qW0x8zWxvW1wpQDPNRzy7W61hR6hEBkH5qgv8AUCACGqlLQi7OkimHXPNPku0Tknp71zUGrLsBb0qpe6gz52ng0nPTQNW9TpX1PJwGGKhk1EDqea403L56mgzsw5Y1HMx6XOok1VQfvVVn1fHQ9KwS/wAvB5qvLLtGSTRdsbmom5JrBfgVWku2bknmscPuOeaeHOKQo1bo6OwkQYPU961ElUDJbiuMS5ZBwSKmW8kbjJq1Oxk7vqdd9rQHhv1qOa8UEYP1rmEndV5NMe5dsjJp8416nTLcqUZiarW14vmOT6+tYD3bbNisafbSgJzU3Hc6hLzLA5q0l7kdc+1col2VBA6VYt7obfmODTTBs2ru92j5etUTet0Y1TmnDqcMNwqo8rHO7gChgp9DctrzEnzHjtU8tzuI2nPvXORSk85xViK42OCxYihEc51BnSG3wCNxFRwXoCNyPqa5u5v2lbC5xRBIxjJJODwKd77CvZHUW9ySpYZ+bvV6G5IgMe/AznFYkUotrdTIe3AqNbkySbcnNXewue51EM4aM5J4HB9KfBOowGPGcVz8NyEiKmQA9cE81at7k3CAlgsa8KMdarcTmdHb35RsryvRRWvDdmQxmJOcY9/rXFxXXO7Hyg4X3rVtJ2Uddsjf+OihGU0mdXNP5snygs79KuRSGeRUQjeq4H1FYVvKAAFkJbPJHRa0YZ1il3BRkA4J6EmqOOfYnuThxJIwXBzhaLlxjbINpOCpXp9aphwxUynj7rf405hiP5iCYycMD0FIgYzs6OqkDHDL6+9G0SOki/IwGAG52n/ChfnQPx1w2P0I/CmOchViOG7k9qmxV7jNwWXqdp6D3opEkjMnKFoznGexooHc6lUKgmPGMACkUAMTwpxxx1oXlAFYHBI57VI2ZERtoGFxmpG2JDnG1iD6+1SlY9gKn96oyT2AqJjiLcoxg4NCkFSAQSaCbjg77QrAnaeT6DtTZ1yS33T0I9akidFPlzAhM5O3ue1Rzyg7sfe/iNAuoiqyAoyjB5AFR3G2M/u8njJHpSpumwY/vnjJPFRvkxH5SM/kaCkSo7SKAAEUD5uetPjYvzuGV5+lV0IEY3MST2FNG9IwrlSzHJC9KaQEzy7UcgjkdfeoDcL5Z6e9LKvykMV2tyAO1Zd67QhmBBBoSZpCNySefyzkng9Ky7m5XJLZ2noahmnLKSDlqzLiR2OGOBQdUIFuadl+YMNvrVNpAz7lP1FQPNtXBPFVJZvLU4P3qZvexduJ+dqn9KjM5CY7is9pwQCTgjrUVxc54RuaL2C9xt6dreYnTvVSa5AwXFTb1CEMcg1halI0UhXqvrUS3uTzX0LgnXeWRvwqld3Lo5KnNZrStj5Saa7s341Ld0XHTUtPdtjDNzUP2x06HiqzHJwRRtDDFRYr2nQt/ay45alExELHdn2qiEx0NPDbRzTIc+4CVhz2JpWmZhg5xTSU5IbFV2mI4FCJdRLcsLIcYzikM3qapl2PU0080WMpYjsXDOgHXNQvcn+EVBikIxTMZVpMk+0OR1prOz9TUdOXmnYz9o3uKGI6HFOEzA03bSYoHzNEwnz1WpFuVzyMfhVWgDNBSqyLpuUxnJPtUD3GT6CocUuPekDrSZZj2EZ3c1MpA4zVAA545qQZA4NFi1XfUvcetNZ8HGaqTTG3t2lboozWfHrytgSR4FVGDeqCWJhF2k7G4GPrRk465qpa3cdymUJb6DpUhyX+Vh+NJo1U01dFkMQPpSSS5+83FNOQOTmlCBh0pFCLMCcdF71eju1YrgAKnNZkkXPTNOhhY87gPxpol+Zeub9pG+ZuB0pq30qo2w4J71Wk8tRgkMx7Cos4HHGO1GorqxpwO0spc5bjmtO1vvKDYI9BntWFHcOkIVflBHPvT3uYxCAM7u+e1WrESd3qdLHqCO6beWXpWlHdupyxyRXH21ysab2PTpWhb3eY9oJaTqT2UU0yGdpZ6g6opVgM8Kp7+9dBbakfsawuQQTnJHSuB066VF38lz+grYguWdQpZlb371aZlNI6qKZntyFKhDkAnrmlVgyKDkKTzisiG9EagD7wI57fjV+BhKw57Z571SMWTQuVUoCACxXj19KenyqmeVzhj2B7UyOFkwX6li34dqmuZBG0gCBlYAFfWpsFysxX7SQmTk8EDvRUkLwxyK0zNsI3KV5yaKQ+Y6jKjKAYzzlu9S7gFKDLIOh6VEzbnUjaFYdO9OKb4yAxx3yMH61JTHlQRlm+XAPHeppfmbIAwF4HTAqALsAKH5vXsRTm3Pvd8ITzQJjwC0RWMAqDnH94VAwBycYwKsl1R8gYUrjFRsY1RSVyQMfj60WBFVnxGHDBVc8L6CovM80s8odxjavOME9KlfYwdm7j5VHY1VkJMfB2qvQU7Foa0nkkBs8dQKDcghVG0KDkYqo03Hynr96qdzcfZ84Gc8AmnaxSjc1pLpVjbJGT6dqxb+dZUYZwO1UZL8qCDyDWbPejbjd1NK5rCnYleZozgnkGoWn3feNU5bpBKMFXB96oXNyEm4YgehpJnQWJpW+bBJFVLi5BTOce1I9zGFxuHPPWsi9udv3cHNDfYV7snuL04IB4rOmv3Jyagkn81uwqAlSSCSDWTZqrIsHUZeMNTGujLkSHcDVQpk8HNOVG/hFCJeo48dD8vvUWCWyTwKWTbGu52wBWTfavHGCsA3MO/amot7GdSrCkrzdjQubuKBd0hwKzJNaiDfu0ZvxrEuLiSd90hJPpUWa6I0UtzyquPnJ+5ojpLLVRczeWV2E/d960HUgAkcGuNjdo3V0OGU5BrstKuY7y2CSYDHn3BqZ00ti6GIc7xk9SMj1pu3mrUsPluQfwNRleOKz5Te76kW3jNIRUmKMUuVhcj200j1qbFOWJmPCmizEyttp0aHOas/ZzjgD3qtNeW1vcCCVwHI6joPrVJNktqOrHMOcUm3FWUSKQbklR8jjBpXtmVc4HTnBpOFh3uVNtG01JijrSsMjAoxUmBTlXmhK4IjVTip7a3adwo49T2FSQ27ycgYQdSeAKW7v4bWH7PaYkk/jl7Z9BVqPcG0tWYviSXy42t48Nz8xHoK5vrW7cDexZ+Se9ZF1GI5eOh5FbU2rWPNxDcpcw2GaSFt0UjIfVTirdrqM8MgZ2Mi9wx61RA55qzBB5jZPAq5W6mdNyT91mpHrbjOYMqfRquRa3CwwwKfUVnLEFT5R+VVbuLb86iseWMtDsWJrQ3dzqI7qKTBVgwPcVKSrHO4Yri4ZpIWzGxU1qWerDIW4X/gQqJUmtYnRSx0ZaT0Z0IXkZGRSyjOMYGO3rVWOcEZAwP51OnK8dfWoudr1V0KUyNzHatRPtIG0lj61Js4HOR3pJo9pz1HfFDRFghUEjdn2+taFvIkKkM2V7/wC0fSqUKSSZWGMucZJxnFPRBuOH+YDv6/WmiGdBb3DDYSiqQdxxXRW25ofMdlRTxyfmP4VzemIqBXcjcpwCedzetaxmdiI1y4B/An/CtYmMjbjZWTegAC8nPc/1rTtZZGUAghV596wreRgAsjAuOPlHCitSyY5ALbueAf51VyGbEDyctuHTnPYVOqLuGQocjJA4yKrwSESLgfeBDDqK0F+RWXcjFPmGfT2oZkynPDGxymNgXnt+AoqVomCqwP3/AJs+4oqbDudAxLksrHKHg1KArjK5GRzz37mnZVQEUY549aachyV3BVGDmpLuKeJQoBKj5sdjSltwBz0XhaNxG1CpHQ49TUjAbgGwB/FgUAxkrhgFHy5xuxULthz5YO1Rgk1M42EMx3E8YFQEhFG8Ajvj2pjRBcg+WXzjd932Hqap3k3mdOW2hVUdOO9Ww7LuEab9xwM9hWTeyMIyyuE7ZosaQV3YrS3DeXsBCyg9xxWLd3rlmiuGJbPyn0pbmSUu/m7iT1NZNzcdVk59Kls6owsRT3jIWD84rPadHYMrjd6GpjIrk7iMVTuIEj+dCR356GpV2aNpMbPIoIbpnuap3VwMHbkmnSsCfnI244A6ZrOnnH8B470aCWuwjzEsecGo0mZQwznd13CohksSDn3oAOeQc1FzSwMqnnNMKknipNoxkgKPeobjULe0iJdl3Y4HrTSuKTjFXkyZU2Ak8D3qndXyx7hEDIfask6jLqMzclIV7DqakHAwOKpx5Wcc8ZzaU/vKlybu7b94fLjPbNIthEo5BJ9SavD3pe1VzvocXs1J80ndmW2nDdwzAUn9m+smPwrV7UbQRT9pIn2EWY09g6AFDvHerUDPDtZG2sBwRVxlxyKgePn9afM3uT7Plehorqc5UBwj8elP/tBCPngH/AWrPAGAfzpwGRmlc1UpGg17AwGYWH0NKt9bg8wt+JrOwKMD0pcw+dmmNQtwcmI0kuogriCIA+rVmbeamUZAouUpSZPNdzzIV3bFPXbxWcLGAPuZSx7ljnNXCPSko5mJwTeoxUVBhBt+lSIzKQVYgjoc0AUUi0rFlLntKm73HBqTzrQEFmkA9MZqlimygDp0pj5mjQa/t4/9TCZOOrcVG2qSZ+SGJfwzWeKWkRzSZLPdTTjEkhK/3RwKrnj6U/FIRTuRJNkUg4rMvx8ycVrEdap31s8m3y+1VBpMxqRbRmxruYAVrwxbFwRzTLGzMXzS/e7D0q9j1oqT1sh0qTtdkQXjA4pkse9SPWp9tG0VlzWNvZmBLGUcqaaQMVpahF8ocD2qgy11QldHFOHK7E9hevauBkmI9VPNb9vcLIoePlT6VyxBq1p9wbeXDE+Wevt71NSF9VudGGxLpvlex1kcmeFIGe1LKf8AaJqnC+cd89xVpeRjOPrXNc9Z9xFLYxlgD6E4NS24RmO4jjoOuaYqrkljk9gOOabjsOFz6800yHE17WdEb7xkbtjoPrWzaXRdQiDaehIHX2rntPD+aqWsDySHg8ZrVtCIZcTMRjIKKRkVaZm4nRWkZ399ydQK27VTcR5XbvQ7WA6n0Nc7YyhXV4DgKM5Jzn61vWUsiOHhYhiMEj+L1/CrRm4s2YZG29VGOw4H4VbjCTkkr0XJU/0qpBL55Dlk24+YbcVety0ZDDG9Bkg85qtzBoliDfZc/wAKHj1HtRTrQloijYyzbuB3/wAKKRJsq5M4b7xUAc9B/wDqoWRSBsOSuTkjuaSORXRizDvkDgfnTGnARMIVcHJPbpxWdzREjbvMG/ll9+lSBwSVcErxjtTIpMRncM0sg+RXXBJBAx2qh3Hvgkbj9TVSXAPcEevWrEbLjY4O7HB9arzOFDb8MenvTAoXUpjcIrEKwxWTegsMdAf4j2rS1G43xLFGhjGeV6lj6msXVS0NusZfdKeWX0Hp9aR0U9DKmnfc8SsGI9+TWNeuQCCoGOx61ZuZevmg4PQjqKy70GU7V+4eQTyalnVy2KM06q3fd/KqdxdYUjJJ7UtxE6DnJHr1rOuH28biT/KpbaKjFMc8pJyM5qNUDcMQM+lCjjLZwPSoLi5C/KgBqByaiWQFHUgD1qCe9SPiIEkd+1Z0jtIcuSfbNNApGEqrexV1TULkvnICnuKw5XLkliSx7mukkiDoQwyDWPNp0okwgBU9PauilOOzPLxMKknfcs6dHstlPGWOTVoCkhj8uJF67RipAPas5Su7m0IcsUhAKMfjTsUoX0qbl8o3HvRjinYzS7aLjURhHFRleRUxBxTCvQ0+YmULjAPSjGTTwKXFHMJRGbfejGKf7YoIpXK5BmOc1MmcEADHeo9tSRg0+YFEKXHtTgMml20XHyjMUYFSbeOlGMdqLhykeKaRlelSYINI4IjA9aLjUSvilxS4INLjPSlcXINxQadtoAPpTuHKNxxSAc1KVA69aaBnrSbFy2YmKMfhTgCBSgZ60iuUaBRipQtG32ouWoFeWPepHrVB7b1FaxXioSnNVGVjGrRuZLQVG8W04rXKDB4qtLFxxWqqHJOlYisLxrZwkgLRfqK6KBkmQNEwce3Wub8s76u2qmL5lJU+oqZpPU6MNXnD3HqjcwMZA5HenJIQcklyBgZAptlcJOPLm+WTHyt2anvGycg4I4rM9NWkroRZpIx+6ZlDdcHFXrJWdfkQsTzuLY/OqcQyc4Jb2FaFqDGRuUqScfj9KEDidJYw7GVSyvz95T1xXQWUSuoH1OfUVz+m28vXcgJwxEjcsPQCul09gqlmKg9WP9AK2izCcTXtYjtCL91eSo6n3+lW4ELMC/3QSRWfazEszplBxlgeAD6ntzWjb5kHORg/fzxmqTOWUS8MbCyqASCpIPH1oqNIuGBGBnJ9DRTMWicqxKpGuGfkqTwPc+2KfC7MrPlNme3Q/SrSAHcFfGRyB3qN1RMDaAuc8Hr9KyUdTVSRNbkkbSo46H+tTKpJwnJHOf73vVB2aKRWB2qRxz/Wp4JSrB+WXGBmqQW6kk0RJUgHPXgdaqTMFjDqMsPuhx+tW5Jj5e1JM9uDWVfTLkBT8wGCxHJpjjq9Shcz9XZhvXpkYzWBqLoEDckscsR1Fal+ryR+hPIrAlTIcMzKe2aV2dMEl1MuecF2HUZwc1nzyQrwo6e/FW76BUPytkflWHfso3LH8gxnnk1m20dMUpbEGoXa78owVuwHQH1rPwDlmIznqR1prsASzdOuSKy729aRikY2oOM1F3JjqzjSjqSX96cGOI89M+lVrZTs+Ykk9STUKrg1oQJ8oFEnZaHDFyqS5pDNlKEqwY6esRxWbkbcpVA5prKPSrLxEVGy4NNMTViuUx70mOuasBM01kwSKakLkuQhadtqTbTgtO4+Qh20uKm2+1IRzSuUoEBWm7anKelNKEHpSci40eYhK0u0VNszSFCKakJ0LEW00EVLtNBUijmCNK7IgOKBUm3JpdnPalct01sCCngc06NM1MsfTrVXuYyhZkIFIR6VbEJx0o8kgUE8pTK1FIc7R6VdZMelVnU5PFJs2p07kIGPekqXac9qXaam9jR0bkWBShemOhqTZQFOOtPmJ9g9hLqIRybfMR+ASV6VEAKl2Uqpz1o5jRYbQjxTlFSiOnrHS5iHRaIgBxxTtlSrHUqR5zRcSgVGTg1Ay1oNH16VXePmhSLVK6KbDtTGWrDJioyKuLOStRIBHg1IiYqQDJqQJTciadB3GgYwR1BzWrDexSqqTrsf+91zVFYjQUIPbFTzHbGDjsbKRBSroxHoy1dEzyHN0xdMY4wKwbWeWAfIfl9K07SdZcEcE9apSNVFPc6LTy5AdYvoTyMexrft42iwJioYgEjPQVzWmzchGwwzgAngV1OnQgAYCszHAUc1pAipBJGpaRFipT7zdAOc++K2LWR0fCBMEDC9vxrMjZYiGYfL35wcelTrKoYBIyFbksckAemas4ZxuaiMzKCvJPGPSilgY+V82cuMAEdB2oqjlfkaKqqKu3G89RnrUibcMAoJYkDPYd6YTGSPQfqadlGJK/eJ6ZxmpJIHGVAH3wflUd/amKpklKphW7HoPrmpN+3LMqtj+7Vd5i+B5augOAh7Uy0xJvkd1jBIH8fSs+8mUoGzyeMf1qzd3HRZMeUOPl45+tZlzMhDbxlh1oN4LuZ15dFcLnHoe1Zd3cEoSBuf0C1NeuQxOQV/unisa7nVdxcneR8pDYwfek2dSplPUpTtI5D4zg9MVzV3cEjMhBYehq5qV0XYdVP8R7GsOdsk56/yrCUjojGyIbqZmXn8BVBRk59annO849Kai+9JOyOCsvaTBV5FaltFkDjpVGJcuM1v2MG4ZrKcjVQ5URC3yCQDUqWxxyMVrQ22QOKuJZb+36VCTZDlY5xrXOflNVpLNy/Q4rsV07nHap3sIwPlUnj0rWEGZubZxBtSqjK81C9vgnI5rrp7Hn7tUJdPmMLzJDI1urbDIF+UN6Z9alp3OmnG5zhhIHI5pwhJ7VupAjKvBJq3DpykcrVI1lTcehzAt2PY04Wz4+7XXR6cuOFH0px08Z5A/Cq5SIxbZx/2Zh2q/omiTavqMVnDJBA0mcSXD7EHHdj0roBp6jPyjNNFmFY/L160KmzdyaVo7mHq3h3UdKuDDe2kkbjoQNysPUEcEVnG2YAZBxXYiOdABFNIqjjAY9KrPZZ5Pah07EqTfxHMfYn8sSbG8skjdjjPpmozAWOAK9As7bU5vDt5ZWtv52nmVZpCEyY3A6juMjrWAtgd/T9KXKwi7XMFLIt/Dn6VKti3pXSQ2agdMn1qx9jTHua2UEZuTucrHalZB8tacNgCoNX5LL5lyeK6PRNHM7hJ5YLNdu4SXOVDfTjmhRM6y0ucn9g4+6ajk084+6RXol/otlbQ7o9R+0zYztjgYLj3Y1jTWqqDlWyRnkYpuBlCLZxy6TJIW27QAMnccfl61Lq/ho2VhZ39vcC4srossbbNjArjdle3WujigiE2+ZSUUEqNobLY4yD2qnLb5XaSdoyQOwz1qOQ7IxlE477GecCkNq2Pumuka25IGM1EyYOCKTgjS7uc75B9DR5BJ6V00dmrgHHWnLYLnnGPpS9mX7Sxy/2c56U5LZs9OK6dtPUdKUWSjAxgUezG6tznPsx9KfHbbjgqa6eO0QjaF5p6acD93HPtS9mSpX3MCLTyegqb+ztozW/FYsnFK9oQeuaORkcpy01rjOBmqUlu3HFdxBYRtn7QSickkDJ+lZl7aZyFGAB0pclkXGVtDjpY8HpUJj56VtzWh3nrTrTTGmb2pJMipZmPFblj0q9Fp8jfwmut07Qchflz711Fn4fAAyoJx6VpGm5bkOaitDzi30iV14Xmll0O4UE7M/hXrVloaLncg/Kr/wDY8J2gqME8nHStVQQlXSZ4PJYSxt9xhj2pYIZd3CkEdvWvePEnhWxsrwxW8yXMTIGVwME5Fc6+gwq+5UBPrR9X7MqFdSSkkcVp0DSRqwBz6V23hhjZM08nmmdRmEoM7T75qnHYLbzuAOM9K1rRgo6tGSPzoULDqNyiWYolfL3eXy3IHQ571dbfMqgnAPAGOi9uPWqgYAEpu2g4G7pn1qe0EjPwSQD8uOrH1+lUcc0bMcRMCO7qIR8hbPzZHt6e9FQCKaOQLkcD5yf4B60U7nI46l3ARDuBwTwf8aDIqHAy2O+OtTld3DevOTyagn2Kd7R5UcDBNBkmiIyIFcMWO/8AhHHPuao3GYWByVDjgmrclxHE4ATDdi5zj8OlZt5cqJieXb1PY0M1hHUZK3lw7GIYMM4rFuZFjXKn681qTspG5nO9uTkdaxbpw2VwOOnvU3sdtJFS6PmKQrqWIxg9R9K5LWblvNMSbn/z61r6o5jXaGxg8ggZzXPXCy7WI6t8qgc9ayk7nVGyMmYs7EDgDrz3qpOD361qSWxXIGTtHP1qr9mZzuIrNlbmayn0pEXrxV2aBl6g1XRMPild2MnTtIltkyy/Wus0q3ygrnrGImUD3ru9DtN6qcVmk3IdaNkW7OzIUHAP4Vpw2AJ6YrTtLHbGmVOT7YzWlDaha7IUzy5z10MEWRB+6PyoNkuDkGumW1BI+XP4VBfwrFH059K0cLBB8zscfeWygFFHPrUt0t1fWtvbzyYtrddsUSLtRffHcn1Na4st7biOvNX0sAFG7pjpUqn1Z6cbQSOTttE82QJDFvkPRVHJpDZGLI285xjHSut+zFGDKSMdCOKY9sshJIyT+lP2aNPbN7nLCEj+GpPsZLDiugFiCaDahPvY4pqKQnNdDBNlx04qvNbrC+HGa2rmWJFOCSR2xWPcFpHywwKmTtsEYuW5BsQjgUn2cMTzk1JwuDkmnRvycio5huFthkcBjfKOyEjB2nHHpULQhT2q42c55qvMjsCVOD6VXNYSg2yCNVMuOKtNCgUkDH1rElnltpSzKceopJdcj2AEk/hUqtHqX9Wk3oaTRhicc+ua29P1a/trQ2fmpNaE7vJnXeoOMZGelcla6oHPI4NacV2GG7OD6U1UTKlh29Gjs08WagkSRWsdlbquA2yEEuB0DZzkD0rL1fVL3U233s5m56EAAewx2rJt3kkdFRGYuwCgdzWvNp01owF8drMAQnej2nYy9hTpO+lzFmwGK1TmB7VsajaCOBmj6KM9azgjBFdwRnkA0k2zeKUldGc0JL5HBpGtvmBwOlXDxIT19afGTnLAYHQUD5CnFFgYwRT/ACmwdqnNXlw3PA96njhHOOtOxNktzICtg7utN+YvyK0jb/MQRzT4rTYCWwSamzHoilCg3cjpVuNG3ZFWYrPP3OatrasF6ZNUlYHylVI2K/NUghXHyj86uRWxJHcH3q9HafLk09TNtIxPspYjPNVr212jAxXSm3AB4qnPb725+7RykcxykUNnGLh9QgeRTGRH5ZxtfsT7Vb0exRkQpkseox0pPEMXl2bheM9K1PCwLQxPg5IAPtTglsYT3uje0ywCKp2jP0rcS1AUHpzS2sZKg4q/GgwBitDJtsqxR5bmpZLddvB49BVjysHhQD9afsBTg5PvQHW5DpklvbvcRXNqtwksexWPVD6isW7tjGpBGNvBGK3LciO6SQ8qh3dK0fGJgvLKG/C7ZpdoOBhSMf41V7C5uWotNzzhbcm6bcuMc896sraB4yFUE9a1Y7YLdKJASCAcHkdKki2xBlMYBA69eKjQ6pS7Eek6ViMPMhlTPKjp+dWjE9veOXKqVG0qDnA9KW1uWZhhT5Z5wTgZpTGqE/x4yTxzk0mcc+Zt8xFL5jOWVgGkwWBop8sRjUE5yVyB6Gig5m0hDISuFOCevHT2ppmZ+CVxnA47U9grgHacN6UwqpTHp0ouZorziPbkYyex/Wsq7jDtgLhvVa1XyHzt3r6YqhPES2YS2/PTpQbwsmZ20uBFIwO3kNWbe7Ap8yNd2MLj09a0ZpXgYh4kckFSHHT3FZF+WMWW6jgVDOyCMG6PnyMNo2A5PvUSWxkfgYUdMDpVxYWkkEYHzHrXRaZpBZQWHPX60oQ5jWcrHJtpbyfKq8dz61PHopwB5dd3DpwJxtxVr+zgM8VfskZqpZnmF/oZKEhTXLX9k1tMuVOCcV7dc6eoGMZrj/FWlRCBn27mHzbenSplSVtDRVLnMaPZBnVgMg967nRoGjxkZX1rJF9Dqt0bq1sYrFHC/uIfuqQMHH1xmuk0iXaNpP5isoxSZpK84HTWMIZRitFYRjpWZayqFBBw3pmrhn4xv/WulTSPMlRbdiy22JCepxWLeu88owMLmrLzqQQXyKrSXChuBS5rs6qFBw1HJGqrnPNJNLxkHgCqVxeFTg8VnXF62MAk5ocrHZGg5O7NNr4KCMimrernqK52a4fJ54qESsrAFutZ+0Zt9WSOlm1FB901nz3ruTgYU1QByASTmrI2svv71XMxeyjEjc8fN36Cqjvlzx19O1XpomGGxVKVGVsmpZSQ+OMueTz2q/BZDjcOTxVaxkHmKWraR0OBxRFJ6nNV5k7ED2SBcYA96qSwKgOBV24uFUjcwqpLcIwIyKe5MVIyL+ASJt28Vz9zpQLkgEeldWWWRuOlRyRjy2bg1MqSZ105uJw3l+TMVPBFa9g4MiKRwetVdci/f5X65FUYrl4nAOQB3rmfuux38vPE9EgYQiLyEIdCGBzxn6VYmkuLucS3EhdwOpPQVzWl6ziNRIN2PSrkupGRTs+QVtGSsefLDT5tUSatOZV8mNsDPPvV29sXl0+0uYgCqwgPg8jBrNCpBErecskjDOBzt+vvUcl4UJCMeRzzgVUWlqy/ZvRR6BtAfA5qeKAMdx6VStXLynOdvrmr4IzwaaZUolswxCEYUbsUQREn0FQrJj71Bu0HBOMVXMiFTdie6jC424zUDZkYL2FNnvYiB82fp1qCKYeYCGyMZqXII031Na2QgYxV8QnHPGaoW1wAv681ow3MbKC3Q96tMxnB3LFvbjjPSpxGqjA7VEJlC/JjHtTFkdmwykD1oMHFslkI2YAqq6FcGriR9M5xjrVK8mCgqv8AD3pkM5vW08+dIl5JPP0ra0G22RgYwM1l26G5vWYjIHArrbCDYEAppCehtWi4jGKuIGxjpUNsmAPerLcDIOaDDqR45OeB/OmyN8owuR29qkJ+U4HP0qpIrgnLEDsMUGkYodGRuB5HbHWpdQlmlsLS3eNQqMShA+YgnvVWPGMsTxz9KsxSNPqFqshZtoBOeoA5xVPYcoq9+xDNBEdb+zW5KxbgoZxyDjmofJ8lrliC6qSpI4yKtRktfJcBDtaUn/61VrlBKoDtJjcc7Dgdah7aDTeg+xzNAhc4j3HHHT0p0sqphFUHGAT/AHjUG8tNFaw7vLLAbj0x3qS4ktrSQxyRyEt8pBPzemaUbpanNUjbchvJ3hdg3MqffHUc0VDfhIbiaAsfl4LfxH0oqjmdi2Iw2QgIc9SO9VNuwhTg84wavCTqeMYxxxg0k3KfPheM5oMotmbc740+U89Cc1nPIwHIJbOMmtO6hZ0UKchup9KyLuURqY2b73X1FSzspq42/wDLwg6tnntXPagMOAeAMnArQ3O5xnK5zz1/Oop4DLJtA5IGfpU3udkI8ugvh+w3t57jJY55HavRbfSoh4aN15W2QT7N4PBXHTHaub0K32qF4Ars2Bj0OBQ7lZJWJXd8vGO1bJWVjDEN3Vu5jJBwOBjtRJHgcirpUDHX3qGUDGBk07iirszJoi4wB+Fcz4ijDrgAdcV1Ur7M9Qa53WUypPXNS2dlOFzi9Ph+y3TqOVJrobYgEBScmqE8ADiTHsat28bAAqeBUOJpT7M10ZnwASDVpd+Ooqjbv0J+lX4sEE7gCKlIqWghHz46miSIgDNM85QSM/jTJLle7dPWnoNJkckIIJPIqjIwSXHG08Z9KtS3KAYDfKayb+ZRC03IUnaDjg/Sk2bwi+oSff2xDdnv6VN/Y18n7zyfNXrlCGrFlvrcWqhPOFxnJO7Cmp9N1ee2k3W9wYsjkE5BqFJX1NZQqW90tnej7XQqenIwatbTGvzEZ/lVO71ya7YNdGNlHUBeSKzr3W0ZjsXb2AyTQ5JCjTlLdGxJcjbyeB61Q1C+UIdp/Cufl1J3yCSKqyTyS8AHnvWftL7HRHDpas0n1IopYE7fUVYsdefcE3fnXOCCV8Lu4JqZbOUNkDkVN5FypwasdRPeNJ82eKSyLzOdx96xYJJFfZKCOOtbuiFTNh+vpW0Hd6mEqahHQ1beA+T39elTvbBbPpnNWYtioxIA7VJKc2pGMgdK6HY4rM4zW7UbwRWHcwoDgDJro9Vbdclc4wKyJoiTyPl9a5Zq7PSpOyRlIHibcDgfWpxcyDndVg24JwMEdqf9kU5zWfIauaIBfybcCmiZ3PBxVpLOMHpzUi24zwBT5GQ5LoFtPInA6GrkVxISB2qa0tFH31yR2rqI9Gik0IyrGkcw5MjHj6VtGm2c1SrGL1Ry7zN1/SomJL885/CtD7NhNxwVXuKkhtBICcZPpT9ncamkZRVgPkQDPU9atx27bsgAZ5wo4FbH9nlQhKYDcZq15CKF4AI4q1RSJdZPYx1R0HGSewNWbRZQu0n6+1Xza/6TgEYI/KrMdoGcg/TNJ0zOVRWEtA+xc1sW0XyAucVBHAEQAg4FOkkJyFJ+lNKxxzfPsWZiqqVUAA1z2qHYp6ZNaEkjBT61l3IM8pB5xxmqRmlYfoFocbmAzXV2sYGOlUNOt9kSLjmtiBMNQZzLcIAGO1TMmenNRxenerG3K5PB7YoOdvUhdCVxyKq3YKrhmJWrcxIO0dKpTqTjJ4zyKDanuUllbJUcitOJpU8y56lYyB+PGay3iBP3WHuK1isiaMHYDy5DtJ7n2pmtW2lupHPHJDp8TKxZvMDYHGMrk1Wt5gG2DJY8kU6VUup49+8kE5QNjGFAFQ3qL9uP2fCqDsyeMjApEqN1ZhGjXF2CBtGRg+pNaczvLdM072TyAhFcj5lasyIvARNliV4BA4HPWrcn2NnX5bn5mLbgvANCOSu9bGPeLKszvvSX5vvjvRVe+ZZJZBESiKTyRgkds0U0jmubCgbRvAJHGT0Ht9aY4LfL1A7U6N12EjLDIz7UEYjbI3KTketJmcSF84IUgtnFZt7YbZmEoIbOSMVemIU7kBGaSWSWYKZ3LZHG7ripvqdVNtPQxTFHAPlXOPWq8QJlLY4wQK2GgySSOMZqOKAJDkqOCRR1O6Mk0XNKCqSIs7R/eroxETFbsx3nliir90fXvWFboI55BhVXjCjpXVCO3m8ORTxykTwEqwZsZB6fWqvqYV/dszKdgz54HPFQz5Ge1Of5mzuwKjnGMljnNBpGNjPuSO3IrAvfnZh6Gty7O4E9hxisO4I83AHFJnoUUrFDyQ25WHFLp1tNdXaWlrG0kznCIvUmrCrmUACo7vzLQfaoGZJo+VZDgr71Ss0Z1E4yuia8tLuxm8u4heKUdVdSDVaW9eM4Kceop0njXU9Ts0ttTm89UbKs6jd/311qFZEuATxn6VlpLZm1KM0v3q18hst3Ht+/09PWs+bUOCM8981YurYjkDr6Vi3aMCS2SP5VlK6OynGIXF+3OzJ9Kz7q6muMB3baOg7CtGOAMAHXAxS/YCWGB8tSoyZrzRiYgQ9ycfWrMCsjBXRge2RW7Bpi7QWwec1fuYPtEym8Hm4UANnBFaKi7GM8SrnMSIsjnZnPepI7NXHTpxW6dMhLqYI2Ud9xzmpFhVZNqxD6mmqXcXt9LIwP7MDHO33py2yqD+76dK3ZI+WKIN3TiomtZVH75QFPtTdNLYXtW9zKW2Q4OBkdRirO1QANg4qVLNg7bXAAOOOpqeaAwIDgnsSe9NLQbkjCvo8yBl+XHrV6zZRCGUnOOvvTGiMkjcZNW7eEbFHYVC30N+mpvaeBJAF5NaF6nl6ec8HFQaNat5WFVizHAAGc1qalbMtk8cgZWUYIYYIrbpc4Kklz2POrtTJcljzk4xSyQD+ErkDnNW0hO5gRjB4NPhRdxVweeuBWaR1N2djJjTB5wfb0q9HbGRsKoB7k1oC3hAIJI44ytWYYl2ZjO78MYqowM51exm/2cCuT0HUmmpafNkYAPFaWJfLfO0r2zRDyo3dB2FXyIhTla4y3gEYGBz606cSPHgFtmeQScGtW3t1f5nBwOcDtVwxIUVmi2gVoomLq67GJHbs5Cj7nXFWYo0UhR8o9jVuzi825bOSq8+1FzCpuDsxjoTTByTlYs6u6xWFmtsg2upJY1khXZwFGTjtW29ot1brhfLhhXaCTyx9hV0JbxaVb28ajzyxZ2I5x6UWZjGqoJK12Y0cDGNT/ABVoRQBIyX7dMVahjTGMACkeMtyenTFQxSm5aEW75cAZJqtKNuTjNXWgfYQAR7Cql0hiT5+uOlSTFroZd3PJGNyrkA/MB3pdNty5DuOSajEBln3sTnsK2bSPtjigcmjQtYwuOtXYwd3y1XtwAMmrkZ54/Cg5ZEsa+oFWeNvJwRzzUKjJpSNqg85Pf2oMtxropHFZ03DtknP8qvOSEzVCcMSQcAnnNBvSK4b5ztbDDkD0q3JcubeKFifL37sVQVtx24y1XIlLPAp42nJoNppW1JnSM3ZFspdI0Lkk4IGaiA3pvA79fSpXLtJcOCSDGFBQDOabEipudtw2DaQPWkc7egn2iSOwSRWcebJt+Xjgd6bLfTyQ7re4dtwwSR0GaqzTTpHFCSTCXwqHpn1qDOT5RV3Ctk7D29MVUTlqruUNScmaWWQn5hnLc8UVneI7q3L+XC0kbscEMd3HvRVo5HKx0sEu8/OQSw7VaiZWXDEjv9KzElDJiQZP1xg1MjufvHvwRwKgcUWJiMHcPm69KgigEzZQM8oyduM4GKfJkZ9uDWeZ54XMsTmNgMcHqO4qJXWx10ot7Fh5cErgAgdKYig27bcht5NLGPPmErA/MMircCKxlXHG0EYoS6nUrRKyki4IO0k4+79K1luGNskOfkViwXtmsPHl3jbm2qRk4rQibJ4YEDtimayimkTryx6YP6U24cqSPvccZpQecjBxzUuu2y2t2sSHIZFfk54IzQJNKSiY077gec/Ssi8kAY8fpWlM2FIwfrWXgSuXySc9KmTsj0KUdLkdtKJJAe+cE1duoBJERjhhg1WlUIUIBHNXBlosngdKcJE1Y81mjlNUxPdR/uVheKMRsU4D46N9cVDAsscw27iD14rZvbQzT5T7xFXZrSyj0m3a2S7S/wB22XcQUb3Hel7O+qCNfkSgzPh+dCGJ471TurVn5QgjGK0kh8iMtLwxGQpqCMM+HIK7u1JrubxlZ6FWzsZmHzrirawE/KF2kcZxVqHftGPmwfWrCXWAc4U9MVcUkRNtkMVsUWN3j3KerU66tDOqzQkDHARupqzHdM7sGwE2jjH61LKq7BvYcDgitk10OVpp3ZjNJ5Y2sgU455rNkuDJL8oZVT7xArXvrUzLlCuByfeoo0UsEwoHfI5zWb1Z0wslcZaXCYJlXch9BzWlDHDLJmMeWgGSXOfyrHvEW3l+QOpP5GoXllVmCM2DjilzW0ZfsefVF65jSOdipVu44qnf3G23yeRTvNkVT0Oe/pVVg10UjHOegqJNGkadtw0yBrl3I4GeM966C20sujAAZHtRZacIoVRfvryMVqwStHHjaFfp14ojGxjVrt6RL/gkxWPiKwF7hYzJwWPAPatb4gtFca7c/Z3RwQMlT3xyK5qePzJYyx+Y+9WJcBRlsMR1qk9LHHKlesq19bWschOgWU7BgmpI4lJ5+uadqa7Ln2IzUUEhilGASMYINJaHou8ldFgwOGVtvy+1WjCwUbO/UZp9mquOJQqk9Cas+UPN2KFcDuKuJzzepmGOSTcEAUDJz1qxaWKtGHZyjjpx0rr18EapNpxvIRCkbLv+/ggY9KPC2gSamDDBJErKuXLmrSOWWMp8jcZbHPW8IiJx83fGePrUl6cxkR5dx/F0Aru38CXMClmuYWiUEnGRgVxNyC5uDn90MgHGOBVkUMRTrO8Hexlac0jE5JIPUVd2GUs4wET5cd6rIV8pSnzMDyfarMUn7psnA9M1J1zTeqLTRYgBBI9Kbp4Lltwx7moRIzgDedq8Vbgy52ocKOpNG5jZpF3bwBnA9Kt2scZKmYfJnBx1qjBEz8gEjPDetXZ547deG3P6AcCoOed9kXNdl09I4106F02D5nkOS1cpeSG4kIFW7u4aQnPJNQi3KIrsMb+lJlUqfs1ZlaGLBye3etC1XpjNRiM4AxxVu3THXNIcpFqNOMY4qxF8pojBKHAxUgAwM96DnbuTRc5P5VLcZUqjA8VDBnIBGRnFT3m4sAeoFBk9ynNwNoHPYmsmfec55IPWtWSQYI7g5rLuptzZIxjg0I6qKZHE6M53g5q7ZSyLebojhokZwT2xVKPDbTzx0PrVqzhaZLyQSeXFEoDMBzgnmmVUt1JjJIhldcq0j53qRw2PSo3yYiJWwzcep+pp0VyPLKEr98/Ow60y4nQoWC444wM0jnk2tLFUy/vEwN8KPuYn06VLdTSwrOLeeAXNxJlJAwwkY9T2qtbfK6B2xvYKSBwB61BqU8ENu7GxjKR3PleX3Ix3PqaqKOKu9TivFF9E11czQsrRbjjA7+o9s0Vg+O7m3sb68htRsWMkD5uh9DRWqRxSkmz0eFiXG7ccDGMdRWgMADnkjjFY9lIWYM7ZbHJU8Vfj25Uljngg+lZG6LeR5ZB/GobhVKYXDDPBpU574AH51UnlYJwQRWbO2infQuxwyQhA7K2OmD61NC+HUDgEY+tZtq+0/fwBnGByKltHBukCybgSQCeKFodfK3dsm1G32TRzbTsPepoHU8gYx3FXtfUyWkLw5ZFXLduayLV22A5Ck9BTejLpNzhcvM3BAyB7d60PE9xFc29hcK4aRoQkmOoK8c1lbzuIOSevWrEt9GdJe28lQfM3CQdSfemJwfNGS6GDcv8ALz2Oap2KnH1NTXLEHb3NNtcMRgdKynuek9IaDr5cQDAwVPWnxZEWG5yKTUQrw4J28j86dApEfLZJ5qo6Mz+xqRbMMpPTpVnblAQx/OocZY9alXjjrWxhy3ZVltiwLDPrTBHnqckVo57HO3HFU3TGWDVLN6bdrMZAArfdyM9OhNb2gXOjwRPDq2kNdyO2RIr4YD0rn2LEccn9aBEZjhWZT6HrmgKlJVI2bt6DrsJHNKYoisTH5Q3PHYZqrLdkKNy4WtG4tYPsw8u5kMw/5ZyLj8jWPOX3AAD6H1pmtOMZbFh7t44h5I+UjFUiZlYSyJx1qzbSEIQ6gE9jVe5mZCSFYEUmbRXRIW5uVkjDAsSvTPas+acBAQTuzzTPNJfDYIPbpTZXycqpI6ZqG7m8aaQhncRsG49M962dEjWGLzGUMWPB9KwJMsVGcc112lJF9kQMVBA71MXdmeJ92Ghei2EsQ2XxyAelPhi+VhjA7ZoiEcbZVB7GniUZJzVs8u2ug28GAkinBTms+4vTKNxbCngCjVr1Y4toPJ9OtYMTtubLdTxWcnZnfRo3jdlq7mMm1gxGOORU9rGj4B++ejetU3bcvJ4xir+mZWPcGGeAAeaqGrLnG0dDYtYhgK1urMepp4iC3CttVMdvWqs1xLCBtCsD6GiK8aUFSh3D26Vumkcns5PU2n1SRUWIzSeQ3BQOf84pLC8NtdLJbymJ4+QQelZiOqh3ypPcHmlRsReYFALHOPWqMnh4Wcbbnpmr+L7afSRbWxkN1Mm1ztxt9a821ZHUBSWCngAVNDc4ljPAbBJJFGoTxTRZGcj1FK9znw+GWGdoLcrWqCO0lAAAPc1VtVRmxn3qLz32lcYB7k0loAj8gkdj60rnoezaTZolAGBAGypbeZQzHG8k8DsKhlG6MfNk+lJGvkklhwe47UmzPlujaiuC8OC3lx9z3b/AU11MkiyHHlqMD3rNjn83gDgdqsruZAOVWkzmdPlZNFbrPMfnWMKOSxpv+sYbiSFGB9KNh24AwKWMYPJyKknW48ID61ahjBwB+tRJ1q1bnDjPNBjJl2NcISeoFKAp4HbuaQNjPUg0A7WGejDnHagwJcbeFPB44p80E4t0lMbiMDBJXGDmo4JjFPGy8qjBsV22thLzQXkiZfmUMOw+lNI56tV05RVtGed3Chs4OCazJEU8Mc54NaU+Bgg8/SqM6kHOBk96SPSpuxFEwjjAIJ9MVBHqpi0+6tIULSzSgk54wOn60SNshk5K49qzYvKihe5Mi7vN2+V/ERjOabZsoRd20Xgs6fupI90ik5APIzVh2k8pECspA/KprO4jnaSZhgueB6VHcPw2xhtHrS3OOtUb0aK26FSkcspXJz8ozk9PyqlrV7cQOLZtWtFIbC7ovm3e59afd3Hkus4KDDbsn/PSuT8XzWLq919l1Z4yd5gWL7x9A3YVrFHl1pHm3xDh8i2lkS6juv35jmeLIMcnXDA8jOKKxfEOqeemoW81tLFqN5eCa6VxhYgudiL3JwRk0VqcTbep7lpczFgw4PU1th8EKAS3UDpiuN0m9kLKGVAqngqc5HrXTW9yGALZJBxntisGjsizTD4b5jkd8DpULwAq7ZPPQdqek5MZXB3H+8KjZtsuwMNpI4zWbR20ZvoLHEVGXfLHIp9sm0hXzvVgQMcfWnKkbn72CD+ftVuKLggAjaO/XFB1e0ujWTNyjwYyvltj0ziuXs3cfM33F45retXzEApGWFYCqVuXRWGFYmmzTDvdFwTZYAD2zVgqjjYFLOOiAZOarwrvJJONp/OrVpfPbXUdxBtWVGyu4Z5p2NXd/CZF+mNxf73QD0qhDOYWIIyMY4rUv2M8rltoLNuOPXvWU8eWYjoT+VZyWp203eNpDribz3QID6H0q7EPlJz2qlbwkMABnntWgvT2FCQqjSVkNUHO6ta6sIFskuLa4DjhWXvuIyaz1H3cdDUyDay5+6OeK0RySu3dEUi/KB6d6rA4yDnHatCbHPAUntWdcb4myBgd6RvT94aoUPkHawPBzXTX2lXn9kLfGWKdoyNwjUbhn3HWuR34xn681YGovHAsaB4n3ZJVyA3pkU00OpSm2uVli68v7PHOGJYsd0eeVPr+NZFyBMd6ge2DzVye8aRyzkCQjrjr9aztw87cwG3pgUXOimmtyRI5BGrqAw9u1UmRmZm2EjPftV0yLK3lx4XOQrdMVHFPKIRBJkw7twGOd1BorrUxrtPnPylWNIi7RjP5VpXSDzCShHsetVZQVK/KcHvWbVmdKldFeWMAUyKeSN1OTge9WzGCjYAP41A0IPPPuKzaa1Q009Ga39rsIkUckDqarnV3V9q881TEXcDjH506G2yy8Yam5S6EKlBak11M1xISScD07UkMTLxnI65NTxwbTx+ORVqSKSJUaVcBxuHHGKOVg5JaIgUEpgAYHNPth5cuQM+oJ6+9EQBHB+WlZVaQKO3XNXFWIZrRRLLEwVVYjoCeRUtrEGVlOIyOCAfvVRhnCFVx8oPUdqslw4/13HbA5NaJnM4vYuxQQ7QAVxu/WpXGcJj5gMZ7VmwXBZx3cdqtPdMvoecfSrbMZQlcsS/I4YrnA4IqjcygJLuJz2A4oad+DuBBOCalitjNZzTAbkiALk8nnpUjsoK8jKc5OGqZc7Mk5C9AKQwv5e/qmccVJCq8ZIAoNr6aDo5GduBg9qsQnzGIY9sGo41Vmwo96twwhWJbAz6UmzGcrIkhhQMT6VI8mHz0HpTXI6gnAqM4ZuOaTZzWvqy5G+6plXJqGBGCgnoe9XI+F4A96RlNpMRBhhjrVyJDvG/7pqKBBjkVbX72AKZzzkKCASDzjilXJb5ulLKucdiOlIfu4Xk+/rQQtQ3A4OMYpJLhjEsYZvLHIXJxmow/QYwec0xiTESvUGi4+VX1I5pPlIA59RVIFtvzZIqxO5C8kD6VWkwV3g/WmjeKKN/Ltik5z2NZcBEsSxkruLk8VcvvutxWTHIq3KqpVjnr0/Kk3Y6ofC7HRWdsyBXjz6HNJd4jBIIXucjr7VdtmdY03ZG5ckVmapMijld2eOtVY8mpNtu5mSTJ50bzhTErBmX0Ga4TxlqurXF9e2emX/mahDcpcQBZRseFs5A7EDjIrd1+aGGNZTKI4gw3u3RV7mvKPEGoQJq9xEPC0MkaOVjdzIS69myOORzxWsVoeXXldmTrSQf8JPqTW7+ZD5xIcNuyT1we4zmin2kKT3ssot1tVZsiBc4j9hnmii7MUjsfCOrC5ZDIdikgZBwK9DtLiSRVwQVxjj2rwHwtqBtrpQ/+rYhTxk/h6V7LpGrpcKI0/cqBxk5z9KTRrTmdjESUwcrj8Knki3Q7hz0wKzLSZpI1OT8w61dhZ2cAHBxnPtWckdtKREk7+eY4gcjqSua3bEgRAkmV+pbofxrPBRJF/dduCpxmtK1DvtzHkuvAQYB+tKx2SqJrYarsshDDafSsu/byL4t1JHH1rWnhIQSHCt0JJ6j1rM1Xa0ayIM7O9JrQ3oSXMN+0EAGTIPUAGnkhirLnJ55FZ8UpOCcHPQ+lWEcljknjgjtRc7uWz0JJFT5cEZPOPeokTnHAw1WDGrklTz6VGiHaRjqeaUioySQ6MfOuMc+nepHH3cZx6UsSDPIxx19KfIm3p0x1oM5S7BHGWG/gAfqamVcMDio0GcfyqUHB759KdzIZMgOTWfOSWIz9CK0mOen5VQuotpG0lm9D0oNqTtoUHHzHqRVeVH3bQS2egNXSMMVAyPeoS5WZWAz6exoOtSY240+7t/8AXwnbgHKnOM1WU/vFyeBnNXRNcLMWEjhiOT61G8ikh2A3k8jGB9aBqUtmQBYTlWbafamFX+ba52DpirY8hpCzqACvKqO46VDLLmTJVE4+UL60FxepU80n5T82eDk1Naac1w5DyRxxryzOcAD+tSJJGFYSIAGbJYAZ/Kp4YlMfXJ9fWhIbm7aaDL6ysIVVNOkluH6tKy7V+gFUXjAwGzWsy7IWMK5c8EsOQPas8AMf3gOPX1oaQqcnbV3IAp65GB0qxbQlsdqNo/g6elW4QVXJUD+lTylSkNdPLIwQfwps3mTRqJGdggwoJ6D0HpVnCsMbgG96Xy/3R5DNTsQpd9yhDF8pwvFRzoUYlTwOtXACqkjg9KiaNnjI5O7riixfNqVI0kYbl27uw61c89fkaN/mHHIx+dSpGERVACnGCfQVQZUS5G0sFPQGnYFJSLKE79xYDufr7VZgnbcS+Pb0qnPHuC9Qegx0xVm13PG8XllwvUgdKdyZbXHS3Co5CnNXLHVJ7EM9u6gPwyEZDD3FZ6oFkK8cUjRYdQOh9+tBEoRkrNF24vr25nMpfYSMbY1AUD6Uy3aFVkEyuScBcdvWnRxjAySCemabNAzNtUjA9DQZ6bIBKgkHkmT/AGi5q/FIAAd2c1nLCBCCCS2cEVLasWfkYI5+tIVRJousSVPNTW6/JkjmqZ3Z3D9au2zlowMfjSMJ6Iuq2foO1Twthvaqykkc4FWIR0AoOSRbTAwQfwqWPnqOnSolAGAxp7MV4BORRY52rl6yuDHI22NZGZCPnGdvvVbYAVIyRzWt4R/5Cksh+6kDN04rLjAuJHCyqhbLZbgetOxkmlNr0KrNtbIHB5z6VGZDtf25psj70Y9T1qszMCcnqKDrjG4SEEDn5e3PeoZGbJJxjGPpSGZU5wCP5VHM4KnbzTSNLWKOpPiFnGc4x1rGRYZbmN4RjhSccYbuav6v/qQgYJvOMngCsHS2Zb0SR/Mo4471L3NUvcbO4yVtwWkZnx1rG1W6jVNzrkr0Hr9a0DKrWivkKQOmeuTXJa5e+V5rzD5OnPFaLc8ao92cf441t5Lm0gaKNwZkURsdq7dwyPT8TWHqUHiVtWufs3iC3FuZCUVb1FCrnhcdsdKz9c1PTJbqVdTsryZAcRNDMFGB1yfrUenv4XJz/ZOoAdgblT/Stnojy5PmkSG3uft1z9tm8653/vJQ4fcfXI60VI5ha5kFkrxWufkR2yQPc0VIzgbeXy24PuPavR/B2rNOsXmzREg8qzYY/SvMh1rQ0m7+y3CyK2HPHtj1qmrmcXZn0dp9w8kWYyAqcgZyMVpm5OwAEbs/MR3Fed+GtW823RQ2WAA3A9vWuztp/MChFXOPWsm7ndTkbEMgMoMeHQNgEjHH0rWhk8rBX16A8n/61YEE4AyAc45qwk5+RBJ8xIwAvIHbmpO6MeY25JGdXUhcA4znAA9Oe9UplEsbQDAJ4FV551iu0R5FbKclv4WonuAzBsbQ4/Wg3px5bWMuJnjBVhkq2D9avWxwDgnAPesuRnS93EjLn5avwyeY4THepR6t7q5p+crIqeWRJyS2ev4U5Vwh/ixUManzCeCMVaC7kJz/AIUGEnbYZEegwMelaWi6cdW1WGBiUQ5aRv7qDrWeBtkAI7Z3Ctvw/e21jpmsyySBbmSIRQr3OTyRS6nPiJNQbjuZN2I0u5RbZMIchC3XGeKFGO+Ce9RIctxjFOYjvwKZcV0ZP5ZZT5eDxk561Rlwx5zx1yO9WA+0gZAPXI6//WqG4nLriUKT13dD+NBpC9zOmG1yeQpHINRfIASeM96bczbgo4IzjJpjkbCc8+lB2paIUSkDjgDOR61TMh8zkDPbnrT0dio3AjJwSB1p5RNwGACO4oNVaI2LdI7bSBjtSyqX9Bk/SpmQLgqpCGpVQL8zbSexPahEuXUqC3JVTngdz1qysZMI3cY70/Z3ZuvepFVY2XzCT6U0glO5AZGxjceBiq8g3DO3g/pVqVQpzjOePwqPySUDbfyNMSlYZDCygZxnvzmrcETOvHP6UqogQkYyO3oasRMFYFAAQOfamyZT7EFtCGudsnAHT3NWZEeP5eCByKigVnkx95u3uanXc3AUZHU5qSXJ31KjqGzjjtSrCFVTuyOhFPkU7vQj0qJSznYOD+VBdyZUQRMWX5Rz64rMmiVt8udzE4RR1HuKuzbioB+WMZGB/EaWCMI+WABbt6UBF8upRjDrGFmJwx61atlchlhZhkHcAcDHqadND50uMlYhyT1qJmaEGJT8uMHHcUFN8w0BsHBBOck0iv8AvU56Hp0zUiSB+AvFNjQhywxtHbFSP1NJAAAW5J6e1JMATnA29/Wq00zumeAQPzp0UzSjy3f5uqgDoKq5zOL3Irhn83CcKD09qmtwApJXn1607yl+UuQxJ61IyhBlQOT0zSG5XVhyDMhPLDtVm2JHBwCTVeHPOFAzxVu3jDfnzQY1HoTlCw4q1C3IA4PtSwjtjilCnOUXJz0Heg5JSuT2dtNeXSQWylpGOAB/M1PqkYs7loPNWRk4Yr0z3retYl8M2AnkYHUp02pHniMHufeuWnd5HZmbc5OcnvQ1Y56c3UndfCvxOh8JP5dpqVwTkRwbfzqpawL/AGdqE+FAiQDJHcn0qlaXT29tPCgws4CsB35q+88cfht4gULSzfvR/EoHShGcoOMm+7X6HP3EoU7l6Hiqksh+YEj1qW9AySPu44ArLmn+VVIy2OvpTPTpxuiQSrn587fQUjuFI6jJ4B9KqByc1MnzspJ6etEXcuojM1eYrLggMDng/TrVfwzxKz8b0GWJPUUmtT/O/wAg2t8ufQiptDtxHbGSQZ8zHUcilvIwrSUaWpe1C42JIWwAegz0NeeeKNYS0jc3Er78HaByM/Sut8Q3oiTBIY/w4rzDxXr7QIjQrCpIKlNoMh/2iewreC1PCrzsjk4baHV5ZJLvUbOxKNtVZkYFx68Ct+w0KyVQP7e05h/uv/hXKaNEl7qtqlwT5Usyq5J7Fuea9TW8jtoL0jQ7IfY71YDD5PzGI5wfrx196cjjic1LHHbXMkUcyTohwsqZ2t7j2oq14ih8rxBfJIyYWX+BQoxgY4HTiiixR5XTlODn9KbRmrMDuvC+qQ71GfLkGBtVsjb9O1emafeI0ZCjKdT6j/61eBWMxhnR0659K9O8KarG6LEjhhn5jjBIrOSOilI9KtZ1dRuXHHLHoB6/SriMXvUeIYXHl5HOT61g2kwI27tydF7cVqYkQholZduCRn9aix6VGZck3w3So8PQ4DdSafczL5T7M5jPeqM9x5d9vV2LsuVjH8TfXtVq1867glW4IYqOoHQ+5pHfDZMzncFwTnI5FXbSQE7yuCB69KzHUsMAcjrTrFixKAnFZ31PRjZxN6CQufl6E9+K1Ih8pB61jQzHdsCg9zmtS3lO0459KZjURNISuc9uwqzaWSXmmajOhPm2gSQL2Kk4NUWYbW55NanheULe3lsTxc2rxj3IGR/Kmc1TmUG47mVF7kfSpcZGcc54qjDJngnGDUwlwTjp/Wka8vY0bG3l1C+itrdN0sh2hccfU1veKfDenaBo6vPM0+oy/LGucKB3IFc34c1ptJ1aK8EQkVCQVJwSDUvjHXhr+qrcRZSJYgqo38J7/rVaJGMqdaVeKTtHqc2tvcy+ZPHC5tY8BnUcLn1pk0jSbRs4U8EjpXdQa/plt4Gl0iOJvt8hIcAcEk53bv0rndG0LUdZulWxttwycsT8q49TS5ex2U8S7SlVXKlov8zMjiIb5wTjGTUtwsaMSiyAk5AJ/KulvvDGpabt+1JFGj/KrvIAufrWZruh3+lxRm8VcSDMciHcjD2NFrDhiqdRrlluYnKsf7vbNWFVWXdIwAzwqnJH1qtGyfL5hO0nGfQ1owW+FBwrhgcHpmmjeb5dxJEVYSUJORzkdDSuYGUc5cenapVspr65gs4QBJIwUe3vU+r+HrzRZ1SdQVb7kyj5XHtSM/aQTUHLVmXJ82MrwKcmCSqsQfbnNPKlpvnOcHI+mK3NU0qDTjbSxTQs08SsyRvuKH3+tMU6ii1F7sxViZyAo4HenMqmRUwdx4yKnLFDuByPaqkrtvLRE+o+lMqN2y3bwMruEkXzEPfinyHDN5e3nrjt7VTjklGZEXrwMnPFTAdATnP55qWDjZjZEY/PkBc9M80MVkkHylcd6f0JwD/tVKtuXCugwwz8vXcP8aSHzW3IpIRgAJg9ie9NVP36MQuAMEk96smQsoxkOOuelV0l3OykDJPP0qhJuw25ADBB0GeR3qncRAKDnA6fU1bkOZsZ69M9qhlTng0mVB2ZXgjIJLAZ6DFWoFEaspwW+8T14oMQWIKMbj1qSCMAD5gTyMD0qS3LQqxHeHOB6Y9qsRoIzuVcsQOvNQRkW8zcZU5BBHSroO4AgdOeOlFiJuxWYPvyVBibrinoyptTqfepRGQGOMqf0qLZ+8G4DJHQGnYhO5OCcgYrS0+CS6uEihUtI/AArNT73U11fgzVLLSrua5vFYuE2xBRk5PWmjmxMpQg3BXZHf2c2nTeRPxLtDFfSqyPsKsDgqQce9T69qv9ram9wFKKcBUPUAVSLrgnG3PY0mc1OMnBc+5evrqS8unnmfLvyaq7+57frUJmXcoyKchIIUjIPOaV7lqHKrEsa7R8h6YOTS3ly/lpEQvlpkjjk5ppOBhjgHgGq8rEEpkMB3B600gSuyK9ceUCM5rEmZstt71euJz5T5PHSsl2JwR06YoZ20lZEyH7uT9asBlWJmB59ahdGOMDA6Gq9/MIodg4JGKa0RnU94zJpI7m5SJ2IG/sOhNbMTkxt852rwB9OOlc/bW0c0wErssXLF16irl5cG2tyJBgAAA55xTgupw4yS0SOa8X6hGikyybTyu5TzxXjepXEbXEqW+djt8zNnJ/Ou28YRm8hkuYJFdQxDIxCsvPp3Nef7QZSFyevXrW6TSueDVlzSsaeh2j3N5BDHjzJXCLn1JxXfpeJpuvuRqd6UCiCW5VQWJXjoeqg+vOK5LRLSfEV1CVURzJGG3gEOeRx6e9d7NBcvcNcTaHpcl4TuaT7YAjN/eKZxSZPQ4/xDHLaaleQXEpeZJDukz9/PO78c0Vk+KLqf8AtK8+2sGu/MJlKsCCfYjjFFapaGbkcoaSlJ46UlJoi44Gt7w47xSGZd4jUgOVHc9BXP1atpp9ghifaoO/GcZOMVJSlY9k0y/3usSjlcAFf4q620lWZF+YNKwxsDc15J4a1mTyEgkh2zRYCttxuHvXoWj3yTRq0i5fd/DwPrWb0Z30Z9TYeV/LDeXsYHbkcnHqKvaPIqDbCxVXBB285Pua52+vYrZ5AX2t0yvOPpV7QbhJruMRMkaIRl2yVJ9xUNrmPThK8DQv4zFckYAyMnFUo5dj7Yxtz3re12NmRSVQE5OVOc+9czOnRx1rOd07nfhJqSszUV2bYE5bGCR6Vs2LBI+hzXO2B2/MRj05rZtpCQTkHPYUJnTUV1ZF9phnkjn2qCSZ438xGKkdCKgL/NyOBSyHcvUnFWtTHlsJC2WyTx6VPuG07uBVGFjmrBO/HYetLqFugS7cnJGD0qr5u0dMkYWlkyAW5pBhu/PXp3pdTWO2oycsOUJznOM11fgXxXN4dmnEkPnW0uC0YOCG9RXMfKzZPDfSrViF+3W6zLviaRQwBxkZpre5FaEKlNwmro9Fn8QR6oTqes2pOnwnEFv1Ej/X+dc74o8S3GvCOL7OkccY/cwxAk+n41rePVs4ILCGzMca7W3QRvuRT6/WuQs9Wm0i6M1uqef5RRGP/LMn+Ie9U2efhaMXFVIR16LsVbpYIJTsimjwoDxy9Q3f6c161o3gbT5tLs5p5py7Rh8KcDnmvHjM9xIZJmZ2bl2Y5Le5Ne7+BNYj1bRIk27ZrdAjL7Y4NEbXFms6tOnGUHbuJYeD9Ns723uIFkE0D71cvnPsa3L61tr23eO8jWSLHO7t7g1yniTxxZ2sdzbWW+S6XKbsYUHuc1yum+NbmDSLm1uX8wshELnqCfX1FU2loeWsJia6VSV7r7zndXW3/tG5Fj8lsGIRWOTgd80rWU8CIZYZY1kTcu8feBqpGHnnURgsxOdqjP6V7Lf65pEOnQR3rRzsUTdGoDEUkkz2MTiJYfljGPNfc8dl8wsUiTJPQKMmo0ZIJGWZNrDv1r1/VL3RfD1ibm3gt2uS3yKAC2SOp9sGvH75hdXJkSPYCSzEnhiSeR6D2pNGuCxLxF7xsh4uN27LZT0xTXlbru6jIPtVZwEXGDjqaejh4xzkDsah6HoKKWqLMMikc/jirqpNhJI1YR54PQHHUZqlbLvUlSq4GRnvV8wXptFuPKkW1BwrHofpTRhUavuVyS0z5G0n5sduaheJW5XII5yaSWUF88jHrQgBiaUuvPy4zz+XpQhtNK5DG0skm1FLOT0AycVJng7lwTXoPgTwss9nbat9rkjn3HYIwDhRwRzTfiXFpqywpaxxrfMcyMnAx7+9VbqcSzCEsR7GKv59jz50ZwT90dBipIFMeeCODinD7igcn0py8DBHQ8VFjvctLEEyhgMDB757mo0djIpYcZxj0qZk4PuePrV/wzo39rXjQvcwWqJ8zyStjPsB3ppESqRhFylsh9rYXmotGlnbPIWPG0f5xWvrXhR9H0KC9uJD9qd9skfGEB6fjW7P4h0jwvZNYaIPtE5X55geN3qT3+gridQ1e6vsveSmRicnB4+uKqyPPpzr1pKUVyx/FlQEZ5GafHMocLnPtiqxmBOAeafA2ZM8bSOD6VJ3taF9GG4/z9KfI/yHJyBUSEL8xI59Kimk3AjPJ4pMxsETB5M5Bx3rTVD0JyazI0xwMY+taMJJTk/hUk1B0rZUNt4zxWfdSMfmVcueCfSrrsPLdT0rNuGIHXgZ4BrRaCpq5n3c/JHBPcVWQ7pgM57/AEpswPmOT0p9nguWHB6Ukjrdoxui2WLH5TgDr6msnVQJHGDznGPStNpI8NtbDDj6Vzlw7PcAK56nNDVjlT6k1qgCncoLSfKqjqeefwrG8WXW2GSKPh2Py7iFC/jWsXkL84Xy14IPSvNPH95JeP8AZYXUsuSQXwTWkVokeViam7ZxmuiVL51llSR1Y4Mb7gPxqCDdJIXc5Pr61VcDeQSxbPIIrQsl455xWp5N23dmxo8Inv7aHZu82RUwTtzk9M9q3dSuvDFrq0lk2l3bRpL5TSfajnOcEhfTNc8jkGIQZExYBNvXdnjHvmunvLqRLoR3d/4dXXgQN8luxdX7BnHy7vfHWhRFJnN+LtMsoYb99Pilt5LC5EE0bymRXDA7WBPIPHI96KxdZ1DUVim0u/AV47hpZzj55JOeWPfGeKKq5ncyeppG6mkBwacTkA09xDaUe9J3oFTYZoaVdy21wGjy3GCvtXpGh37Mke9kLbeMEDj1JryuOVkBCMRkYOO9bXh2+NrNg9OuD0NTJG1KVmeuX86zWkJjRCcbcYzk/WkspZkk2yIdi4+RRjP1NVNKuPPtY3Rxx/CO3rVxvtH2zZE6kRgMM8Eg/wA6xaW56uHq9DrrWQm3ETABeq5OdoqjcRtDkOOetO027aA4mhj3n+90B9aLqV3hVWCsyZy470SV1dHXSk1IrpLllBO0DNX4nwF2fLnp71SVQV5XJ71KhDHj5cYwKxR60XzIv7z9SetTNJ8mOlQoVA9zUcsgAxgiriRLUWNvmOTVhJmToAcVQV+R6VOhDggEimDQ6VxI+f4RmpcAKu0jdjBqv91SM/UVLC2OoBx60h7LQYm5W5bjPJNT7mbHlqck8n0qvKwJBHrTlmYJhT2p3DVmnePG4jWN5Cdg3s397vj2qjIykFiTle5qj9okLBA3y5P4VL5m5QByPWhu44QcSVHwyn19K0tO16+0+Ix2VwYkYkkjgnP86x+MHacEc0hcNnGc0i3CM9JK5oLI0sm52Yk9c1Kz4DIVXjpVK3kG3Gee+aJZDuDdaA5dbHUeELO5vdQEllF5jWqmZwP4sdB+NOubgyebO6KskrksqrtArL0HXLzSTMLGYRG4XYxUZyPb0NTSyh1Cv1I6nvVHFOnL2rbWnT9RJCd2SzE5HJOaimfBUquQePrVGS4ZTjgbDW9oelwapZzzXOsWtkkR+5J94++PSg2k1SXNLYxJZXLAYGP5+1JEys2OnPc8LV+KCxbTr2d7kefCwWOID/WA9WrKUj1+X0pM6IS500uh6RYab4c0+OCafVhPccSL8uUB68jHNbvii30u+8PSahEz+XGoEaKSqqxPUr2rySC5liz5bFSRjHtWvLq07wPbrdyyW77TIsnUsB/KmmeXVwE/aRnzt6/gUbgBmIHHriiKNk5IAjPIJ6Go2c5BIy2a3/DyadJfw/2yzizAJYjpu7D2FI7q0/ZxvudJJ4gTSvBNjb2UgW7nVuQeUGeTXDPM7uzuSzNySTkn8a0vH81nJrudPdGtViRV8v7o9qwopBtyMn/ZNNu5z4ShGEPaWs5a+ZMjkORnA7ZFT3OIWUrJFIJEBIQ/dPoaqpN5UyyKob2boaZcOAd6gZPP40kdLV2TXEgGFHXtj1qpK2QGzz2xTPMyxySajZmYsF4PXr2pXNFGwu8Djdn1qyzZj+U4z6c1nZHfjirCN8oKnnHOKaZUlsNYFXBGBnsat2hZMgr7g+tUbiXZKvyg9MCrgmUoXB5xyKVxTu0aSKSDgjOPyqBt3m4J6cVWjmZ9u05P1xVheZhuoOezRcjIUk5Gc8A1fBG1cYJPXtWbGoMmByPWrqtngfjSOeoPkKjIUcYrGuiEZua0bghSNxPFZF7JtRhjnqTVDpGXLI7ScZC5xzVuBNqAg8YqiX+Zd2SSa00YLH1I4pxRpXk1ZWM2aUoxU4BznHas5hhncL05JPoe1WtQ+dywYDPAArLu5mSEoy5XOWI607HNVlaNyPVb5raC4QTBIuMqozyPevE9cvYri8aWAybiSG3dOvau78e6gILAQq4UycYA5x65rzB8Z+XNapang4id3YdDnfnqa1bc7VzwKzYOuaubsJ1/OrsctycXrWd5DcR4LwusgB6HBzirl4fDd/fSX0l/exLK5lezEG58k5Kh84xnvVKz0W91iKV7I2+2MhW8ydUOcdgTzU6eDNWEik/YsAg/8fcf+NN6EN3MrxJdS3uuXlxcQNbySSZMTDBQdgffGKKteOGDeLNTZWDAzHkHIPA70VIjCp6nAplKKFoA8jjI6U2jdxjtSkd6u9wEFathFaCBJ72SSJS+1RH8xOOpwe1ZVLmkB6L4VvXvJ5tjjMQ3ZOFyPp/SusgLvKq7xgKCePvDqOa8e0u4kiuoivPOMAc16No99t8sxSZfONxPP/6qyatod1Co9ztNJSKQuyuZGXkquen41vRWr3ETLDGWUjIAPQVz+m3CyFvOwrN852cD8q3o5Ge3CJIVGcHaOSPT2oSSR6Cm3ZlKSNoHaKRdsinBBogwXbeRjGRmprvzDInmbWIG3f3b6+tQsMA5xXNJWZ6uHqXViVnQ5EbVFI7bsN27VBlCQoJ9eKWYneApP40XOy3YkLkHFSxyNkZFUZHIwSanifeAB1FFzMllkG8En5gQakjaRiMHgevWq7HJ5IyaVHbeAw74BpgloWxnncMU1vu43Dk8j0psjAxkDr61EZigAx8wFFwW44J5bqdvGTmpFRlUEZOM9KYZN0fBAxnGacHKA89RzQim2Tc+XlxyelRMF6jjFLG+5RknAqGTjcc0yovUsLMMgLzRK2WyDiqvmqABjJYZpTIAOcUi7WZftXIz0BX9atrNvcZPC9qx7eXDHPIFW4rgBsj8qIsmcLsdfjLt8wBzyPX61Wid2G0kEA095M7mIbr19KiD7V4HPY460zWOisWIycnFTLwQRzntUNuxJJYBWxwKmByMjjApCuTrLtfIxmpVnCwlMLyd+cc5+tUAce1KTgZBOc0A4JlsTMzZ2gj1qx/aMnk+TyIi24Dtms7eQnJxSvIqhRktk5wOtAnBErOHY5yR6VPCSqgtjA6Af1qikv7wYAGa1Lm6sf7KtYoIpVvAT5z7shh2wKaIqXVkkU522uNje+KieUBGyRuyPxpWIIba2doqlM3yHoB/I0NlRXQnWVSGCt85p0Um5W3MBtGM+9ZVvMDcMMhe5+tPklIztyCTzUpluOti7PIF2kHJx1oSYheeDyCKo+dyAxLLU27AO0cAcmi4ONiSVjK6fOAydM1bjBVCvYjvWVvIIYfhV4TsEUnp2NMmasi15u3BC/e64rRicMu4HntWRvEmDnGBzV2CTCRkHIx+dMwmtDShOB9anDNyBzVIvlwfWn+YAfc0I5JRLFzIO/BrC1F9oYDIJ61ozTZJz6Hise7fzWJGMCm2XSVivbnzJDnotW2dkjcueT0NVrYbAfXOTVqTEikDj1HtTiia07yKkUImTqARzz3rB1mdY5GxgMPlNdDdTxQxYX7u3AJPHqa838U6i8cU8xY7CCVLcZP0rRHmYio9ThvF179t1V1j3GOIYUD9awB1rTu75TayW6OZc4KysmGAP3l+lZiDkVpax4spXdy3DgYJpt3Lj7vAqMsVAx1qtI25qshsaxLHJoZGXllIHuK6nwmkw0vULjSoI7jV0dAisgdkiIOWRT1OcfSrdjf+MJ7pImtri4UnDRXFqPLI9GyOB71DJOKorT8TR2sOvX0WnlfsqykJtOQPUA+mc0UAZdFFFABT1NMopp2AkPSmmlU560EVTVwJIJ5YcmJ2Qnupwa6fw7erMjxSozOB/C2PxNcoOlW7C5a0cSI2QeHXPUVDVzSEuVnsnhyeKRVkMzqwG0lxkD2rsYnUXHzKEQ4H7skj6815n4VvrOaylErMZx/q4wvUH1NdFYSzsBCplkx03kAisnKx61F852l0Mgq0bJxlRjvWdMAy7/4fQVXjuLjfC0yP8owMdGq7OWjOHA3YzgDpWc3fU76N46GfOdhAC85606Jgd3rRIWb396S3+/IrgZHSsVueqneJXu2+Yg02GfZjnrT7yMBgATk1Qb5cjOOaJK2olZmk0+ccYIPGO9WEkBGW4rGjckkZPFWYbgjg8ZojO42rLQ1Cw2HBqCVg/GTn1qHzxtwDTkwSCDV6MiLtqPi3A7QM+9T8lcnt2NEJG84OPah2Unk0loDndlmJlAC4xTLoKQdp61AsiY69OmajmmAXG7cPSm3YcdxfMC4AHQYpHYt0quGDHAGKXPA9OlZ8x0XuSeYQMD71PjuRlec46iq7Bs8An6VHEdp56ZxT5jRK5pNOSApGPWmpIxl65I6VUFwQp2rnPT1qazk+b585B9KtMfLZGksvmEArtx1qUsMAAZ9arocJl8DninKynkHjvTMx5bIPfHWkZsjIJ9OKRDuGV6UjMc5I4oLQ7eQF4I5qUsNob8c1SklA6cgDrVdrllIXdkY/Ki5Vrl1nxzyT2pjSlcZJB9qqrJnkkio5p/nG0/NUuQlA0HnGOOO1VJnLqR0zyKjmc44+8fShVzGu7rRcVrD9imUZOGAGSe9LKVLBTzgdaQEBBIQOOCM8monwTvBOPShbEt3Y7lXUAZA9DirCHcQoPDdRVZHVzgNjHrU+dsgPQYzQOQ9VAOAee1WWXch5571VLBmBIz6H0qcZXHTHvVGUiS2XBwhzWhDh1BOAR0rKtT+/yuev4VpFicfw884oMp6FkNnPI54qXIAx3x1qrHw/ytx/OpppMxZJGfaqRzS3IbiQ4JXn1PtWZI4EmAeGOauSltgwAM1SUbpgCB16+lJ7hzWTLkK5AXHXkmiYIqEOG3gE49auIFCMFYP2UqcVn38rsp3A5C8jPBH+NbJHE5nMazcnyg07EBSdsQPGK8n8W3wecxoSGLbic9u1d34qvjbSvKj7VgG07vmy3U15Je3DXNzJKx5Yk04rU8vF1ehCTkk55pQcfWmA0prVLuedcdJJxxUPejNJSbuSbWgaLe6oJptPngia3+Zi8wjZR/e+nvWtNo+tzR+XNrtm6f3W1EEfzrH8MQ6nJqSy6PHumiGWLY2BTwQ+eMHpzVyTwjqjsxh+xTyEk+VBcoW/AZ/SkBh39q1ldy28jxu8bbS0ThlP0I60VFIjxuySKVdTgqwwQfQ0UAMooooAKKKKAFpwOaZS00wHUopM5opjRueG9RezvY2DHCnn3FeswstxGkyiIGT5gAMbT9a8NRyrqR1r0XwjrB+y+UWGSMbjz+FQ0deHqNaHoGnXLq6iGIYzktuzWjc3bTMBNguDywGCa5qzulUokUfJHLJ0b61t2W2Uqsu7b/Fxkis2tD2KTW7HooZyG6k1KI0G5sZyO9I0Kpl4s7N3BNKzsGI7H1rCSsd0Kl9CreHkFcZHas+5j3cmtF13licVSmypwelRfudHMloU0XBP86a0mMipJu+elWtG0K81mXFupSAHDSsOB9PWotd2RMq0YLmkzEkuJFk/dn8K29Js9VvcGOzk2H+NhtFeh6N4U03TFV/KE0/GZH55+nat1LXd90cfpVqklq2edUzLpBHA2/hrUGwZWij/ABzWrF4PRwvmXM7HqQqgCu0itCMfNVr7MT1atUl2OSWMqvqcC3g1Odsspx796ry+DHY/LckHPde9ejG1APDHJ96Y9oSQNxwORScU+gRxlRdTy668KalACYzFKB2Bwf1rA1CC6sji6gkjPv0Ne2PBJyCAR71QvLGO6geKZFweoIqHTXQ7KWYzT9/U8ct7pg3yv14IzUsrhl28hieta3ibwy1gzy2gJjHJTuPpXNRsc88E1g24uzPYo14VVzRNSDCKCc4A61NA4SXLHAPNUIJihIZs9qtx7SuWIIz61pGR0mkk4x9OgzTevTvVZWwcryO4q6HJjDoACBzmtbi2I1k28ZHNNlmOwknj2qCaQKGCevFVjP8AKynkDsO1Q5GkY3LG8MQVP1FQuRu2DjPWq3mfvCxPAHHvUc7sWLZ5NQ5GvIXPN2/LjioWYknNQQvuBBJP0p5xkdcGle5LVidN24MTxmtRIx5QI5AFUIuu714q/G4EYAORjpVxOWrIjkGIjjPPWqZ3K/U4PJz/ACq9JhYsKffNU2+/x3psUJXHW8JYE9SOoqfyzu/kKdZ42k5xj1qzjDYHQc04hKo7jYowo5GeMYNSADYOuR2pWbrj+dIkvyc9asycm9Qt0wpYnBzkfSrSsT0/M1U3YyMcmrioGjb170GM3dliAdeflHenORz0INRW52gE5BPHNEzbUz6dKZjPRlW5Zs8DOPenWURZ9xVjk9AM59qjCmedU4XJ5J6Cta5gNrpyE3BjmBJQp2NXCPUwqztZFOdmU/Mphccem36isbVrvyFbkkAbmXHJ9BU93LM5Bu23ydS5PLD39a4zxVqckS7UmKzOCzFSAQBWr0Oaq7K5wnjHU2kJt45H2yN5joexrkSas31w91cvNIxYsep9Kqmqijwqk+Z3CkJ5oJptU2ZMKKKUVIjf0O6tJdIvNKvblrITyJMk+0spKgja4HOOc/hUsWiadbypLP4isxGhDZt1dpOPQYHNO8OgWuhajqNtaRXd7DLHGBKnmCJCCS+36gDPapktrXxDCt1p1vHb6pbkNcWkQwsyZ5eMeo7r+NAGJ4iv01TWry9iQpHNIWVT1x7+9FWvGyInivU1jVVQTHCqMAcelFAGHRRRQAUUUUAFFFFACg04EEUylBxTTsA6tXw/eNbXiqNpVjjDHisoY705SVIIPNDVyoy5Xc9x0vEttbkSxl25ZEXGzHY10MUyEbLdw4PzFyuCTXl/g7U0aIb3yIwC4Y45/rXcWGpwMRtDMh7KMGs3JLc9WhJtaHRKE8vBK56mmsnmZGMGorG8tXBTdknoW6Zq/AUZCATuB/OoaTO1VHEoPGyAKcHjjisy6UjJI471u3WD+Heo9J0/+0LwGVcwxnJz3NYyj0NXXtG7I/D3h86iVnuwRbA5Vehf/wCtXoFrEsMKQW0YVFGAAOAKZbxlhtj4UccDFa1vGFUADFUl0R5lWrKo7yCGA4G4VcRFA64qJnCComlzz2q0rEKDZdTC1KGU1l+fyDmpEuM/dNBfsmX2Yb+QOlAZeeMVUV2bryajMgBwDSBUzR+UjkVFPArj1psEoxn0pTPliexoaDkaZj6ja702suR9K811zw35EjzWx+Qn7hH8q9dmKuvvWHf24fKsuVrKaXU6KVWUNUeOlHRgpUg+jdamVm2jPSu+1bQo7nOxQYyMgjqp71x+oac9jL5cin/Zb1rGUOXbY9vC41VPdluNiYA/N0PNWVcbBzjA6VSij5+YHB6+9TB1TJ5OKqLPQdmSSqeoGQOR2qhKQqY3ZPf2qzK52bg2Qe56VnzMXYANx0HvQ2awHr8xwcAZokiyD146VYtEXK4GV9akuehXbk+oFLlshudnYqIuBkLTgSDgjg9+9SbTu+YDFJIC4wAc+ppIiUu45XUD5mAPpU6TqPu4qslqznbErO3ooya0rTw/qMuCts6g934prm6HFUr01uyCSQOD6Y6VVkkXcccDg10cHhK+P+skiQkdzmh/B96CVV4mb8qpxm+hjHG0V1Mi1f5cZqyrkuAOh60Xmj39lky27YHUryKopMVbHIPvxSTa3LVSM/hZoM3AzzTFb5cfjVSSUHofrT7di3B6L+FVzXK2Vy9AmTk9KvRDglWI5xgiqMMgXceeKvROQeDgNWhzyuSlgqbTg8dKZLkoBTzGCMgc0Rw/NubP+NUlc55yQlrETIuF+ZulMv8AMibt5JxypzjGatQzLbyhnQMQpPzdB6Vn3C798kZ2eYfu5/OtoqxzSlrdmdfXm1CzDbHGM464968Z8Z6s11JIvykyN97GDtHSu98ZX5igMXmMFJ3MFHO33rx3UJ/tN1LLlirMcZ64qtzzcVUsrIrMc0wmlJptU2eaxKKKKQgooooAtWF7dWMrPZTyQyOpQlDjcDwQfWniG/0547nyrm1ZTlJSrJg+xrd8IWoEIuEYJcTT/Z0l27mhUIXdlH98gYH40mh6hLM+osbq7mEUbTLFcN5kcsan5lkB7kdCO9AHO3t1Ne3UlzdSNLPIdzu3Vj60VZ1+0jsdXureHPlK2Uz1CkZAP0BooAz6KKKACiiigAooooAKXtSUUAKKcGplKKaAv6Zdm0uUbGVPDD1r0fTCstqlxGxVSOgIOPrXlsfLius8Os32TGTjPTNRUijsws5J2R6HYbZpEZJjheTn19K6u2uN4DvgHGAB0FcdoQHkpx/EK6G2++axirHqt3NGXdPIAnOfTtXSaLAkEIX/ACaxdAVTc8gH8K3tP4K0SOStJ3sbsG0AelWDJge1Vk/1YpGPymnsZw1JnkqF35NNaoqaOyEUToc8sRVlJ4woCg+tUf4PxpadtRyVy89wXbsB6Cot3NQdqVOtFhpWLAlI9gakEvy/yqm3UU9egqSrJlrzO+cmopMSKQaZ/DTY/vj61EkZNWFaMrDtZQA2Dnvis3VNLju4Nsg3HpWtN3+gpo+9+NSRBtO6PLtVsZLC68tskdQ2O1VE5OT8wrsfFgHlScdq40ff/GsXo7I+jwVV1Keo2WMMC2PlHQdqqBWMgAHXv2rVbofrVKL/AFrCix6EHoW7eIxxAk/QVHM2G+boOc1P/ClQX3SP61dtDklNqQtlbz31yUgjLZ4wOgrsdL8LRIoN987f3QeBVvwdGi6SrKihj1IHNb9v1H0ohFJXPFxeLqSlyrQZZ6ZBbqFhijQey/1q6lm+/BfAPtU6dBVhv9Wa1SPNcm9zPeyIOCzGmNbBfvZrTk+6KhfrVAmZjWxZW6kehrFv9BtZ2PmxAZPUdq66T7o+lUZuh+lS0aQnJPRnnmp+FHjbdZuWA6A8iskwz2hKzoy+5716bZf61/x/lWVqaIwYMqke4qeRWudlLFz+F6nH2y+Yuc9TV1Bsx1IHaqzDbcsF4HoKt+n0qoq52OTaLCSbhxVpQXwAcEVTj+631q7b9vqa0ijlqaFif7G9r5dsyyuzZYMuD+BrmtWaO1ik+zTb425BfnHqCO1W9RJWVSpIO4dK53xUSLFyDglST71qjknddTyzx3qcj3MkIym44YBuw7VxTN2rR1sltRuCxJOe9Zh6mmtEeRXbc2IaSiigxCiiigAooooA19C1RLIPDciX7O7LIrxHEkMi/ddffkjHcVszavYpGzS3ovEbDPbwWa2/nEHI8xv7vqBnNcfRQBYvrqW9u5rmdt0srF2PuaKr0UAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Canker sores are open sores that are white or yellow in the middle, and red around the edges. This person has canker sores on the inside of the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16675=[""].join("\n");
var outline_f16_18_16675=null;
var title_f16_18_16676="Exaggerated CCL view";
var content_f16_18_16676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exaggerated craniocaudal (XCCL) view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The XCCL view (Panel A) includes the more posterior and lateral breast tissue than the standard CC view (Panel B).",
"    <div class=\"footnotes\">",
"     XCCL: exaggerated craniocaudal; CC: craniocaudal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16676=[""].join("\n");
var outline_f16_18_16676=null;
var title_f16_18_16677="Upper airway imaging in obstructive sleep apnea in adults";
var content_f16_18_16677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Upper airway imaging in obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16677/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16677/contributors\">",
"     Richard J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16677/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16677/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16677/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16677/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/18/16677/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway imaging is currently not part of the routine diagnostic evaluation for obstructive sleep apnea (OSA) because it can neither confirm nor exclude the disorder. Despite this, it has several roles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper airway imaging provides information about soft tissue and craniofacial anatomy, which is giving important new insights into the pathogenesis of OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/1-7\">",
"       1-7",
"      </a>",
"      ]. As an example, it is now widely accepted that enlargement of upper airway soft tissue structures and reduction in the size of craniofacial structures are important risk factors for OSA.",
"     </li>",
"     <li>",
"      Upper airway imaging can be clinically useful in patients with OSA who are imaged to identify potential sites of upper airway obstruction prior to surgical intervention, although validation of this approach has not been addressed with well-performed clinical trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The methods of upper airway imaging and the clinical settings in which upper airway imaging may be helpful are reviewed here. The diagnostic evaluation of OSA is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UPPER AIRWAY ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper airway is a complicated site that performs several physiologic functions, including respiration, vocalization, and swallowing. It can be divided anatomically into three regions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79199 graphicRef50443 \" href=\"UTD.htm?10/40/10889\">",
"     image 1A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nasopharynx (the region between the nasal turbinates and the hard palate)",
"     </li>",
"     <li>",
"      The oropharynx, which can be subdivided into the retropalatal region (also called the velopharynx) and the retroglossal region",
"     </li>",
"     <li>",
"      The hypopharynx (the region from the base of the tongue to the larynx)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The upper airway is smallest in the oropharynx in both normal subjects and patients with OSA, particularly in the retropalatal region [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Airway closure during sleep occurs in the retropalatal region in the majority of patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMAGING MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal upper airway imaging modality would be inexpensive, noninvasive, radiation-free, performed in the supine position during sleep, and dynamic (to visualize apneic events), while providing high-resolution images. Unfortunately, such an ideal modality does not exist and available modalities have both benefits and drawbacks.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) and nasopharyngoscopy are the best choices among the available options for imaging the upper airway in patients with OSA. Other modalities include cephalometry, computed tomography, acoustic reflection, and optical coherence tomography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is expensive, but offers numerous advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is widely available",
"     </li>",
"     <li>",
"      Radiation is not required",
"     </li>",
"     <li>",
"      Resolution of the soft tissue boundaries of the upper airway is excellent",
"     </li>",
"     <li>",
"      Upper airway cross-sectional area and volume can be accurately determined",
"     </li>",
"     <li>",
"      Sagittal, coronal, and axial images can be obtained (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79199 graphicRef50443 \" href=\"UTD.htm?10/40/10889\">",
"       image 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74113 graphicRef78076 \" href=\"UTD.htm?36/31/37366\">",
"       image 2A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Three-dimensional reconstruction of the airway and soft tissue structures (ie, tongue, soft palate, fat pads, and lateral pharyngeal walls) is possible (",
"      <a class=\"graphic graphic_figure graphicRef77480 \" href=\"UTD.htm?36/20/37188\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dynamic imaging is possible using ultrafast MRI",
"     </li>",
"     <li>",
"      Spectroscopic imaging for quantitation of fat and water in soft tissues can be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI may not be possible if patients have contraindications (eg, morbid obesity, claustrophobia, metallic devices). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nasopharyngoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngoscopy is a widely available and easy way to evaluate the lumen of the nasal passages, oropharynx, and vocal cords (it cannot visualize the surrounding soft tissue structures). It has been used in numerous studies to evaluate the site of airway obstruction, airway changes in patients with OSA, and the effects of mandibular repositioning devices, weight loss, or uvulopalatopharyngoplasty (UPPP) on airway caliber.",
"   </p>",
"   <p>",
"    Nasopharyngoscopy can be performed with the patient in either the sitting or supine position during wakefulness, spontaneous sleep, or sedative-induced sleep. Sleep nasopharyngoscopy is thought to be superior to awake nasopharyngoscopy at identifying sites of upper airway closure, but the supportive data are not robust. It does not involve radiation exposure, but it is invasive and requires nasal anesthesia.",
"   </p>",
"   <p>",
"    A Mueller maneuver (ie, inhalation with the nasal passages occluded and the mouth closed) performed during the procedure may simulate an obstructive apnea and provide insight into the location of upper airway obstruction. Since the Mueller maneuver is effort dependent, both the amount of negative pressure generated during the maneuver and the percentage of airway narrowing during the Mueller maneuver should be quantified in order to compare changes across subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cephalometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalometry is a lateral radiograph of the head and neck. It is widely available, easily performed, and inexpensive. However, it requires standardized radiographic equipment and techniques, as well as interpretative skills. In addition, it is performed only while the patient is sitting or standing, and cannot be performed when the patient is asleep or supine.",
"   </p>",
"   <p>",
"    Cephalometry provides two-dimensional evaluation of skeletal and soft tissue structures, giving limited information about anterior-posterior structures and no information about lateral soft tissue structures. It is useful in the evaluation of patients with bony facial abnormalities, such as retrognathia, and in the evaluation of oral appliances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link\">",
"     \"Oral appliances in the treatment of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is a widely available but expensive study that can only be performed when the patient is in the supine position. Radiation exposure limits its usefulness for performing studies during wakefulness and sleep.",
"   </p>",
"   <p>",
"    CT permits accurate determination of upper airway cross-sectional area and volume, with excellent resolution of the airway and bony structures. Images are acquired only in the axial plane, but spiral (ie, helical) CT provides direct three-dimensional volumetric reconstruction of images, allowing reconstruction of bony structures (cranium, mandible, hyoid) and the airway (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80062 \" href=\"UTD.htm?11/56/12160\">",
"     image 3",
"    </a>",
"    ). CT is also useful in the evaluation of patients with sleep apnea who are being considered for bony manipulations (dental appliances and maxillomandibular advancement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acoustic reflection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acoustic reflection is a technique that allows measurement of airway caliber on the basis of reflected sound waves. The advantages of acoustic reflection are that it is noninvasive, has no associated radiation, and can be readily repeated. However, it is performed in the sitting position and does not provide high-resolution anatomical representation of the airway or soft tissue structures. In addition, it is performed through a mouth piece and opening the mouth alters upper airway anatomy. Acoustic reflection has been used primarily as a research tool and its clinical utility has not been assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Optical coherence tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optical coherence tomography is a new technique for real-time imaging of the upper airway during wakefulness and sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/12\">",
"     12",
"    </a>",
"    ]. It involves placement of a thin, transparent catheter through the nares to the level of the mid esophagus, through which an optical probe can move freely. As the probe moves along the length of the airway, it creates images based upon changes in the characteristics of the light reflected back from the tissues.",
"   </p>",
"   <p>",
"    Optical coherence tomography avoids exposure to radiation and can be performed without sedation. The major limitation is that tissues can be hidden from the optical probes in patients with a very irregular upper airway. In addition, optical coherence tomography does not directly examine the surrounding deeper soft tissue structures. The initial evidence suggests that optical coherence tomography correlates well with CT scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway imaging is not indicated in the routine evaluation and management of most patients with OSA. However, it may be helpful in certain circumstances, such as the planning of upper airway surgery. Validation of this approach has not been addressed in well done clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Uvulopalatopharyngoplasty (UPPP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;UPPP is the most common surgical procedure for patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/13\">",
"     13",
"    </a>",
"    ]. The success rate is related to the site of obstruction, with patients demonstrating retropalatal obstruction having better results than those with retroglossal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/13\">",
"     13",
"    </a>",
"    ]. UPPP is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we consider MRI of the upper airway prior to UPPP because it can identify patients with retroglossal collapse who are not ideal candidates for this type of surgery. Whether outcome is improved among those patients selected for UPPP based upon the results of MRI has not been studied.",
"   </p>",
"   <p>",
"    Alternatively, it is reasonable to perform nasopharyngoscopy with a Mueller maneuver prior to UPPP in order to determine if collapse occurs in the retropalatal or retroglossal regions. There are no data that suggest that the Mueller maneuver mimics apneic events during sleep, but the procedure has minimal risk.",
"   </p>",
"   <p>",
"    For patients in whom MRI demonstrates primarily retroglossal narrowing or in whom nasopharyngoscopy with the Mueller maneuver demonstrates retroglossal collapse, we consider surgery directed at advancing the tongue (eg, geniohyoid advancement or maxillomandibular advancement) in addition to UPPP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maxillomandibular advancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we consider computed tomography (CT) prior to maxillomandibular advancement, a surgical procedure that moves the top of the jaw (maxilla) and the bottom of the jaw (mandible) forward. CT is the preferred imaging modality because it is superior at evaluating bony structures and can provide three-dimensional image reconstructions of the airway and bony skeleton (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80062 \" href=\"UTD.htm?11/56/12160\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cephalometry is an alternative if three-dimensional CT is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/14\">",
"     14",
"    </a>",
"    ]. However, it is a second-line modality because it is two dimensional and provides information only about anterior-posterior structures and not lateral structures. Cephalometry has successfully identified soft tissue and bony abnormalities in patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16677/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Oral appliances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalometry provides information about the posterior airway space, retrognathia, micrognathia, hyoid position, mandibular position, tongue size, and soft palate size. We consider cephalometry for some patients prior to constructing the oral (dental) appliance. However, cephalometry is not necessary for most patients who are going to be treated with an oral appliance. In particularly complicated cases, three-dimensional CT may better evaluate relationships between the airway and bony skeleton than cephalometry.",
"   </p>",
"   <p>",
"    The role of oral appliances in the treatment of OSA is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link\">",
"     \"Oral appliances in the treatment of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Oral appliances'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper airway imaging is not yet part of the routine diagnostic evaluation for obstructive sleep apnea (OSA) because it can neither confirm nor exclude the disorder. However, we have found imaging to be clinically useful in the planning of upper airway surgery, although validation of this approach has not been addressed with well-performed clinical trials. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) and nasopharyngoscopy are the best choices among the available options for imaging the upper airway in patients with OSA. Other modalities include cephalometry, computed tomography, acoustic reflection, and optical coherence tomography. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Imaging modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRI is the preferred imaging modality because upper airway soft tissue resolution is excellent and there is no radiation exposure. In addition, it is widely available and both the cross-sectional area and volume of the upper airway can be accurately determined. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasopharyngoscopy is a widely available and easy way to evaluate the lumen of the nasal passages, oropharynx, and vocal cords. It can be performed during wakefulness, spontaneous sleep, or sedative-induced sleep, with the patient in either the sitting or supine position. Nasopharyngoscopy does not involve radiation exposure, but it is invasive and requires nasal anesthesia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nasopharyngoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/1\">",
"      Schwab RJ, Gupta KB, Gefter WB, et al. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls. Am J Respir Crit Care Med 1995; 152:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/2\">",
"      Mortimore IL, Marshall I, Wraith PK, et al. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. Am J Respir Crit Care Med 1998; 157:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/3\">",
"      Ciscar MA, Juan G, Mart&iacute;nez V, et al. Magnetic resonance imaging of the pharynx in OSA patients and healthy subjects. Eur Respir J 2001; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/4\">",
"      Arens R, McDonough JM, Costarino AT, et al. Magnetic resonance imaging of the upper airway structure of children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2001; 164:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/5\">",
"      Malhotra A, Huang Y, Fogel RB, et al. The male predisposition to pharyngeal collapse: importance of airway length. Am J Respir Crit Care Med 2002; 166:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/6\">",
"      Welch KC, Foster GD, Ritter CT, et al. A novel volumetric magnetic resonance imaging paradigm to study upper airway anatomy. Sleep 2002; 25:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/7\">",
"      Schwab RJ, Pasirstein M, Pierson R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med 2003; 168:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/8\">",
"      Schwab RJ, Pasirstein M, Kaplan L, et al. Family aggregation of upper airway soft tissue structures in normal subjects and patients with sleep apnea. Am J Respir Crit Care Med 2006; 173:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/9\">",
"      Trudo FJ, Gefter WB, Welch KC, et al. State-related changes in upper airway caliber and surrounding soft-tissue structures in normal subjects. Am J Respir Crit Care Med 1998; 158:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/10\">",
"      Morrell MJ, Arabi Y, Zahn B, Badr MS. Progressive retropalatal narrowing preceding obstructive apnea. Am J Respir Crit Care Med 1998; 158:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/11\">",
"      Ritter CT, Trudo FJ, Goldberg AN, et al. Quantitative evaluation of the upper airway during nasopharyngoscopy with the M&uuml;ller maneuver. Laryngoscope 1999; 109:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/12\">",
"      Armstrong JJ, Leigh MS, Sampson DD, et al. Quantitative upper airway imaging with anatomic optical coherence tomography. Am J Respir Crit Care Med 2006; 173:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/13\">",
"      Shepard JW Jr, Thawley SE. Evaluation of the upper airway by computerized tomography in patients undergoing uvulopalatopharyngoplasty for obstructive sleep apnea. Am Rev Respir Dis 1989; 140:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16677/abstract/14\">",
"      Schwab RJ. Imaging for the snoring and sleep apnea patient. Dent Clin North Am 2001; 45:759.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7679 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16677=[""].join("\n");
var outline_f16_18_16677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UPPER AIRWAY ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMAGING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nasopharyngoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cephalometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acoustic reflection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Optical coherence tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Uvulopalatopharyngoplasty (UPPP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maxillomandibular advancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Oral appliances",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7679|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/23/40308\" title=\"diagnostic image 1A\">",
"      Normal upper airway MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/14/7396\" title=\"diagnostic image 1B\">",
"      Retropalatal anatomy MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/27/11698\" title=\"diagnostic image 2A\">",
"      Small airway OSA MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/3/35888\" title=\"diagnostic image 2B\">",
"      Small upper airway OSA MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/56/12160\" title=\"diagnostic image 3\">",
"      Upper airway anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7679|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/20/37188\" title=\"figure 1\">",
"      3D airway anatomy MRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=related_link\">",
"      Oral appliances in the treatment of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_18_16678="Maprotiline: Drug information";
var content_f16_18_16678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Maprotiline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/38/4709?source=see_link\">",
"    see \"Maprotiline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Maprotiline;",
"     </li>",
"     <li>",
"      Teva-Maprotiline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tetracyclic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate depression/anxiety:",
"     </b>",
"     Oral:  Initial: 75 mg/day for 2 weeks (lower doses may be considered in some patients); Maintenance: Increase by 25 mg as tolerated up to 150 mg/day; given in  divided doses or in a single daily dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe depression:",
"     </b>",
"     Oral: Initial: 100-150 mg/day for 2 weeks; Maintenance: Increase by 25 mg as tolerated up to 225 mg/day; given in divided doses or in a single daily dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression/anxiety:",
"     </b>",
"     Oral: Initial: 25 mg/day for 2 weeks; Maintenance: Increase by 25 mg as tolerated; usual dose: 50-75 mg/day, higher doses may be necessary in nonresponders",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16317812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 25 mg, 50 mg, 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089129.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089129.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder (MDD) or of anxiety associated with depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F191387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic pain; panic attacks",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ludiomil [multiple international markets] may be confused with Lamictal brand name for lamotrigine [U.S., Canada, and multiple international markets]; lamotrigine [U.S., Canada, and multiple international markets]; Lomotil brand name for diphenoxylate [U.S, Canada, and multiple international markets] and brand name for loperamide [Mexico, Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%), nervousness (6%), fatigue (4%), headache (4%), anxiety (3%), agitation (2%), insomnia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (6%), nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4%), tremor (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Accommodation disturbances, agranulocytosis, akathisia, arrhythmia, ataxia, confusion, delusions, disorientation, dysarthria, dysphagia, eosinophilia, extrapyramidal symptoms (EPS), hallucinations, heart block, hyper-/hypotension, impotence, interstitial pneumonitis, jaundice, liver function tests altered, mania, MI, paralytic ileus, peripheral neuropathy, photosensitivity, rash, seizure, Stevens-Johnson syndrome, stroke, syncope, thrombocytopenia, tinnitus, toxic epidermal necrolysis, urinary retention, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to maprotiline or any component of the formulation; seizure disorder; use of MAO inhibitors within 14 days; use in a patient during the acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Maprotiline is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma or increased intraocular pressure; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Maprotiline is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold; use contraindicated in patients with a history of seizure disorder. The risk of seizures may be decreased by initiating therapy at a low dose and increasing it gradually to the minimally effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Recommended to discontinue prior to elective surgery requiring general anesthesia. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F191386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Maprotiline may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Maprotiline may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F191360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12851578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not seen in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12851579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12851580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast milk concentrations of maprotiline are similar to maternal serum concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F191352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Maprotiline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $90.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $134.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $184.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F191341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and pulse rate prior to and during initial therapy; evaluate mood and somatic complaints, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased); monitor appetite and weight; ECG in older adults; CBC in patients who develop fever or sore throat during therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F191353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Keproline (TW);",
"     </li>",
"     <li>",
"      Ladiomil (HR);",
"     </li>",
"     <li>",
"      Ludiomil (AE, AR, AT, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HU, IE, IN, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ludiomil[inj.] (HU, LU);",
"     </li>",
"     <li>",
"      Lunaline (MY);",
"     </li>",
"     <li>",
"      Maprolu (HU, LU);",
"     </li>",
"     <li>",
"      Matilina (PY);",
"     </li>",
"     <li>",
"      Melodil (IL);",
"     </li>",
"     <li>",
"      Retinyl (GR);",
"     </li>",
"     <li>",
"      Sandepril (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Traditionally believed to increase the synaptic concentration of norepinephrine in the central nervous system by inhibition of its reuptake by the presynaptic neuronal membrane. However, additional receptor effects have been found including desensitization of adenyl cyclase, down regulation of beta-adrenergic receptors, and down regulation of serotonin receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F191348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to active and inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum: 27-58 hours (mean: 51 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Within 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70%); feces (30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alkalay D, Wagner WE Jr, Carlsen S, et al, \"Bioavailability and Kinetics of Maprotiline,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1980, 27(5):697-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/7371367/pubmed\" id=\"7371367\" target=\"_blank\">",
"        7371367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hrdina PD, Rovei V, Henry JF, et al, &ldquo;Comparison of Single-Dose Pharmacokinetics of Imipramine and Maprotiline in the Elderly,&rdquo;",
"      <i>",
"       Psychopharmacology",
"      </i>",
"      , 1980, 70(1):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/6775331/pubmed\" id=\"6775331\" target=\"_blank\">",
"        6775331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maguire KP, Norman TR, Burrows GD, et al, \"An Evaluation of Maprotiline Intravenous Kinetics and Comparison of Two Oral Doses,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1980, 18(3):249-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/7439244/pubmed\" id=\"7439244\" target=\"_blank\">",
"        7439244",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells BG and Gelenberg AJ, \"Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects, and Efficacy of the Antidepressant MaprotilineHydrochloride,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1981, 1(2):121-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/6765485/pubmed\" id=\"6765485\" target=\"_blank\">",
"        6765485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;New Antidepressant Medications,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1997, 45(1):24-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/18/16678/abstract-text/9171475/pubmed\" id=\"9171475\" target=\"_blank\">",
"        9171475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyss PA, Serena S, and Meier PJ, &ldquo;Dose-Dependency of Seizures in Maprotiline (Ludiomil&reg;) Intoxications,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35:341.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9588 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16678=[""].join("\n");
var outline_f16_18_16678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709026\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191362\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191391\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191366\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191367\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317812\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317813\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191344\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191329\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874839\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191387\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191397\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191389\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191349\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191333\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191386\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191337\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191360\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191338\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851578\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851579\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851580\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191352\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191341\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191353\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191332\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191348\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/38/4709?source=related_link\">",
"      Maprotiline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_18_16679="Leiomyosarcoma A";
var content_f16_18_16679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well differentiated uterine leiomyosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Mann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16679=[""].join("\n");
var outline_f16_18_16679=null;
var title_f16_18_16680="Biology and physiology of thrombopoietin";
var content_f16_18_16680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology and physiology of thrombopoietin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16680/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16680/contributors\">",
"     David J Kuter, MD, DPhil",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16680/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16680/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/18/16680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin is the physiologically relevant regulator of platelet production. Although the concept of a platelet growth factor analogous to erythropoietin had been proposed over 40 years ago, it was not until 1994 that the existence of this hematopoietic growth factor was demonstrated and the protein purified [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Although historically called \"thrombopoietin\" [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/6\">",
"     6",
"    </a>",
"    ], its discoverers also called it by several other names, including megapoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/3\">",
"     3",
"    </a>",
"    ], megakaryocyte growth and development factor (MGDF) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/4\">",
"     4",
"    </a>",
"    ], and c-Mpl ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/2\">",
"     2",
"    </a>",
"    ]. The last name is often used instead of thrombopoietin because the receptor for thrombopoietin, called c-Mpl, was discovered prior to the identification of thrombopoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/7\">",
"     7",
"    </a>",
"    ] and was instrumental in helping to purify the ligand (ie, the c-Mpl ligand) that bound to it.",
"   </p>",
"   <p>",
"    This topic will review the biology and physiology of thrombopoietin. The potential clinical applications of thrombopoietin, ranging from the management of thrombocytopenic states to improving yields from platelet apheresis, are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE OF THROMBOPOIETIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin is produced primarily in liver parenchymal cells with much smaller amounts being made in the kidney and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It is synthesized as a 353 amino acid precursor protein with a molecular weight of 36 kDa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/2,4,11\">",
"     2,4,11",
"    </a>",
"    ]. Following the removal of the 21 amino acid signal peptide, the remaining 332 amino acids undergo glycosylation to produce a 95 kDa glycoprotein (",
"    <a class=\"graphic graphic_figure graphicRef62134 \" href=\"UTD.htm?11/0/11274\">",
"     figure 1",
"    </a>",
"    ). The glycoprotein is then released into the circulation with no apparent intracellular storage in the liver or kidney.",
"   </p>",
"   <p>",
"    Thrombopoietin is an unusual hematopoietic growth factor in a number of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is much larger than most other regulators of blood cell production such as G-CSF (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      ) and erythropoietin.",
"     </li>",
"     <li>",
"      It has an unusual structure in that the first 153 amino acids of the mature protein are 23 percent homologous with human erythropoietin&nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef62134 \" href=\"UTD.htm?11/0/11274\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/12\">",
"       12",
"      </a>",
"      ] and probably 50 percent similar if conservative amino acid substitutions are considered. This region also contains four cysteine residues just like those in erythropoietin and is highly conserved among different species. Despite these similarities, thrombopoietin does not bind the erythropoietin receptor and erythropoietin does not bind to the thrombopoietin receptor.",
"     </li>",
"     <li>",
"      Amino acids 154 to 332 comprise a novel sequence that contains six-N-linked glycosylation sites and is less well conserved among different species. Structure-function studies have demonstrated that the first 153 amino acids of the c-Mpl ligand are all that is required for its thrombopoietic effect in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]; however, this truncated molecule has a markedly decreased circulatory half-life compared with the 20 to 40 hour half-life of the native protein [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/13\">",
"       13",
"      </a>",
"      ]. Presumably, the glycosylated second half of the molecule confers stability and prolongs the circulatory half-life. Similar carbohydrate sequences regulate the stability of erythropoietin&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The crystal structure of TPO has been determined and reveals an antiparallel four-helix bundle fold with two different binding sites for the TPO receptor. One has a binding constant for the TPO receptor of 3.3 x 10",
"    <sup>",
"     -9",
"    </sup>",
"    M and the other 1.1 x 10",
"    <sup>",
"     -6",
"    </sup>",
"    M [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THROMBOPOIETIN GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a single copy of the gene for thrombopoietin on human chromosome 3q27-28 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/11,12,16\">",
"     11,12,16",
"    </a>",
"    ]. The gene spans approximately 7 kb with seven exons, the first two of which are noncoding. The third exon contains part of the 5'-untranslated sequence and part of the signal peptide. The erythropoietin-like region is coded for by exons 4 to 7 and all of the carbohydrate domain is encoded by exon 7.",
"   </p>",
"   <p>",
"    Comparison with the erythropoietin gene shows conservation of the boundaries of the coding exons except for the addition of the carbohydrate domain sequence in the final exon of the thrombopoietin gene. In addition to the functional mRNA encoded (TPO-1), two other nonfunctional mRNA sequences (TPO-2 and TPO-3) are present due to alternative splicing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THROMBOPOIETIN RECEPTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin acts through the thrombopoietin receptor called c-Mpl. Prior to the identification of thrombopoietin, a murine myeloproliferative leukemia virus was identified that contained a retroviral oncogene,",
"    <strong>",
"     v-Mpl",
"    </strong>",
"    (ie,",
"    <strong>",
"     m",
"    </strong>",
"    yelo",
"    <strong>",
"     p",
"    </strong>",
"    roliferative",
"    <strong>",
"     l",
"    </strong>",
"    eukemia); this oncogene encoded the cytoplasmic portion of a membrane protein which had all the characteristics of a new hematopoietic growth factor receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the full-length homolog (",
"    <strong>",
"     c-Mpl",
"    </strong>",
"    ) was cloned [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/7\">",
"     7",
"    </a>",
"    ], its mRNA was found to be present at significant levels primarily in platelets and megakaryocytes and in a small percentage of CD34+ cells (which are early hematopoietic precursors) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/18\">",
"     18",
"    </a>",
"    ]. The identification of c-Mpl as the putative thrombopoietin receptor was further strengthened by the demonstration that the formation of megakaryocyte (Meg-CFC), but not myeloid (GM-CFC) or erythroid (E-BFU), precursors in bone marrow culture was decreased when synthesis of the c-Mpl protein was inhibited by the addition of c-Mpl antisense constructs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is now known that the thrombopoietin receptor (c-Mpl) is present on platelets and megakaryocytes and, at a lesser density, on most other hematopoietic precursor cells. Studies with human platelets indicate the presence of approximately 56 &plusmn; 17 receptors per human platelet with an affinity of 163 &plusmn; 31",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon binding to thrombopoietin, the receptor undergoes dimerization that results in a number of signal transduction events that prevent apoptosis, improve cell viability, promote growth, and possibly increase differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, binding to the receptor provides the major mechanism by which thrombopoietin is removed from the circulation by platelets and possibly megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/3,22-25\">",
"     3,22-25",
"    </a>",
"    ]. After thrombopoietin binding to platelets, the receptor-ligand complex undergoes internalization and the bound thrombopoietin is degraded [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/20,26\">",
"     20,26",
"    </a>",
"    ]. The receptor is not re-expressed on the surface [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF THROMBOPOIETIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much has been learned about the normal physiology of thrombopoietin, its effects upon megakaryocytes, platelets, and bone marrow precursor cells, and regulation of its concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effects on platelet production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin is the only physiologically relevant regulator of platelet production; it acts to \"amplify\" the basal production rate of megakaryocytes and platelets. When thrombopoietin or its receptor have been \"knocked-out\" by homologous recombination in mice, the megakaryocyte and platelet mass are reduced to approximately 10 percent of normal but the animals are healthy and do not spontaneously bleed (",
"    <a class=\"graphic graphic_figure graphicRef68869 \" href=\"UTD.htm?32/25/33181\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The neutrophil and erythrocyte counts are normal. In animals in which only one of the thrombopoietin genes has been deleted, the platelet count is reduced to approximately 65 percent of normal. Such thrombopoietin-deficient mice can increase their platelet count if treated with other thrombopoietic growth factors such as interleukin (IL)-6, IL-11, and stem cell factor (c-kit ligand) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/32\">",
"     32",
"    </a>",
"    ]. However, neither endogenous IL-6 nor endogenous IL-11 appears to be responsible for the residual platelet production in these animals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Binding of thrombopoietin to its receptor prevents apoptosis of megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/34\">",
"     34",
"    </a>",
"    ] and increases their number, size, and ploidy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link\">",
"     \"Megakaryocyte biology and the production of platelets\"",
"    </a>",
"    .) The rate of cellular maturation is probably also increased. These events are mediated via signal transduction pathways involving JAK, STAT, and other intracellular mediators (",
"    <a class=\"graphic graphic_figure graphicRef74891 \" href=\"UTD.htm?14/36/14915\">",
"     figure 3",
"    </a>",
"    ). Furthermore, the addition of thrombopoietin to CD34+ cells in culture results in the majority of cells becoming megakaryocytes and then shedding platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/35\">",
"     35",
"    </a>",
"    ]. This last step, the shedding of platelets from megakaryocytes, does not require, and actually may be inhibited by, the presence of thrombopoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A predictable response occurs after the daily administration of a recombinant form of thrombopoietin to normal baboons (",
"    <a class=\"graphic graphic_figure graphicRef59564 graphicRef72350 \" href=\"UTD.htm?12/8/12431\">",
"     figure 4A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. During the first four days of administration, bone marrow megakaryocyte ploidy rises to a maximum but there is no change in the platelet count. On day five, the platelet count begins to rise and does so at a dose-dependent rate. With continued administration of thrombopoietin, a dose-dependent plateau platelet count is attained on days 8 to 12. There is a log-linear relationship between the thrombopoietin dose and the plateau platelet count with the maximum response being a sixfold increase in the rate of platelet production. Upon stopping the thrombopoietin, the platelet count returns to its baseline over 10 days without a rebound thrombocytopenia.",
"   </p>",
"   <p>",
"    A similar time course and platelet response have been demonstrated after thrombopoietin administration to humans with no apparent toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .) There is no effect on red or white blood cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effects on platelet function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to increasing the number of megakaryocytes and platelets, thrombopoietin can also affect the function of platelets. When thrombopoietin binds to its platelet receptor, it induces phosphorylation of the c-Mpl receptor and a number of other molecules in several different signal transduction pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Although thrombopoietin does not cause platelet activation directly, it reduces the threshold for activation by other platelet agonists such as ADP and collagen by 50 percent. It is unclear if this is a clinically relevant effect posing a risk for thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effects on bone marrow precursor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thrombopoietin affects late cellular maturation events only in megakaryocytes, it and its receptor (c-Mpl) appear to play an important role in the regulation of the growth of early precursors of other lineages and even of the pluripotential stem cell [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Most evidence suggests that binding of thrombopoietin to c-Mpl enhances the survival and proliferation of already committed precursor cells, rather than a true stimulation of differentiation from stem cells. Homozygous knock-in mice, in which the gene for c-Mpl was replaced by a gene for a chimeric molecule consisting of the extracellular domain of c-Mpl and the cytoplasmic domain of the G-CSF receptor, have a normal platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/48\">",
"     48",
"    </a>",
"    ]. Since the intracellular domain of the G-CSF receptor can functionally replace the signaling activity of c-Mpl, this result suggests that thrombopoietin primarily affects cells already committed to the megakaryocyte lineage.",
"   </p>",
"   <p>",
"    When administered to normal animals, thrombopoietin increases bone marrow and peripheral blood megakaryocyte precursor cells (Meg-CFC), bone marrow megakaryocytes, and the platelet count. In addition, both erythroid and multipotential precursor cells are increased in the bone marrow and peripheral blood but without affecting the erythrocyte or neutrophil count.",
"   </p>",
"   <p>",
"    In animals made deficient in thrombopoietin or its receptor (c-Mpl), Meg-CFC are reduced by 90 to 95 percent as expected, and myeloid and erythroid precursor cells are reduced by 60 to 80 percent (",
"    <a class=\"graphic graphic_figure graphicRef79858 \" href=\"UTD.htm?28/3/28734\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. The normal neutrophil and erythrocyte counts in these animals are presumably maintained by intact feedback mechanisms mediated by G-CSF and erythropoietin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Regulation of circulating levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic thrombopoietin production is constitutive; circulating levels are determined by the circulating platelet mass (",
"    <a class=\"graphic graphic_figure graphicRef78686 \" href=\"UTD.htm?8/48/8960\">",
"     figure 6",
"    </a>",
"    ). In contrast to the production of red blood cells, which is regulated by a system that senses hypoxia and alters the rate of transcription of the erythropoietin gene, there is no such \"sensor\" of the platelet mass [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/3,22-24,49\">",
"     3,22-24,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H18#H18\">",
"     \"Regulation of erythropoiesis\", section on 'Hypoxia and EPO expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombopoietin mRNA is produced at the same rate in normal and thrombocytopenic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/50\">",
"     50",
"    </a>",
"    ] and no drug or clinical condition has been shown to increase hepatic thrombopoietin production. There is also no evidence for post-transcriptional regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma thrombopoietin concentrations are regulated by platelet production rates. Platelets and megakaryocytes contain high affinity thrombopoietin (c-Mpl) receptors that bind and clear thrombopoietin from the circulation, directly determining the circulating thrombopoietin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/20\">",
"     20",
"    </a>",
"    ]. Evidence for this includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When platelet production is decreased, as in thrombocytopenia due to megakaryocytic hypoplasia, clearance of thrombopoietin is reduced and levels rise [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/20,23\">",
"       20,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasma thrombopoietin concentrations fall after platelet transfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This sort of feedback system is not unusual in hematology. As an example, both M-CSF and G-CSF are normally regulated primarily by the amount of circulating monocytes and neutrophils, respectively. It seems as if only erythropoietin has a true sensor of the circulating blood cell mass that in turn alters production of this hematopoietic growth factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DISORDERS OF THROMBOPOIETIN AND ITS RECEPTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding of the physiology of thrombopoietin has led to consideration of a number of possible clinical disorders ranging from excess thrombopoietin production to decreased expression of the thrombopoietin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/49\">",
"     49",
"    </a>",
"    ]. Some of these postulated disorders have now been identified in humans or animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Familial thrombocythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial thrombocythemia, also called hereditary or inherited thrombocythemia or thrombocytosis, is a rare disorder that is transmitted in an autosomal dominant pattern. This disorder results from activating mutations in the genes for TPO or c-Mpl or from mutations in the genes for other proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Mutations in the TPO or c-MPL genes do not appear to be involved in the much more common, sporadic cases of essential thrombocythemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Familial essential thrombocythemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the liver is the primary site of thrombopoietin production and the thrombopoietin gene is apparently not inducible, thrombopoietin deficiency may be responsible (perhaps along with splenic sequestration) for the thrombocytopenia seen in patients with liver failure. Partial resection of the liver in animals results in a proportional decrease in the platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/55\">",
"     55",
"    </a>",
"    ] and plasma thrombopoietin concentrations appear to be inappropriately low in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/56\">",
"     56",
"    </a>",
"    ]. Upon liver transplantation into patients with liver failure, thrombopoietin levels rise and platelet counts return to normal levels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/57\">",
"     57",
"    </a>",
"    ]. This observation has led to the suggestion that thrombopoietin treatment may be an effective therapy in patients with liver failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Thrombocytopenia due to anti-thrombopoietin antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a clinical trial, administration of one recombinant thrombopoietin, PEG-rHuMGDF, caused the appearance of antibodies to the recombinant molecule in some subjects. The antibody cross-reacted with endogenous thrombopoietin and neutralized its activity. Since thrombopoietin is produced in a constitutive fashion, these patients developed thrombopoietin deficiency and severe amegakaryocytic thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. One other individual with amegakaryocytic thrombocytopenia was diagnosed with an anti-thrombopoietin antibody and no prior exposure to recombinant thrombopoietin. This patient had severe thrombocytopenia and improved following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/60\">",
"     60",
"    </a>",
"    ]. Subsequently, many patients with apparent idiopathic thrombocytopenic purpura have been screened; of 205 ITP patients screened, only one has been found to have an anti-thrombopoietin antibody as the genesis for the thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Amegakaryocytic thrombocytopenia and absent thrombopoietin receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare disorder that presents with severe thrombocytopenia and absence of megakaryocytes in the bone marrow. Some of these patients are homozygous for mutations that produce an inactive thrombopoietin receptor (c-Mpl) leading to minimal platelet production similar to that seen in c-Mpl knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/62\">",
"     62",
"    </a>",
"    ]. Some of these patients ultimately develop bone marrow aplasia, confirming the multi-potential effect of thrombopoietin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link&amp;anchor=H5#H5\">",
"     \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Amegakaryocytic thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thrombocytosis and chromosomal defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hematopoietic disorders associated with thrombocythemia or abnormal megakaryocyte formation have been associated with defects involving chromosome 3q [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/65\">",
"     65",
"    </a>",
"    ] and some myeloid leukemias associated with thrombocytosis have a characteristic rearrangement of chromosome 3q21 and 3q26 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/16\">",
"     16",
"    </a>",
"    ]. Since the thrombopoietin gene is located on chromosome 3q27-28 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/11,12,16\">",
"     11,12,16",
"    </a>",
"    ], it has been suggested that the thrombopoietin gene might be mediating these effects. However, closer analysis of these chromosome regions in these patients has not demonstrated involvement of the thrombopoietin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/16,66\">",
"     16,66",
"    </a>",
"    ] and blood thrombopoietin levels have been normal. These findings suggest that other genes close to the thrombopoietin gene may be responsible for other aspects of megakaryocyte differentiation and growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ASSAYS FOR THROMBOPOIETIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the circulating concentration of thrombopoietin has not yet been proven to be clinically useful; nonetheless, assays for TPO will soon be commercially available. Current assays are performed using thrombopoietin-dependent cell lines, soluble forms of the c-Mpl receptor, or standard antibody-based ELISA assays. The first two assays lack sensitivity to normal circulating amounts of thrombopoietin, while the ELISA assays may detect biologically inactive molecules. Although this area is rapidly evolving, several conclusions may be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombopoietin concentrations are increased 10 to 20-fold over normal in bone marrow failure states such as aplastic anemia or following myeloablative chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombopoietin levels are only slightly elevated above normal in idiopathic thrombocytopenic purpura (ITP) at platelet counts comparable to those seen in states of bone marrow failure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/67\">",
"       67",
"      </a>",
"      ]. The relatively normal plasma thrombopoietin concentration in ITP probably reflects enhanced thrombopoietin clearance by the increased mass of bone marrow megakaryocytes and by the increased flux of platelets through the circulation.",
"     </li>",
"     <li>",
"      Thrombopoietin levels are normal or slightly elevated in essential thrombocythemia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombopoietin levels may allow the distinction between states of increased (normal concentrations) versus decreased platelet production (elevated concentrations) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16680/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2367497\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin (TPO), a 95 kDa glycoprotein (",
"    <a class=\"graphic graphic_figure graphicRef62134 \" href=\"UTD.htm?11/0/11274\">",
"     figure 1",
"    </a>",
"    ) primarily produced in the liver, is the physiologically relevant regulator of platelet production, amplifying the basal production rate of megakaryocytes and platelets. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Physiology of thrombopoietin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TPO acts through its receptor (c-Mpl), present on platelets and megakaryocytes and, at a lesser density, on most other hematopoietic precursor cells. Binding of TPO to its receptor prevents apoptosis of megakaryocytes and increases their number, size, and ploidy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thrombopoietin receptor'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link\">",
"       \"Megakaryocyte biology and the production of platelets\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatic TPO production is constitutive; circulating levels are determined by the circulating platelet mass (",
"      <a class=\"graphic graphic_figure graphicRef78686 \" href=\"UTD.htm?8/48/8960\">",
"       figure 6",
"      </a>",
"      ). TPO production may be reduced in liver failure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Regulation of circulating levels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Liver failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders involving TPO or c-Mpl include the following. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Disorders of thrombopoietin and its receptor'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Familial thrombocythemia is a rare autosomal dominant disorder most commonly resulting from activating mutations in the genes for TPO or c-Mpl.",
"     </li>",
"     <li>",
"      Antibodies to TPO are a rare cause of thrombocytopenia.",
"     </li>",
"     <li>",
"      Congenital amegakaryocytic thrombocytopenia is a rare disorder with severe thrombocytopenia and absence of bone marrow megakaryocytes. Some patients are homozygous for inactivating mutations of c-Mpl.",
"     </li>",
"     <li>",
"      Acquired amegakaryocytic thrombocytopenia is a rare disorder due to an autoantibody directed against c-Mpl, most often reported in systemic lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link&amp;anchor=H5#H5\">",
"       \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Amegakaryocytic thrombocytopenia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/1\">",
"      Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem 1995; 118:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/2\">",
"      de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/3\">",
"      Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994; 91:11104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/4\">",
"      Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/5\">",
"      Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/6\">",
"      KELEMEN E, CSERHATI I, TANOS B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 1958; 20:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/7\">",
"      Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 1992; 89:5640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/8\">",
"      Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/9\">",
"      Nomura S, Ogami K, Kawamura K, et al. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997; 25:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/10\">",
"      Qian S, Fu F, Li W, et al. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 1998; 92:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/11\">",
"      Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A 1994; 91:13023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/12\">",
"      Gurney AL, Kuang WJ, Xie MH, et al. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995; 85:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/13\">",
"      Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86:4486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/14\">",
"      Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989; 73:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/15\">",
"      Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A 2004; 101:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/16\">",
"      Schnittger S, de Sauvage FJ, Le Paslier D, Fonatsch C. Refined chromosomal localization of the human thrombopoietin gene to 3q27-q28 and exclusion as the responsible gene for thrombocytosis in patients with rearrangements of 3q21 and 3q26. Leukemia 1996; 10:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/17\">",
"      Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/18\">",
"      Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/19\">",
"      Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/20\">",
"      Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999; 106:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/21\">",
"      Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/22\">",
"      Kuter DJ. Thrombopoietin: Biology and Clinical Applications. Oncologist 1996; 1:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/23\">",
"      Kuter DJ. Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apher 1996; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/24\">",
"      Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/25\">",
"      Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/26\">",
"      Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/27\">",
"      Saur SJ, Sangkhae V, Geddis AE, et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010; 115:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/28\">",
"      Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/29\">",
"      Alexander WS, Roberts AW, Nicola NA, et al. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996; 87:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/30\">",
"      Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/31\">",
"      de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/32\">",
"      Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 1996; 88:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/33\">",
"      Gainsford T, Nandurkar H, Metcalf D, et al. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 2000; 95:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/34\">",
"      Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 1997; 90:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/35\">",
"      Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/36\">",
"      Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 1996; 95:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/37\">",
"      Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/38\">",
"      Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/39\">",
"      Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/40\">",
"      Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/41\">",
"      Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/42\">",
"      Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86:4054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/43\">",
"      Kubota Y, Arai T, Tanaka T, et al. Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells 1996; 14:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/44\">",
"      Montrucchio G, Brizzi MF, Calosso G, et al. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/45\">",
"      Kaushansky K, Lin N, Grossmann A, et al. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996; 24:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/46\">",
"      Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Blood 1998; 92:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/47\">",
"      Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/48\">",
"      Stoffel R, Ziegler S, Ghilardi N, et al. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci U S A 1999; 96:698.",
"     </a>",
"    </li>",
"    <li>",
"     Kuter DJ. The regulation of platelet production. In: Thrombosis and Thrombopoietins: Molecular, Cellular, Preclinical and Clinical Biology, Kuter DJ, Hunt P, Sheridan W, et al. (Eds), Humana Press, Totowa 1997. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/50\">",
"      Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/51\">",
"      Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol 1999; 105:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/52\">",
"      Scheding S, Bergmann M, Shimosaka A, et al. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002; 42:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/53\">",
"      Wiestner A, Padosch SA, Ghilardi N, et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol 2000; 110:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/54\">",
"      Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/55\">",
"      Siemensma NP, Bathal PS, Penington DG. The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med 1975; 86:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/56\">",
"      Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/57\">",
"      Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/58\">",
"      Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/59\">",
"      Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/60\">",
"      Shiozaki H, Miyawaki S, Kuwaki T, et al. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 2000; 95:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/61\">",
"      Aledort LM, Hayward CP, Chen MG, et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/62\">",
"      Heckl D, Wicke DC, Brugman MH, et al. Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. Blood 2011; 117:3737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/63\">",
"      Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999; 96:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/64\">",
"      van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000; 110:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/65\">",
"      Pinto MR, King MA, Goss GD, et al. Acute megakaryoblastic leukaemia with 3q inversion and elevated thrombopoietin (TSF): an autocrine role for TSF? Br J Haematol 1985; 61:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/66\">",
"      Bouscary D, Fontenay-Roupie M, Chretien S, et al. Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br J Haematol 1995; 91:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/67\">",
"      Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87:4068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16680/abstract/68\">",
"      Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90:4031.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6673 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16680=[""].join("\n");
var outline_f16_18_16680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2367497\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE OF THROMBOPOIETIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THROMBOPOIETIN GENE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THROMBOPOIETIN RECEPTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSIOLOGY OF THROMBOPOIETIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effects on platelet production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effects on platelet function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effects on bone marrow precursor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Regulation of circulating levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DISORDERS OF THROMBOPOIETIN AND ITS RECEPTOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Familial thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Thrombocytopenia due to anti-thrombopoietin antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Amegakaryocytic thrombocytopenia and absent thrombopoietin receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thrombocytosis and chromosomal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ASSAYS FOR THROMBOPOIETIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2367497\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6673|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/0/11274\" title=\"figure 1\">",
"      Human TPO sequence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/25/33181\" title=\"figure 2\">",
"      TPO or c Mpl deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/36/14915\" title=\"figure 3\">",
"      Activation TPO receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/53/22366\" title=\"figure 4A\">",
"      Dose response PEG rHuMGDF A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/34/9773\" title=\"figure 4B\">",
"      Dose response PEG rHuMGDF B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/3/28734\" title=\"figure 5\">",
"      TPO and BM progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/48/8960\" title=\"figure 6\">",
"      TPO physiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=related_link\">",
"      Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_18_16681="Approach to the adult with interstitial lung disease: Diagnostic testing";
var content_f16_18_16681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult with interstitial lung disease: Diagnostic testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16681/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16681/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16681/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/18/16681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diffuse parenchymal lung diseases, often collectively referred to as the interstitial lung diseases (ILDs), are a heterogeneous group of disorders that are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations (",
"    <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The descriptive term \"interstitial\" reflects the pathologic appearance that the abnormality begins in the interstitium, but the term is somewhat misleading, as most of these disorders are also associated with extensive alteration of alveolar and airway architecture.",
"   </p>",
"   <p>",
"    The initial evaluation of patients with ILD is aimed at identifying the etiology of the ILD and its severity. The results of laboratory, radiographic, and pulmonary function tests guide the decisions about whether to pursue bronchoalveolar lavage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transbronchoscopic, thoracoscopic, or open lung biopsy.",
"   </p>",
"   <p>",
"    An overview of the diagnostic testing that is helpful in the diagnosis of ILD will be presented here (",
"    <a class=\"graphic graphic_algorithm graphicRef69044 \" href=\"UTD.htm?17/14/17632\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The clinical findings that aid in the diagnosis of ILD and the individual causes of ILD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of diffuse parenchymal lung disease (ILD) includes those ILDs that are associated with a broad range of diseases (",
"    <a class=\"graphic graphic_table graphicRef64034 \" href=\"UTD.htm?37/56/38795\">",
"     table 1",
"    </a>",
"    ), exposures (",
"    <a class=\"graphic graphic_table graphicRef80757 graphicRef62236 \" href=\"UTD.htm?4/14/4334\">",
"     table 2A-B",
"    </a>",
"    ), and drugs (",
"    <a class=\"graphic graphic_table graphicRef56668 \" href=\"UTD.htm?26/50/27437\">",
"     table 3",
"    </a>",
"    ). ILD may also occur as an idiopathic condition (",
"    <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"     algorithm 1",
"    </a>",
"    ). The treatment choices and prognosis vary among the different causes and types of ILD, so ascertaining the correct diagnosis is important.",
"   </p>",
"   <p>",
"    A variety of infectious processes cause interstitial opacities on chest radiograph, including fungal pneumonias (eg, coccidioidomycosis, cryptococcosis, Pneumocystis jirovecii), atypical bacterial pneumonias, and viral pneumonias. These infections often occur in immunocompromised hosts and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common identifiable causes of ILD are exposure to occupational and environmental agents (",
"    <a class=\"graphic graphic_table graphicRef80757 graphicRef62236 \" href=\"UTD.htm?4/14/4334\">",
"     table 2A-B",
"    </a>",
"    ), especially to inorganic or organic dusts, and drug-induced pulmonary toxicity (",
"    <a class=\"graphic graphic_table graphicRef56668 \" href=\"UTD.htm?26/50/27437\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22234?source=see_link\">",
"     \"Chronic beryllium disease (berylliosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33145?source=see_link\">",
"     \"Silicosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=see_link\">",
"     \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link\">",
"     \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ILD can potentially complicate the course of most of the connective tissue diseases (eg,",
"    <span class=\"nowrap\">",
"     polymyositis/dermatomyositis,",
"    </span>",
"    rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease).",
"   </p>",
"   <p>",
"    Idiopathic causes of ILD include sarcoidosis, cryptogenic organizing pneumonia, and the idiopathic interstitial pneumonias (",
"    <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"     algorithm 1",
"    </a>",
"    ). The idiopathic interstitial pneumonias have been further characterized: idiopathic pulmonary fibrosis (usual interstitial pneumonia), desquamative interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease, acute interstitial pneumonia, and nonspecific interstitial pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine laboratory evaluation typically includes biochemical tests to evaluate hepatic and renal function; hematologic tests with differential blood count to check for evidence of anemia, polycythemia, leukocytosis, or eosinophilia; urinalysis; and creatine kinase for myositis (",
"    <a class=\"graphic graphic_table graphicRef55597 \" href=\"UTD.htm?26/12/26828\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/1\">",
"     1",
"    </a>",
"    ]. Depending on the clinical situation and results of hepatic function tests, hepatitis serology and HIV testing may be appropriate.",
"   </p>",
"   <p>",
"    Serologic studies are obtained to ensure that hypersensitivity pneumonitis and subclinical connective tissue disease are not overlooked. However, not all patients with positive serologic tests will develop a well-differentiated connective tissue disease. We typically obtain a hypersensitivity precipitin panel, anti-nuclear antibodies (ANA), rheumatoid factor, anti-topoisomerase (anti-Scl70), and anti-neutrophil cytoplasmic antibodies (ANCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/2\">",
"     2",
"    </a>",
"    ]. We also obtain anti-JO-1 antibodies even in the absence of clinical myositis, as ILD precedes the onset of myositis in about 70 percent of patients with the anti-synthetase syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a positive ANA, we usually obtain anti-double-stranded DNA and anti-extractable nuclear antigen antibodies (anti-Sm, anti-ribonucleoprotein) to further evaluate for systemic lupus erythematosus and mixed connective tissue disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients presenting with pulmonary hemorrhage, we typically test for antiglomerular basement membrane antibodies, ANCA, ANA, antiphospholipid antibodies, and antistreptococcal antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H13#H13\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Clues to a specific etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally do not find it helpful diagnostically to obtain a C-reactive protein level or a sedimentation rate, as these are entirely nonspecific. Hypergammaglobulinemia is commonly observed in patients with ILD, but is also nondiagnostic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum angiotensin converting enzyme (ACE) levels are generally not helpful in the initial evaluation of ILD, because of the low sensitivity and specificity of the test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Serum ACE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of serum markers suggestive of ILD have been identified, including surfactant protein A and B (SP-A, SP-B), monocyte chemoattractant protein-1 (MCP-1), and Kerbs von Lungren (KL)-6, a circulating, high-molecular weight glycoprotein expressed by type II pneumocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/4-6,8,9\">",
"     4-6,8,9",
"    </a>",
"    ]. In one report, the receiver operating characteristics of these four markers were evaluated in a mixed population of patients with idiopathic ILD, collagen vascular disease-associated ILD, and controls with and without pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/5\">",
"     5",
"    </a>",
"    ]. KL-6 was associated with the highest sensitivity, specificity and diagnostic accuracy for the presence of ILD (94, 96, and 94 percent, respectively). The clinical role of these serum markers in the diagnosis of ILD is unclear and these tests are generally not commercially available.",
"   </p>",
"   <p>",
"    In the future, the KL-6 assay may help to identify and monitor interstitial lung disease in patients with rheumatoid arthritis and other connective tissue diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     \"Interstitial lung disease in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common radiographic abnormality on routine chest radiograph is a reticular pattern (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82072 \" href=\"UTD.htm?22/20/22854\">",
"     image 1",
"    </a>",
"    ); however, nodular (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67606 \" href=\"UTD.htm?40/10/41126\">",
"     image 2",
"    </a>",
"    ) or mixed patterns (alveolar filling and increased interstitial markings) are not unusual (",
"    <a class=\"graphic graphic_table graphicRef59082 graphicRef69806 graphicRef82499 \" href=\"UTD.htm?14/24/14735\">",
"     table 5A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the chest radiograph is useful in suggesting the presence of ILD, the correlation between the radiographic pattern and the stage of disease (clinical or histopathologic) is generally poor. Only the radiographic finding of honeycombing (small cystic spaces) correlates with pathologic findings and, when present, portends a poor prognosis.",
"   </p>",
"   <p>",
"    In the evaluation of ILD, it is important to review all previous chest films to assess the rate of change in disease activity.",
"   </p>",
"   <p>",
"    The chest radiograph is normal in as many as 10 percent of patients with some forms of ILD, particularly those with hypersensitivity pneumonitis. Thus, a complete evaluation should be undertaken even if a symptomatic patient has a normal chest radiograph or an asymptomatic patient has radiographic evidence of ILD. Failure to adequately evaluate such individuals may lead to disease progression that is irreversible by the time the patient seeks additional medical attention. The radiologic patterns and disease distributions associated with specific ILDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=see_link\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution computed tomography (HRCT) is obtained in almost all patients with diffuse pulmonary parenchymal disease. We typically obtain both supine and prone images to avoid confusing dependent atelectasis with interstitial opacities. Comparing inspiratory and expiratory views is helpful when bronchiolitis is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link&amp;anchor=H12#H12\">",
"     \"Bronchiolitis in adults\", section on 'Chest imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HRCT provides greater diagnostic accuracy than the plain chest radiograph, but several series have reported inconsistency among observers in the accuracy of differentiating between the ILDs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In addition, it is difficult to extrapolate from the diagnostic accuracy in carefully controlled series to that in routine clinical practice because of variability in radiologic experience and scanning protocols.",
"   </p>",
"   <p>",
"    However, certain HRCT findings help to narrow the differential diagnosis of ILD. The correlations between the various HRCT patterns and likely diagnoses are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef51094 graphicRef64841 \" href=\"UTD.htm?28/52/29517\">",
"     table 6A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/7,13-16\">",
"     7,13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral symmetric hilar adenopathy and upper lung zone reticular opacities suggest sarcoidosis or another granulomatous disease",
"     </li>",
"     <li>",
"      Pleural plaques with linear calcification suggest asbestosis",
"     </li>",
"     <li>",
"      Centrilobular nodules that spare the subpleural region are seen in hypersensitivity pneumonitis, sarcoidosis, Langerhans cell histiocytosis and also respiratory, follicular, and cellular bronchiolitis",
"     </li>",
"     <li>",
"      Irregular cysts associated with nodules in the upper and middle lung zones suggest pulmonary Langerhans cell histiocytosis",
"     </li>",
"     <li>",
"      Subpleural and bibasilar reticular opacities associated with honeycomb changes and traction bronchiectasis are suggestive of idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonitis, or ILD-associated with rheumatoid arthritis",
"     </li>",
"     <li>",
"      In an asymptomatic patient, diffuse, calcified, nodular, interstitial opacities may reflect healed varicella-zoster pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gallium-67 lung scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium-67 lung scanning is of limited value as a means of evaluating patients with ILD. We do not obtain gallium-67 lung scans in the evaluation of patients with ILD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     FDG-PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of (18)F-2-deoxy-2-fluoro-D-glucose (FDG) positron emission tomography (PET) scanning in the evaluation of ILD is unclear. In a series of 35 patients with pulmonary lymphangitic carcinomatosis, diffuse uptake of FDG was noted in 30 patients and focal uptake in four [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/18\">",
"     18",
"    </a>",
"    ]. However, positive FDG uptake can also be seen in sarcoidosis and pulmonary Langerhans cell histiocytosis. We do not typically obtain PET scans in the evaluation of ILD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'PET scan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link&amp;anchor=H10#H10\">",
"     \"Pulmonary Langerhans cell histiocytosis\", section on 'Fluorodeoxyglucose-PET scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CARDIAC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram is typically obtained to evaluate for evidence of pulmonary hypertension or concurrent cardiac disease. If heart failure is suspected, a serum brain natriuretic peptide level is measured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the patient with dyspnea\", section on 'Heart failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the patient with dyspnea\", section on 'Plasma BNP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no clear guidelines on when to obtain a transthoracic echocardiogram in a patient with ILD. A reasonable approach is to perform echocardiography in patients with an abnormal electrocardiogram, suspected heart failure, rapid onset of radiographic findings, or a moderate to severe reduction in diffusing capacity (DLCO); this later feature may suggest concomitant pulmonary hypertension. If it has not been performed previously, echocardiography is typically performed before obtaining a surgical lung biopsy to exclude occult heart failure. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diffusing capacity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link&amp;anchor=H12#H12\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Echocardiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment for concomitant pulmonary hypertension is important because the presence of pulmonary hypertension may be a clue to the underlying ILD etiology (eg, systemic sclerosis, mixed connective tissue disease) or severity. In addition, among patients with idiopathic pulmonary fibrosis (IPF), pulmonary hypertension is associated with increased disease severity and decreased survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=see_link&amp;anchor=H15#H15\">",
"     \"Pulmonary hypertension associated with interstitial lung disease\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PULMONARY FUNCTION TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete lung function testing (spirometry, lung volumes, diffusing capacity) and resting and exercise pulse oximetry are obtained in virtually all patients with suspected ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/1,19,20\">",
"     1,19,20",
"    </a>",
"    ]. Measurement of lung function is most helpful for assessing the severity of lung involvement in patients with ILD. In addition, the finding of an obstructive, restrictive, or mixed pattern is useful in narrowing the number of possible diagnoses.",
"   </p>",
"   <p>",
"    Arterial blood gases are often obtained to corroborate results of pulse oximetry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Spirometry and lung volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the interstitial disorders have a restrictive defect with reductions in total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) are decreased, but usually the changes are in proportion to the decreased lung volumes; thus, the",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio is usually normal or increased (",
"    <a class=\"graphic graphic_figure graphicRef67232 \" href=\"UTD.htm?14/31/14846\">",
"     figure 1",
"    </a>",
"    ). The reductions in lung volumes become more pronounced as lung stiffness increases with disease progression (",
"    <a class=\"graphic graphic_figure graphicRef59121 \" href=\"UTD.htm?1/4/1102\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Restrictive lung disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, an interstitial pattern on chest radiograph accompanied by obstructive airflow limitation (ie, a reduced",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio) on lung function testing is suggestive of any of the following processes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Lymphangioleiomyomatosis",
"     </li>",
"     <li>",
"      Hypersensitivity pneumonitis",
"     </li>",
"     <li>",
"      Pulmonary Langerhans cell histiocytosis",
"     </li>",
"     <li>",
"      Tuberous sclerosis and pulmonary lymphangioleiomyomatosis",
"     </li>",
"     <li>",
"      Combined COPD and ILD",
"     </li>",
"     <li>",
"      Constrictive bronchiolitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diffusing capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in the diffusing capacity (DLCO) is a common, but nonspecific finding in ILD. The decrease in DLCO is due, in part, to effacement of the alveolar capillary units but more importantly, to the extent of mismatching of ventilation and perfusion of the alveoli. In some ILDs, particularly sarcoidosis, there can be considerable reduction in lung volumes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe hypoxemia but normal or only slightly reduced DLCO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Moderate to severe reduction of DLCO in the presence of normal lung volumes in a patient with ILD suggests one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Combined emphysema and ILD",
"     </li>",
"     <li>",
"      Combined ILD and pulmonary vascular disease",
"     </li>",
"     <li>",
"      Pulmonary Langerhans cell histiocytosis",
"     </li>",
"     <li>",
"      Pulmonary lymphangioleiomyomatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary vascular disease, and thus a reduction in DLCO, can develop in patients with ILD as a consequence of hypoxemic vasoconstriction, thromboembolic disease complicating the ILD, or a disease with both ILD and pulmonary hypertension, such as scleroderma.",
"   </p>",
"   <p>",
"    In general, the severity of the DLCO reduction does",
"    <strong>",
"     not",
"    </strong>",
"    correlate well with disease prognosis, unless the DLCO is less than 35 percent of predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/23\">",
"     23",
"    </a>",
"    ]. Longitudinal changes in DLCO have been used to assess disease progression or regression. Due to difficulties with reproducibility in measuring DLCO, a change of 15 percent is needed to identify a true change in disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gas exchange at rest and on exertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resting arterial blood gases may be normal in early ILD or may reveal hypoxemia (secondary to mismatching of ventilation to perfusion) and respiratory alkalosis. Carbon dioxide retention is rare and usually a manifestation of end-stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal values for resting arterial partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) or pulse O",
"    <sub>",
"     2",
"    </sub>",
"    saturation do not rule out significant hypoxemia during exercise or sleep. Thus, it is important to perform exercise testing with serial measurement of arterial blood gases or pulse oximetry (",
"    <a class=\"graphic graphic_figure graphicRef80997 \" href=\"UTD.htm?0/16/270\">",
"     figure 3",
"    </a>",
"    ). Exercise testing may take the form of a cardiopulmonary exercise test, a six-minute walk test, or informal ambulatory oximetry including a stair climb to replicate the patient's usual daily activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Oxygen desaturation during exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a cardiopulmonary exercise test, arterial oxygen desaturation, a failure to decrease dead space appropriately with exercise (ie, a high",
"    <span class=\"nowrap\">",
"     VD/VT",
"    </span>",
"    ratio), and an excessive increase in respiratory rate with a lower than expected recruitment of tidal volume provide useful information regarding physiologic abnormalities and the extent of disease. Full cardiopulmonary exercise testing is not necessary for every patient with ILD. However, when the significance of symptoms or radiographic abnormalities is unclear, a normal maximal cardiopulmonary exercise test effectively excludes significant ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial assessment of resting and exercise gas exchange is one of the methods used to follow ILD activity and responsiveness to treatment, especially in idiopathic pulmonary fibrosis (IPF). As an example, the results of six-minute walk testing (6MWT) have correlated with prognosis in several studies of IPF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Pulse oximetry desaturation to 88 percent or below during the 6MWT is associated with a median survival of 3.21 years compared with a median survival of 6.63 years in those who did not desaturate below 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/25\">",
"     25",
"    </a>",
"    ]. The distance walked during the 6MWT is a reproducible measure and correlates with the maximal oxygen consumption (VO",
"    <sub>",
"     2",
"    </sub>",
"    max) obtained during a maximal exercise test [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ROLE OF BRONCHOALVEOLAR LAVAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL) is performed during flexible fiberoptic bronchoscopy to obtain samples of cells and fluid from the distal airways and alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/28\">",
"     28",
"    </a>",
"    ]. The lavage fluid is sent for cell counts, cultures for mycobacterial, viral and fungal pathogens, and cytologic analysis (",
"    <a class=\"graphic graphic_table graphicRef55231 \" href=\"UTD.htm?24/0/24588\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64886 \" href=\"UTD.htm?15/50/16171\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76619 \" href=\"UTD.htm?7/23/7547\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63294 \" href=\"UTD.htm?41/19/42299\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Virtually all patients presenting with hemoptysis and radiographic ILD should undergo BAL promptly to confirm an alveolar source of bleeding and identify any infectious etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H16#H16\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Hemorrhagic BAL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with an acute onset of ILD will undergo BAL to evaluate for acute eosinophilic pneumonia, alveolar hemorrhage, malignancy, and opportunistic or atypical infection, which can often be diagnosed on the basis of BAL findings (",
"    <a class=\"graphic graphic_table graphicRef55231 \" href=\"UTD.htm?24/0/24588\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Eosinophilic BAL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H16#H16\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Hemorrhagic BAL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\", section on 'Invasive procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a subacute or chronic presentation of ILD, BAL is often performed when sarcoidosis, hypersensitivity pneumonitis, pulmonary Langerhans histiocytosis, or infection are suspected based on the radiographic pattern (eg, upper lobe predominance of reticular opacities, hilar lymphadenopathy, irregular cystic airspaces), history of exposure (eg, bird keeping, farming), or concomitant clinical findings (eg, hemoptysis, renal insufficiency). In these patients, the results of BAL analysis may be used to narrow the differential diagnostic possibilities between various types of ILD, but tissue confirmation is usually required (",
"    <a class=\"graphic graphic_table graphicRef69908 \" href=\"UTD.htm?3/47/3835\">",
"     table 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63294 \" href=\"UTD.htm?41/19/42299\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H35#H35\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H3#H3\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Lymphocytic BAL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link&amp;anchor=H13#H13\">",
"     \"Pulmonary Langerhans cell histiocytosis\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BAL is less likely to be helpful in patients with a radiographic pattern suggestive of idiopathic pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. BAL does not have an established role in the assessment of ILD progression or response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ROLE OF LUNG BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the results of the above evaluation do not allow the clinician to make a confident diagnosis of a given type or stage of ILD, lung biopsy with careful examination of lung tissue may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16681/abstract/1,31\">",
"     1,31",
"    </a>",
"    ]. This decision must be made on a case-by-case basis, weighing the morbidity of the procedure, the likely diagnoses, the toxicity of therapy, and the values and preferences of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically obtain a lung biopsy in patients with atypical or progressive symptoms and signs (age less than 50 years, fever, weight loss, hemoptysis, signs of vasculitis), atypical radiographic features, unexplained extrapulmonary manifestations, rapid clinical deterioration, or sudden change in radiographic appearance.",
"   </p>",
"   <p>",
"    Occasionally, the noninvasive evaluation will yield conflicting findings, which may require a lung biopsy for clarification. As an example, a cardiopulmonary exercise test may indicate that ILD is the most likely cause of a patient's symptoms and signs, while their high resolution computed tomography (HRCT) shows only minimal interstitial changes. In this situation, a lung biopsy may be indicated to confirm that an ILD, rather than another process, is the cause of the patient's clinical findings, thus enabling appropriate treatment.",
"   </p>",
"   <p>",
"    Lung biopsy may also be indicated to exclude neoplastic and infectious processes. As an example, sarcoidosis can sometimes have a similar HRCT appearance to lymphangitic carcinomatosis or hypersensitivity pneumonitis (",
"    <a class=\"graphic graphic_table graphicRef51094 graphicRef64841 \" href=\"UTD.htm?28/52/29517\">",
"     table 6A-B",
"    </a>",
"    ). Or, a patient with rheumatoid arthritis might develop ILD due to the underlying disease, drugs used in treatment, or tuberculosis.",
"   </p>",
"   <p>",
"    Patients with minimal symptoms, signs, physiologic impairment, and radiographic abnormalities may prefer close observation over several months with interval repetition of pulmonary function tests and HRCT, rather than proceeding immediately to lung biopsy. Other patients prefer to undergo a lung biopsy sooner to obtain a definitive diagnosis, rather than watchful waiting.",
"   </p>",
"   <p>",
"    Lung biopsy may be obtained by flexible fiberoptic bronchoscopy, video-assisted thoracoscopic (VATS) biopsy, or open lung biopsy. These techniques and the reasons to choose one over another are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link&amp;anchor=H6#H6\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Specimen collection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histopathologic pattern found on the lung biopsy specimen is evaluated in combination with the clinical information to determine the diagnosis. The histopathologic patterns of common interstitial lung diseases are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H11388814#H11388814\">",
"     \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Interpretation of histopathologic patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=see_link\">",
"       \"Patient information: Idiopathic pulmonary fibrosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"       \"Patient information: Interstitial lung disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse parenchymal lung diseases, often collectively referred to as interstitial lung diseases (ILDs), are a heterogeneous group of disorders that are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations (",
"      <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of diffuse parenchymal lung diseases includes a broad range of diseases, from those that are associated with a long list of known causes (",
"      <a class=\"graphic graphic_table graphicRef80757 graphicRef62236 \" href=\"UTD.htm?4/14/4334\">",
"       table 2A-B",
"      </a>",
"      ) and associations (",
"      <a class=\"graphic graphic_table graphicRef64034 \" href=\"UTD.htm?37/56/38795\">",
"       table 1",
"      </a>",
"      ) to those that are idiopathic (",
"      <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment choices and prognosis vary among the different causes and types of ILD, so ascertaining the correct diagnosis is important. An algorithm for evaluating a patient with ILD is provided in the figure (",
"      <a class=\"graphic graphic_algorithm graphicRef69044 \" href=\"UTD.htm?17/14/17632\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The routine laboratory evaluation is often nonspecific, but should include biochemical tests to evaluate hepatic and renal function; hematologic tests with differential blood count to check for evidence of anemia, polycythemia, leukocytosis, or eosinophilia; urinalysis; and creatine kinase for myositis (",
"      <a class=\"graphic graphic_table graphicRef55597 \" href=\"UTD.htm?26/12/26828\">",
"       table 4",
"      </a>",
"      ). Additional serologic testing is often obtained, based on the results of the clinical findings. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High resolution computed tomography (HRCT) is obtained in almost all patients with diffuse pulmonary parenchymal disease. We typically obtain both supine and prone images to avoid confusing dependent atelectasis with interstitial opacities. Expiratory views are helpful when a condition associated with air-trapping (ie, bronchiolitis) is suspected. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"       \"High resolution computed tomography of the lungs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain HRCT findings help to narrow the differential diagnosis of ILD. The correlations between the various HRCT patterns and likely diagnoses are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef51094 graphicRef64841 \" href=\"UTD.htm?28/52/29517\">",
"       table 6A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"       \"High resolution computed tomography of the lungs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An electrocardiogram is typically obtained to evaluate for evidence of pulmonary hypertension or concurrent cardiac disease. If heart failure is suspected, a serum brain natriuretic peptide level is measured. An echocardiogram is also obtained when there is suspicion for heart failure or pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiac evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete lung function testing (spirometry, lung volumes, diffusing capacity) and exercise pulse oximetry are obtained in all patients with suspected ILD. Resting room air arterial blood gases are often obtained to corroborate findings of pulse oximetry. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pulmonary function testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In virtually everyone presenting with hemoptysis and radiographic ILD, BAL is performed promptly to confirm an alveolar source of bleeding and identify infectious etiologies, if present. The majority of patients with an acute onset of ILD will also undergo bronchoalveolar lavage (BAL) to evaluate for alveolar hemorrhage, malignancy, and opportunistic or atypical infection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Role of bronchoalveolar lavage'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"       \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with a more chronic presentation, the BAL is less helpful, as the findings are typically nonspecific. However, when sarcoidosis, hypersensitivity pneumonitis, pulmonary Langerhans histiocytosis, or infection are suspected based on the radiographic pattern, history of exposure, or concomitant clinical findings, BAL may help to narrow the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Role of bronchoalveolar lavage'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"       \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When it is not possible to make a confident diagnosis or to stage the disease after an initial noninvasive evaluation, lung biopsy with careful examination of lung tissue may be necessary. This decision is made on a case-by-case basis, weighing the morbidity of the procedure, the likely diagnoses, the toxicity of therapy, and the values and preferences of the patient. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Role of lung biopsy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"       \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/1\">",
"      Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/2\">",
"      Mittoo S, Gelber AC, Christopher-Stine L, et al. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/3\">",
"      Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/4\">",
"      Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995; 108:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/5\">",
"      Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/6\">",
"      Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/7\">",
"      Pipavath S, Godwin JD. Imaging of interstitial lung disease. Clin Chest Med 2004; 25:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/8\">",
"      Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/9\">",
"      Al-Salmi QA, Walter JN, Colasurdo GN, et al. Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease. Chest 2005; 127:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/10\">",
"      Aziz ZA, Wells AU, Hansell DM, et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004; 59:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/11\">",
"      Wells A. Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis. Thorax 1998; 53:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/12\">",
"      Johkoh T, M&uuml;ller NL, Cartier Y, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999; 211:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/13\">",
"      Wittram C, Mark EJ, McLoud TC. CT-histologic correlation of the ATS/ERS 2002 classification of idiopathic interstitial pneumonias. Radiographics 2003; 23:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/14\">",
"      Lynch DA, Travis WD, M&uuml;ller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005; 236:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/15\">",
"      Elliot TL, Lynch DA, Newell JD Jr, et al. High-resolution computed tomography features of nonspecific interstitial pneumonia and usual interstitial pneumonia. J Comput Assist Tomogr 2005; 29:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/16\">",
"      Sumikawa H, Johkoh T, Ichikado K, et al. Usual interstitial pneumonia and chronic idiopathic interstitial pneumonia: analysis of CT appearance in 92 patients. Radiology 2006; 241:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/17\">",
"      Floudas CS, Kanakis MA, Andreopoulos A, Vaiopoulos GA. Nodular lung calcifications following varicella zoster virus pneumonia. QJM 2008; 101:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/18\">",
"      Prakash P, Kalra MK, Sharma A, et al. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis. AJR Am J Roentgenol 2010; 194:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/19\">",
"      Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/20\">",
"      Caminati A, Harari S. Which prognostic indicator should we use for clinical practice in the initial evaluation and follow-up of IIP: should we depend on PFT, HRCT or...what? Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 Suppl 1:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/21\">",
"      Lama VN, Martinez FJ. Resting and exercise physiology in interstitial lung diseases. Clin Chest Med 2004; 25:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/22\">",
"      Chetta A, Marangio E, Olivieri D. Pulmonary function testing in interstitial lung diseases. Respiration 2004; 71:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/23\">",
"      Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/24\">",
"      Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005; 25:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/25\">",
"      Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/26\">",
"      Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/27\">",
"      Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171:1150.",
"     </a>",
"    </li>",
"    <li>",
"     Costabel U, Guzman J. Bronchoalveolar lavage. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/29\">",
"      Kinder BW, Wells AU. The art and science of diagnosing interstitial lung diseases. Am J Respir Crit Care Med 2009; 179:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/30\">",
"      Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16681/abstract/31\">",
"      Raghu G. Interstitial lung disease: a diagnostic approach. Are CT scan and lung biopsy indicated in every patient? Am J Respir Crit Care Med 1995; 151:909.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4358 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16681=[""].join("\n");
var outline_f16_18_16681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LABORATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gallium-67 lung scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FDG-PET scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CARDIAC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PULMONARY FUNCTION TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Spirometry and lung volumes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diffusing capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gas exchange at rest and on exertion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ROLE OF BRONCHOALVEOLAR LAVAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ROLE OF LUNG BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4358|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/30/43502\" title=\"algorithm 1\">",
"      Classification diffuse lung dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?17/14/17632\" title=\"algorithm 2\">",
"      Approach to patient with ILD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4358|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/20/22854\" title=\"diagnostic image 1\">",
"      Reticular opacities PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/10/41126\" title=\"diagnostic image 2\">",
"      Small nodules PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4358|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/31/14846\" title=\"figure 1\">",
"      Maximal flow volume curve IPF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/4/1102\" title=\"figure 2\">",
"      IPF static deflation volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/16/270\" title=\"figure 3\">",
"      Exercise testing in IPF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/56/38795\" title=\"table 1\">",
"      Diseases associated with ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/11/41148\" title=\"table 2A\">",
"      Exposures associated with ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/21/42332\" title=\"table 2B\">",
"      Exposures associated with ILD I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/50/27437\" title=\"table 3\">",
"      Drugs that induce ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/12/26828\" title=\"table 4\">",
"      Laboratory findings in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/11/11453\" title=\"table 5A\">",
"      Radiographic patterns in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/20/37197\" title=\"table 5B\">",
"      Radiographic patterns in ILD I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/29/30172\" title=\"table 5C\">",
"      Radiographic patterns in ILD II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/11/22716\" title=\"table 6A\">",
"      HRCT patterns in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/29/21980\" title=\"table 6B\">",
"      HRCT patterns in ILD I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/0/24588\" title=\"table 7\">",
"      Diagnostic value of BAL in ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/50/16171\" title=\"table 8\">",
"      ILD associated BAL eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/23/7547\" title=\"table 9\">",
"      ILD associated BAL neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/19/42299\" title=\"table 10\">",
"      T lymphocyte ratios in disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/47/3835\" title=\"table 11\">",
"      ILD with BAL lymphocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22234?source=related_link\">",
"      Chronic beryllium disease (berylliosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=related_link\">",
"      Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=related_link\">",
"      Interpretation of lung biopsy results in interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=related_link\">",
"      Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=related_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16889?source=related_link\">",
"      Pulmonary hypertension associated with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33145?source=related_link\">",
"      Silicosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_18_16682="Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)";
var content_f16_18_16682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16682/contributors\">",
"     Paul E Holtzheimer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16682/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/18/16682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/18/16682/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/18/16682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31837777\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with unipolar major depression do not respond to standard treatment with pharmacotherapy and psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and are thus candidates for noninvasive neuromodulation procedures, including repetitive transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Although ECT is more efficacious than repetitive TMS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], patients may prefer repetitive TMS because it is better tolerated and unlike ECT, TMS does not require general anesthesia and induction of seizures. &nbsp;",
"   </p>",
"   <p>",
"    This topic reviews transcranial magnetic stimulation for treating unipolar major depression in adults. Other neuromodulation procedures, including ECT, magnetic seizure therapy, focal electrically administered seizure therapy, transcranial direct current stimulation, transcranial low voltage pulsed electromagnetic fields, cranial electrical stimulation, vagus nerve stimulation, deep brain stimulation, direct cortical stimulation, and ablative neurosurgery, are discussed separately, as is treatment resistant depression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=see_link\">",
"       \"Unipolar depression in adults: Overview of neuromodulation procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"       \"Overview of electroconvulsive therapy (ECT) for adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5097?source=see_link\">",
"       \"Unipolar depression in adults: Treatment with surgical approaches\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31837784\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive transcranial magnetic stimulation (TMS) treats major depression by modulating activity in cortical regions and associated neural circuits [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8\">",
"     8",
"    </a>",
"    ]. The intervention uses an alternating current passed through a metal coil placed against the scalp to generate rapidly alternating magnetic fields, which pass through the skull nearly unimpeded and induce electric currents that depolarize neurons in a focal area of the surface cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The magnetic field generated by repetitive TMS is comparable to that of a standard magnetic resonance imaging (MRI) device (approximately 1.5 to 3 Tesla) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/12\">",
"     12",
"    </a>",
"    ]. Repetitive TMS is comparable to electroconvulsive therapy (ECT) in that both are noninvasive neuromodulation therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=see_link&amp;anchor=H29061923#H29061923\">",
"     \"Unipolar depression in adults: Overview of neuromodulation procedures\", section on 'Noninvasive neuromodulation therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TMS can be delivered either as a single pulse (stimulus) or as a series of pulses called a train; stimulation with a train is called repetitive TMS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/12\">",
"     12",
"    </a>",
"    ]. The depth of stimulation is approximately two to three cm beneath the coil and most repetitive TMS devices depolarize cortical neurons in a circular area with a diameter of about two to three cm. Parameters of repetitive TMS include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequency &ndash; number of magnetic pulses per second (hertz)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High (fast) frequency refers to stimulation delivered at &gt;1 pulse per second (typically 10 pulses per second)",
"     </li>",
"     <li>",
"      Low (slow) frequency denotes stimulation delivered at &le; 1 pulse per second",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensity &ndash; expressed as a percentage of the resting motor threshold, which is established by stimulating the motor cortex and determining the minimum amount of energy that is required to evoke a motor response in a specific muscle group (generally the contralateral small hand muscles). The motor response is assessed visually or with electromyography. Intensity is generally set at 100 to 120 percent of resting motor threshold.",
"     </li>",
"     <li>",
"      Train duration (on time; eg, 4 seconds)",
"     </li>",
"     <li>",
"      Intertrain interval &ndash; time between successive trains (off time, eg, 26 seconds)",
"     </li>",
"     <li>",
"      Number of trains per session (eg, 75)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies report the number of pulses per session (eg, 3000), which is calculated from the frequency, train duration, and number of trains per session.",
"   </p>",
"   <p>",
"    In addition to its use as a therapeutic tool, TMS has been used in attempts to map brain functions and connections between different brain regions, and assess cortical excitability and brain-behavior relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174821082\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical trials of repetitive TMS for unipolar major depression have stimulated a single cortical site [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8\">",
"     8",
"    </a>",
"    ]. Generally, the left dorsal lateral prefrontal cortex is targeted, and neuroimaging of depressed patients has found hypoactivity in the dorsal lateral prefrontal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/14\">",
"     14",
"    </a>",
"    ]. However, some trials have stimulated the right dorsal lateral prefrontal cortex, and other trials have sequentially or simultaneously stimulated two cortical sites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174821090\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of repetitive TMS is unknown. One hypothesis is that stimulation of discrete cortical regions alters pathologic activity within a network of grey matter brain regions that are involved in mood regulation and connected to the targeted cortical sites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. This is supported by functional imaging studies that show repetitive TMS can change activity in brain regions remote from the site of stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/17-29\">",
"     17-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repetitive TMS has many molecular effects comparable to electroconvulsive therapy (ECT), including increased monoamine turnover and normalization of the hypothalamic pituitary axis (HPA) axis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/12\">",
"     12",
"    </a>",
"    ]. In one neuroimaging study of depressed patients, a prefrontal serotonin deficiency at baseline normalized after treatment with repetitive TMS.",
"   </p>",
"   <p>",
"    The effect of repetitive TMS appears to vary according to the frequency; high frequency stimulation is thought to excite the targeted neurons (and is typically used to activate the left prefrontal cortex), whereas low frequency stimulation appears to inhibit cortical activity (and is usually directed at the right prefrontal cortex) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174821604\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive TMS is generally an outpatient procedure, with patients awake and seated in a reclining chair during treatment. Anesthesia is not used and patients can thus drive themselves to and from sessions, which typically last about 30 to 40 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6090175\">",
"    <span class=\"h3\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For acute treatment of unipolar major depression, repetitive TMS is usually administered by stimulating the left dorsal lateral prefrontal cortex daily (Monday through Friday) over four to six weeks, using the following parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8,30,31\">",
"     8,30,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      10 magnetic pulses per second (hertz)",
"     </li>",
"     <li>",
"      3000 pulses per session",
"     </li>",
"     <li>",
"      100 to 120 percent of motor threshold (ie, the magnetic field intensity relative to the patient&rsquo;s resting motor threshold)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the stimulation parameters required to optimize efficacy are not known and administration of repetitive TMS is thus not standardized. As an example, a meta-analysis of nine randomized trials (252 patients with major depression) found that low frequency (&le; 1 pulse per second) repetitive TMS was significantly more effective than sham treatment; in addition, the trials used fewer pulses per session (ranging from 120 to 2000) and fewer sessions (5 to 16) than is customary, and over half of the trials stimulated the right prefrontal cortex rather than the left [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/32\">",
"     32",
"    </a>",
"    ]. Tolerability may be better with lower stimulation parameters compared with higher parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8,33\">",
"     8,33",
"    </a>",
"    ]. The safety and adverse effects of repetitive TMS are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H31837798\">",
"     'Safety and adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The number of treatments necessary for patients with acute major depression is not clear. In an observational study, 73 patients with unipolar major depression who did not respond to daily repetitive TMS for four to six weeks were treated for an additional six weeks; response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/31\">",
"     31",
"    </a>",
"    ]. Some authorities suggest that a trial of repetitive TMS should last a minimum of three to four weeks before determining whether the treatment is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatments can be spaced rather than administered on a daily basis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/34\">",
"     34",
"    </a>",
"    ]. In a randomized trial, repetitive TMS given three days per week for six weeks (18 sessions) was compared with repetitive TMS given five days per week for four weeks (20 sessions) in 77 patients with major depression; improvement and tolerability were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positioning the magnetic coil to stimulate the left dorsal lateral prefrontal cortex is typically performed by first identifying the optimal spot on the scalp for evoking a motor evoked potential in the hand muscles, and then advancing the coil 5 cm anteriorly in a parasagittal plane along the skull surface (some authorities measure 6 to 7 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/13,36\">",
"     13,36",
"    </a>",
"    ]. However, the utility of this approach is limited because patients have varying brain sizes and morphology. Thus, neuronavigation guided by MRI scans has been used in some research protocols to localize the prefrontal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Safety measures for repetitive TMS include use of hearing protection (eg, ear plugs) and keeping oxygen and anticonvulsant medications available for treatment of seizures, which are consistent with repetitive TMS safety guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The risk of hearing loss and seizures is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H31837798\">",
"     'Safety and adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Concomitant psychotropic (eg, antidepressants) and nonpsychotropic medications are generally safe to use during a course of repetitive TMS for major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, proconvulsant medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , tricyclics, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ) should be tapered and discontinued prior to administering repetitive TMS, or used only if the potential benefit outweighs the increased risk and with monitoring of the motor threshold to ensure that stimulation intensity does not exceed the recommended safety range [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/42\">",
"     42",
"    </a>",
"    ]. Intensity is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H31837784\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A psychiatrist should supervise treatment of major depression with repetitive TMS, although individual treatments are often provided by a nurse, physician&rsquo;s assistant, or medical assistant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/12,39\">",
"     12,39",
"    </a>",
"    ]. We recommend that all providers receive training through a formal certification course as well as training on the specific repetitive TMS system to be used. &nbsp;In addition, all personnel should be trained to recognize and initially manage generalized seizures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediately terminate the procedure",
"     </li>",
"     <li>",
"      Assess airway breathing and circulation",
"     </li>",
"     <li>",
"      Turn patients onto one side after convulsions cease to help clear the airway and prevent aspiration &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6091275\">",
"    <span class=\"h4\">",
"     Experimental techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several variations of administering repetitive TMS to patients with major depression have been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Accelerated repetitive TMS",
"      </strong>",
"      &ndash; To address the logistical constraint of standard repetitive TMS protocols that call for one session per day for several weeks, an observational study administered 15 repetitive TMS sessions over two days (15,000 pulses in total) in an inpatient setting in 14 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/44\">",
"       44",
"      </a>",
"      ]. Response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in 6 patients (43 percent), and discontinuation of treatment due to adverse events in 2 (14 percent).",
"     </li>",
"     <li>",
"      <strong>",
"       High dose repetitive TMS",
"      </strong>",
"      &ndash; Delivering more pulses than usual over the same treatment time frame (eg, 6000 pulses per session rather than 3000 pulses) has been tested as a means of improving response. An observational study of high dose repetitive TMS (6800 pulses per session) in 19 patients found that remission occurred in 12 (63 percent) and discontinuation of treatment due to adverse events in 2 (11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Theta burst repetitive TMS",
"      </strong>",
"      &ndash; Observational studies suggest that a 50 hertz burst of repetitive TMS delivered five times per second (which appears to exert longer lasting effects upon motor cortex excitability than conventional repetitive TMS), may possibly be safe and beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. As an example, a study of theta burst repetitive TMS in 32 patients found that response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in 18 patients (56 percent), and discontinuation of treatment due to adverse events in 2 (6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Deep repetitive TMS",
"      </strong>",
"      &ndash; Clinicians have attempted to directly stimulate brain structures beneath the superficial prefrontal cortex using magnetic coils (H coils) that can induce a magnetic field with a deeper and wider distribution than standard (figure eight) coils [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Several studies suggest that deep repetitive TMS may possibly be safe and beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/51\">",
"       51",
"      </a>",
"      ]. As an example, a five week randomized trial that compared different types of deep stimulation coils in 57 patients found that response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in 37 percent, and adverse events were limited to headache and scalp discomfort [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Bilateral repetitive TMS",
"      </strong>",
"      &ndash; Studies have combined high frequency stimulation of the left dorsolateral prefrontal cortex with low frequency stimulation of the right dorsolateral prefrontal cortex during each session to test the hypothesis that stimulation of each side may activate complementary mechanisms that enhance efficacy. However, multiple randomized trials have found no advantage for bilateral repetitive TMS over unilateral repetitive TMS [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/15,53-57\">",
"       15,53-57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6090183\">",
"    <span class=\"h3\">",
"     Maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance treatment with repetitive TMS has been used for patients with unipolar major depression who respond to acute treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/38\">",
"     38",
"    </a>",
"    ]. The stimulation parameters used during acute treatment are usually maintained and the treatment schedule is tapered over a few weeks. As an example, daily treatments can be reduced to three sessions in week one, two in week two, and one in week three. After one session per week for several weeks (eg, four), the schedule can be tapered further to two sessions per month for two months and then to one session per month. The frequency of sessions can be increased or decreased depending upon the patient&rsquo;s clinical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2497412\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive TMS is indicated for patients with unipolar major depression who have failed at least one antidepressant medication; in many studies, patients have failed multiple courses of pharmacotherapy and psychotherapy as well as a trial of ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/31\">",
"     31",
"    </a>",
"    ]. Use of repetitive TMS for treatment resistant depression is consistent with treatment guidelines from the American Psychiatric Association [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] and Canadian Network for Mood and Anxiety Treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14226517\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to repetitive TMS treatment, the patient should be evaluated to confirm the primary diagnosis of treatment resistant depression and whether the intervention can be used safely. The assessment includes a psychiatric history and mental status examination, with emphasis upon depressive symptoms (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ), length of the current depressive episode, types and number of failed treatments during the present episode, as well as the number, length, and treatment history of prior depressive episodes. In addition, a general medical history and physical examination is performed, as well as laboratory tests and neuroimaging studies that are guided by the history and examination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. The medical work-up should emphasize risk factors for seizures and preexisting neurologic disease (eg, epilepsy, intracranial masses, and vascular abnormalities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2497405\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive TMS is contraindicated in patients with [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/39,61,62\">",
"     39,61,62",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased risks for seizures (See",
"      <a class=\"local\" href=\"#H31837798\">",
"       'Safety and adverse effects'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Implanted metallic hardware (eg, aneurysm clips or bullet fragments)",
"     </li>",
"     <li>",
"      Cochlear implants",
"     </li>",
"     <li>",
"      Implanted electrical devices (eg, pacemakers, intracardiac lines, and medication pumps)",
"     </li>",
"     <li>",
"      Unstable general medical disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may be possible to safely use repetitive TMS in depressed patients with a personal or family history of seizures if the stimulation frequency is low (&le; 1 pulse per second) and the motor threshold is monitored to ensure that stimulation intensity does not exceed the recommended safety range [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/38\">",
"     38",
"    </a>",
"    ]. However, patients at increased risk for seizures should be considered for repetitive TMS only if the potential benefit outweighs the increased risk; as an example, the depressive episode has not responded to multiple (eg, six) courses of pharmacotherapy, including monotherapy and combination treatment, as well as trials of psychotherapy and electroconvulsive therapy. Stimulation frequency and treatment resistant depression are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H31837784\">",
"     'Overview'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 13-item, clinician-administered questionnaire can be used to screen patients for contraindications to repetitive TMS (",
"    <a class=\"graphic graphic_table graphicRef85964 \" href=\"UTD.htm?12/43/12988\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychotic features (delusions and hallucinations) are not a contraindication for treating major depression with repetitive TMS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/41\">",
"     41",
"    </a>",
"    ], but most randomized trials have excluded psychotic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/40,53,56,61,64,65\">",
"     40,53,56,61,64,65",
"    </a>",
"    ]. Psychosis and treatment of psychotic depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4105?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Acute treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31837791\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259860039\">",
"    <span class=\"h2\">",
"     Acute transcranial magnetic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with acute major depression who have not responded to at least one antidepressant medication, meta-analyses of randomized trials have found that repetitive transcranial magnetic stimulation (TMS) is superior to sham treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/32,66-74\">",
"     32,66-74",
"    </a>",
"    ], but less effective than electroconvulsive therapy (ECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2613176\">",
"    <span class=\"h3\">",
"     Compared with sham treatment (placebo)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of 34 randomized trials that compared repetitive TMS with sham treatment in 1383 patients with major depression who did not respond to one or more trials of pharmacotherapy, improvement was significantly greater with active treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/70\">",
"     70",
"    </a>",
"    ]. However, absolute rates of response (improvement from baseline on the depression rating scale &ge; 50 percent) and remission (depression rating scale score less than or equal to a specific cutoff) are modest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of randomized trials (1092 patients with unipolar major depression) found that among patients treated with active repetitive TMS [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/71\">",
"       71",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Response occurred in 25 percent",
"     </li>",
"     <li>",
"      Remission in 14 percent (all remitters were also responders)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 92 patients treated with active repetitive TMS in a subsequent trial, response occurred in 15 percent and remission in 14 percent (all remitters were also responders) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8\">",
"       8",
"      </a>",
"      ] &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is worth noting that depressed patients who have previously failed pharmacotherapy are generally less responsive to subsequent pharmacotherapy or electroconvulsive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2497627\">",
"    <span class=\"h4\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although individual studies of repetitive TMS for major depression have found factors associated with response (eg, number of antidepressant medications that have failed to resolve the presenting episode [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/75\">",
"     75",
"    </a>",
"    ]), no consistent predictors have been identified in meta-analyses. As an example, a meta-analysis of 30 randomized trials (1164 patients) found that improvement was significantly greater with active repetitive TMS than sham treatment; however, the effect of repetitive TMS was comparable in trials with medication resistant depression and trials with nonmedication resistant depression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, a meta-analysis (34 randomized trials, 1383 depressed patients) compared left dorsal lateral prefrontal cortex repetitive TMS with right dorsal lateral prefrontal cortex stimulation, and found that efficacy was comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/70\">",
"     70",
"    </a>",
"    ]. Other meta-analyses suggest that the efficacy of high frequency (&gt;1 pulse per second) and low frequency (&le; 1 pulse per second) repetitive TMS may be comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/32,68\">",
"     32,68",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174821114\">",
"    <span class=\"h3\">",
"     Compared with electroconvulsive therapy (ECT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of major depression, repetitive TMS is less efficacious than electroconvulsive therapy (ECT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=see_link&amp;anchor=H21629511#H21629511\">",
"     \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\", section on 'Compared with transcranial magnetic stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259859970\">",
"    <span class=\"h3\">",
"     Durability of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective, observational studies suggest that recurrence of major depression is common in patients who improve with acute repetitive TMS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 99 patients who partially responded (improvement from baseline on the depression rating scale &ge; 25 percent) to repetitive TMS and were treated with maintenance pharmacotherapy for six months, symptomatic deterioration occurred in 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/76\">",
"       76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among 21 patients who responded (improvement from baseline on the depression rating scale &ge; 50 percent) to repetitive TMS and were treated with maintenance pharmacotherapy for six months, relapse occurred in 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among 16 patients who responded (improvement from baseline on the depression rating scale &ge; 50 percent) to repetitive TMS, were subsequently medication-free, and treated only with repetitive TMS for depressive relapses, the mean interval between relapses was five months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with unipolar major depression who improve with a course of repetitive TMS and subsequently relapse, another course of repetitive TMS using the same stimulation parameters may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/13,45,76,78,79\">",
"     13,45,76,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14226488\">",
"    <span class=\"h3\">",
"     Combined with pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most randomized trials that compared active repetitive TMS with sham for treating major depression, the experimental procedure was added onto antidepressant medications that were ineffective for the presenting episodes, but were nevertheless maintained during the trials so that all patients received active treatment. As an example, in a meta-analysis of 34 trials that found active repetitive TMS was superior to sham treatment, patients were free of antidepressant medications in only seven trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear if simultaneously starting repetitive TMS plus pharmacotherapy for major depression is superior to initiating pharmacotherapy alone. Multiple randomized trials that concurrently started pharmacotherapy plus either active or sham repetitive TMS found that combination treatment decreased time to response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/40,41,65,80,81\">",
"     40,41,65,80,81",
"    </a>",
"    ], and increased the number of responders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/40,41,80\">",
"     40,41,80",
"    </a>",
"    ], whereas other trials found no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/56,82-84\">",
"     56,82-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259860078\">",
"    <span class=\"h2\">",
"     Maintenance transcranial magnetic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known if maintenance treatment with repetitive TMS for unipolar major depression is beneficial; small observational studies of patients who responded (improvement from baseline on the depression rating scale &ge; 50 percent) to acute treatment with repetitive TMS showed the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of maintenance treatment (mean duration 92 weeks and mean number of TMS sessions 183; 6 patients received adjunctive antidepressants) in 10 patients found that relapse did not occur in 5 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A prospective study of maintenance treatment (one session every one to two weeks) in 8 patients found that none relapsed [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A retrospective study of maintenance treatment (one session every one to four weeks, many patients received adjunctive medications) in 42 patients found that relapse did not occur in 26 (62 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31837798\">",
"    <span class=\"h1\">",
"     SAFETY AND ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive TMS is generally safe and well-tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8,12,61,66\">",
"     8,12,61,66",
"    </a>",
"    ]. As an example, a randomized trial of 301 patients found that study discontinuation due to adverse effects was comparable for active and sham repetitive TMS (5 and 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most serious adverse effect of repetitive TMS is a generalized tonic-clonic seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/39,62\">",
"     39,62",
"    </a>",
"    ]. However, the risk during a treatment course is probably less than 0.5 percent when safety guidelines regarding patient selection and stimulation parameters are followed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/12,39\">",
"     12,39",
"    </a>",
"    ]. Seizures that have occurred were self limited, required no medications, and did not recur.",
"   </p>",
"   <p>",
"    Factors that increase the risk of seizures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Personal and family (parent, sibling, or child) history of epilepsy",
"     </li>",
"     <li>",
"      Preexisting neurologic disorder (eg, prior head injury with loss of consciousness, prior brain surgery, or congenital brain malformation)",
"     </li>",
"     <li>",
"      Medications that lower seizure threshold (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , stimulants, tricyclic antidepressants, antipsychotics, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recent discontinuation of alcohol, benzodiazepines, or anticonvulsants",
"     </li>",
"     <li>",
"      Sleep deprivation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repetitive TMS stimulation parameters (See",
"      <a class=\"local\" href=\"#H31837784\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6090175\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Higher frequency",
"     </li>",
"     <li>",
"      Increased intensity",
"     </li>",
"     <li>",
"      Shorter intertrain interval",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypomania and mania have been described in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/86\">",
"     86",
"    </a>",
"    ] as well as case reports of patients with major depression (both unipolar and bipolar) who were treated with repetitive TMS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/87-95\">",
"     87-95",
"    </a>",
"    ]. However, the clinical significance is not known because patients with bipolar major depression can switch to mood elevated states in the absence of an antidepressant treatment. A review pooled results from 10 randomized trials (520 patients with major depression) that addressed switching to mania, and found that treatment emergent mania was comparable for active repetitive TMS and sham treatment (0.8 and 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of unipolar major depression with repetitive TMS does not appear to increase suicidal ideation or behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8\">",
"     8",
"    </a>",
"    ]. In a randomized trial that compared active repetitive TMS with sham treatment in 323 patients with unipolar major depression, there were no completed suicides, and self harm occurred in one patient in the sham group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, increased suicidal ideation occurred in 10 patients who received sham treatment and 1 patient in the active treatment group. &nbsp;",
"   </p>",
"   <p>",
"    Common side effects of repetitive TMS include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/39,62\">",
"     39,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache and scalp pain &ndash; A review of randomized trials in patients with major depression found that the incidence of headache with active treatment and sham treatment was 28 and 16 percent, and the incidence of scalp pain with active and sham treatment was 39 and 15 percent. No migraine headaches have been reported. Headache and scalp pain may be more pronounced when higher stimulation frequencies and intensities are used; topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      may reduce scalp pain [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/96\">",
"       96",
"      </a>",
"      ]. Reducing stimulation intensity can decrease scalp discomfort, but this can also reduce efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/13\">",
"       13",
"      </a>",
"      ]. Headache and scalp pain generally resolve quickly, although some patients may require an analgesic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Transient (&lt;4 hours) increase in auditory threshold &ndash; Caused by repeated clicks that are produced as current passes through the stimulating magnetic coil and mechanically deforms it; hearing loss is prevented with foam earplugs or noise protection ear coverings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repetitive TMS in patients with major depression does not impair cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/8,39,61,62,97-100\">",
"     8,39,61,62,97-100",
"    </a>",
"    ]. Although many uncontrolled studies suggest that neuropsychological functioning may possibly improve during a course of treatment, randomized trials indicate that improvement of cognitive functioning does not differ significantly between active and sham treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/62,100\">",
"     62,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety and long-term adverse effects of repetitive TMS for clinicians administering the procedure over years is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31837812\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31837820\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;For elderly patients with major depression, repetitive TMS can be beneficial if the stimulation intensity is sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/12\">",
"     12",
"    </a>",
"    ]. Prefrontal atrophy in older patients can increase the distance between the coil and cortex to the point that lower intensity stimulation (which typically penetrates to a depth of two to three cm) does not affect cortical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]; increasing the intensity above the motor threshold can overcome the added distance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared active repetitive TMS using an intensity set at 110 percent of the motor threshold with sham treatment in 62 patients (age &ge; 50 years) with vascular depression (ie, late-life depression accompanied by clinical evidence of cerebrovascular disease); improvement was significantly greater with active treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/104\">",
"       104",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A randomized trial compared active repetitive TMS using an intensity set at 110 percent of the motor threshold with sham treatment in 20 patients (mean age approximately 64 years) with poststroke depression; improvement was significantly greater with active treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/105\">",
"       105",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast, a randomized trial in 20 patients (mean age 61 years) with treatment refractory depression found that active repetitive TMS using an intensity set at 80 percent of motor threshold provided no advantage over sham treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and treatment of late life depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31837834\">",
"    <span class=\"h2\">",
"     Pregnancy and postpartum depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant and postpartum patients with major depression, observational studies suggest that repetitive TMS may possibly be safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/107-111\">",
"     107-111",
"    </a>",
"    ]. It appears unlikely that the fetus is directly affected by repetitive TMS because magnetic fields rapidly attenuate with distance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/18/16682/abstract/39\">",
"     39",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Depression during pregnancy and postpartum depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=see_link\">",
"     \"Depression in pregnant women: Clinical features and consequences\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20666?source=see_link\">",
"     \"Postpartum blues and depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2800570\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with major depression who do not respond to standard treatment with pharmacotherapy and psychotherapy are candidates for noninvasive neuromodulation procedures, including repetitive transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=see_link&amp;anchor=H29061923#H29061923\">",
"       \"Unipolar depression in adults: Overview of neuromodulation procedures\", section on 'Noninvasive neuromodulation therapies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"       \"Overview of electroconvulsive therapy (ECT) for adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repetitive TMS modulates activity in cortical regions and associated neural circuits by passing an alternating current through a metal coil placed against the scalp to generate rapidly alternating magnetic fields, which pass through the skull and induce electric currents that depolarize neurons in a focal area of the surface cortex. Repetitive TMS is delivered as a series of pulses called a train; stimulation parameters include frequency, intensity, train duration, intertrain interval, and number of trains per session. (See",
"      <a class=\"local\" href=\"#H31837784\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive TMS generally targets the left dorsal lateral prefrontal cortex, but some studies have stimulated the right dorsal lateral prefrontal cortex. (See",
"      <a class=\"local\" href=\"#H174821082\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treating unipolar major depression, repetitive TMS is usually administered daily over four to six weeks, using 10 magnetic pulses per second; 3000 pulses per session; 100 to 120 percent of motor threshold.",
"      <br/>",
"      <br/>",
"      However, the stimulation parameters, number of treatments, and position of the magnetic coil required to optimize efficacy for major depression are not known and administration is thus not standardized. A psychiatrist should supervise the procedure, and safety measures include ear plugs and keeping oxygen and anticonvulsant medications available for treatment of unintended seizures. Proconvulsant medications should generally be discontinued prior to administering repetitive TMS. (See",
"      <a class=\"local\" href=\"#H6090175\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Investigational techniques of administering repetitive TMS include an accelerated schedule as well as high dose, theta burst, deep, and bilateral stimulation. (See",
"      <a class=\"local\" href=\"#H6091275\">",
"       'Experimental techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive TMS is indicated for patients with unipolar major depression who have failed at least one antidepressant medication, and contraindicated in patients with increased risks for seizures, implanted metallic hardware, cochlear implants, implanted electrical devices (eg, pacemakers, intracardiac lines, and medication pumps), and unstable general medical disorders. (See",
"      <a class=\"local\" href=\"#H2497412\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2497405\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute major depression who have not responded to at least one antidepressant medication, meta-analyses of randomized trials have found that repetitive TMS is superior to sham treatment, but less effective than ECT. However, many patients who respond subsequently suffer a recurrence. It is not known if maintenance treatment with repetitive TMS for unipolar major depression is beneficial. (See",
"      <a class=\"local\" href=\"#H31837791\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive TMS is generally safe and well-tolerated. Serious adverse effects include generalized tonic-clonic seizures, but the risk is low. Factors that increase the risk of seizures include patient factors (history of epilepsy; preexisting neurologic disorder; proconvulsant medications; recent discontinuation of alcohol, benzodiazepines, or anticonvulsants; and sleep deprivation) and stimulation parameters (higher frequency, increased intensity, and shorter intertrain interval). Common side effects include headache, scalp pain, and transient hearing loss. (See",
"      <a class=\"local\" href=\"#H31837798\">",
"       'Safety and adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For elderly patients with major depression, repetitive TMS is beneficial if the stimulation intensity is sufficient to bridge the distance between the coil and cortex, which is increased by prefrontal atrophy. For pregnant and postpartum patients with major depression, repetitive TMS may possibly be safe and effective. (See",
"      <a class=\"local\" href=\"#H31837812\">",
"       'Special populations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/1\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/2\">",
"      Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 2011; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/3\">",
"      American Psychiatric Association. Practice Guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. file://psychiatryonline.org/guidelines.aspx (Accessed on April 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/5\">",
"      Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord 2009; 117 Suppl 1:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/6\">",
"      Eranti S, Mogg A, Pluck G, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry 2007; 164:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/7\">",
"      Fitzgerald PB. Repetitive transcranial magnetic stimulation is not as effective as electroconvulsive therapy for major depression. Evid Based Ment Health 2007; 10:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/8\">",
"      George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010; 67:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/9\">",
"      Allan C, Kalu UG, Sexton CE, Ebmeier KP. Transcranial stimulation in depression. Br J Psychiatry 2012; 200:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/10\">",
"      Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology 2003; 28:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/11\">",
"      Lisanby SH. Update on magnetic seizure therapy: a novel form of convulsive therapy. J ECT 2002; 18:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/12\">",
"      George MS, Post RM. Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry 2011; 168:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/13\">",
"      Fitzgerald PB, Daskalakis ZJ. A practical guide to the use of repetitive transcranial magnetic stimulation in the treatment of depression. Brain Stimul 2012; 5:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/14\">",
"      Baeken C, De Raedt R. Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin Neurosci 2011; 13:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/15\">",
"      Fitzgerald PB, Hoy KE, Herring SE, et al. A double blind randomized trial of unilateral left and bilateral prefrontal cortex transcranial magnetic stimulation in treatment resistant major depression. J Affect Disord 2012; 139:193.",
"     </a>",
"    </li>",
"    <li>",
"     Mayberg, HS. Defining Neurocircuits in Depression: Insights from functional neuroimaging studies of diverse treatments. Psychiatric Annals 2006;36(4):258-266.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/17\">",
"      Kito S, Fujita K, Koga Y. Regional cerebral blood flow changes after low-frequency transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in treatment-resistant depression. Neuropsychobiology 2008; 58:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/18\">",
"      Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 2001; 21:RC157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/19\">",
"      Baeken C, De Raedt R, Van Hove C, et al. HF-rTMS treatment in medication-resistant melancholic depression: results from 18FDG-PET brain imaging. CNS Spectr 2009; 14:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/20\">",
"      Li CT, Wang SJ, Hirvonen J, et al. Antidepressant mechanism of add-on repetitive transcranial magnetic stimulation in medication-resistant depression using cerebral glucose metabolism. J Affect Disord 2010; 127:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/21\">",
"      Luborzewski A, Schubert F, Seifert F, et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J Psychiatr Res 2007; 41:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/22\">",
"      Fitzgerald PB, Sritharan A, Daskalakis ZJ, et al. A functional magnetic resonance imaging study of the effects of low frequency right prefrontal transcranial magnetic stimulation in depression. J Clin Psychopharmacol 2007; 27:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/23\">",
"      Fregni F, Ono CR, Santos CM, et al. Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology 2006; 66:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/24\">",
"      Michael N, G&ouml;sling M, Reutemann M, et al. Metabolic changes after repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex: a sham-controlled proton magnetic resonance spectroscopy (1H MRS) study of healthy brain. Eur J Neurosci 2003; 17:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/25\">",
"      Nadeau SE, McCoy KJ, Crucian GP, et al. Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/26\">",
"      Conca A, Fritzsche H, Peschina W, et al. Preliminary findings of simultaneous 18F-FDG and 99mTc-HMPAO SPECT in patients with depressive disorders at rest: differential correlates with ratings of anxiety. Psychiatry Res 2000; 98:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/27\">",
"      Loo CK, Sachdev PS, Haindl W, et al. High (15 Hz) and low (1 Hz) frequency transcranial magnetic stimulation have different acute effects on regional cerebral blood flow in depressed patients. Psychol Med 2003; 33:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/28\">",
"      Speer AM, Kimbrell TA, Wassermann EM, et al. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry 2000; 48:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/29\">",
"      Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/30\">",
"      Avery DH, Holtzheimer PE 3rd, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006; 59:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/31\">",
"      Avery DH, Isenberg KE, Sampson SM, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry 2008; 69:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/32\">",
"      Schutter DJ. Quantitative review of the efficacy of slow-frequency magnetic brain stimulation in major depressive disorder. Psychol Med 2010; 40:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/33\">",
"      O'Reardon JP, Blumner KH, Peshek AD, et al. Long-term maintenance therapy for major depressive disorder with rTMS. J Clin Psychiatry 2005; 66:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/34\">",
"      Turnier-Shea Y, Bruno R, Pridmore S. Daily and spaced treatment with transcranial magnetic stimulation in major depression: a pilot study. Aust N Z J Psychiatry 2006; 40:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/35\">",
"      Galletly C, Gill S, Clarke P, et al. A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments? Psychol Med 2012; 42:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/36\">",
"      Padberg F, George MS. Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. Exp Neurol 2009; 219:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/37\">",
"      Sch&ouml;nfeldt-Lecuona C, Lefaucheur JP, Cardenas-Morales L, et al. The value of neuronavigated rTMS for the treatment of depression. Neurophysiol Clin 2010; 40:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/38\">",
"      Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry 2012; 73:e567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/39\">",
"      Rossi S, Hallett M, Rossini PM, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009; 120:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/40\">",
"      Rumi DO, Gattaz WF, Rigonatti SP, et al. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry 2005; 57:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/41\">",
"      Ray S, Nizamie SH, Akhtar S, et al. Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of left prefrontal cortex in depression: a randomized sham controlled study. J Affect Disord 2011; 128:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/42\">",
"      Mufti MA, Holtzheimer PE 3rd, Epstein CM, et al. Bupropion decreases resting motor threshold: a case report. Brain Stimul 2010; 3:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/43\">",
"      Rosa MA, Lisanby SH. Somatic treatments for mood disorders. Neuropsychopharmacology 2012; 37:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/44\">",
"      Holtzheimer PE 3rd, McDonald WM, Mufti M, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety 2010; 27:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/45\">",
"      Hadley D, Anderson BS, Borckardt JJ, et al. Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. J ECT 2011; 27:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/46\">",
"      Holzer M, Padberg F. Intermittent theta burst stimulation (iTBS) ameliorates therapy-resistant depression: a case series. Brain Stimul 2010; 3:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/47\">",
"      Wu CC, Tsai CH, Lu MK, et al. Theta-burst repetitive transcranial magnetic stimulation for treatment-resistant obsessive-compulsive disorder with concomitant depression. J Clin Psychiatry 2010; 71:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/48\">",
"      Chistyakov AV, Rubicsek O, Kaplan B, et al. Safety, tolerability and preliminary evidence for antidepressant efficacy of theta-burst transcranial magnetic stimulation in patients with major depression. Int J Neuropsychopharmacol 2010; 13:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/49\">",
"      Levkovitz Y, Roth Y, Harel EV, et al. A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation. Clin Neurophysiol 2007; 118:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/50\">",
"      Zangen A, Roth Y, Voller B, Hallett M. Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil. Clin Neurophysiol 2005; 116:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/51\">",
"      Bersani FS, Minichino A, Enticott PG, et al. Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review. Eur Psychiatry 2013; 28:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/52\">",
"      Levkovitz Y, Harel EV, Roth Y, et al. Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of antidepressant and cognitive effects in depressive patients. Brain Stimul 2009; 2:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/53\">",
"      Pallanti S, Bernardi S, Di Rollo A, et al. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience 2010; 167:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/54\">",
"      Fitzgerald PB, Hoy K, Gunewardene R, et al. A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression. Psychol Med 2011; 41:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/55\">",
"      Conca A, Di Pauli J, Beraus W, et al. Combining high and low frequencies in rTMS antidepressive treatment: preliminary results. Hum Psychopharmacol 2002; 17:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/56\">",
"      Hausmann A, Kemmler G, Walpoth M, et al. No benefit derived from repetitive transcranial magnetic stimulation in depression: a prospective, single centre, randomised, double blind, sham controlled \"add on\" trial. J Neurol Neurosurg Psychiatry 2004; 75:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/57\">",
"      Blumberger DM, Mulsant BH, Fitzgerald PB, et al. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry 2012; 13:423.",
"     </a>",
"    </li>",
"    <li>",
"     Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/59\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/61\">",
"      O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/62\">",
"      Loo CK, McFarquhar TF, Mitchell PB. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol 2008; 11:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/63\">",
"      Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Screening questionnaire before TMS: an update. Clin Neurophysiol 2011; 122:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/64\">",
"      Grunhaus L, Schreiber S, Dolberg OT, et al. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 2003; 53:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/65\">",
"      Huang ML, Luo BY, Hu JB, et al. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial. Aust N Z J Psychiatry 2012; 46:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/66\">",
"      Holtzheimer PE 3rd, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull 2001; 35:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/67\">",
"      Kozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatr Pract 2002; 8:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/68\">",
"      Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med 2009; 39:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/69\">",
"      Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol 2002; 5:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/70\">",
"      Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010; 71:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/71\">",
"      Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry 2008; 53:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/72\">",
"      Allan CL, Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. Neuropsychobiology 2011; 64:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/73\">",
"      Herrmann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. J Clin Psychiatry 2006; 67:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/74\">",
"      McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 2001; 31:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/75\">",
"      Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009; 34:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/76\">",
"      Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul 2010; 3:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/77\">",
"      Dannon PN, Dolberg OT, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals--preliminary report. Biol Psychiatry 2002; 51:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/78\">",
"      Demirtas-Tatlidede A, Mechanic-Hamilton D, Press DZ, et al. An open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. J Clin Psychiatry 2008; 69:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/79\">",
"      Rosenberg O, Isserles M, Levkovitz Y, et al. Effectiveness of a second deep TMS in depression: a brief report. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/80\">",
"      Bretlau LG, Lunde M, Lindberg L, et al. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Pharmacopsychiatry 2008; 41:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/81\">",
"      Rossini D, Magri L, Lucca A, et al. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. J Clin Psychiatry 2005; 66:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/82\">",
"      Poulet E, Brunelin J, Boeuve C, et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur Psychiatry 2004; 19:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/83\">",
"      Garc&iacute;a-Toro M, Pascual-Leone A, Romera M, et al. Prefrontal repetitive transcranial magnetic stimulation as add on treatment in depression. J Neurol Neurosurg Psychiatry 2001; 71:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/84\">",
"      Herwig U, Fallgatter AJ, H&ouml;ppner J, et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. Br J Psychiatry 2007; 191:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/85\">",
"      Benadhira R, Saba G, Samaan A, et al. Transcranial magnetic stimulation for refractory depression. Am J Psychiatry 2005; 162:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/86\">",
"      Xia G, Gajwani P, Muzina DJ, et al. Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. Int J Neuropsychopharmacol 2008; 11:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/87\">",
"      Dolberg OT, Schreiber S, Grunhaus L. Transcranial magnetic stimulation-induced switch into mania: a report of two cases. Biol Psychiatry 2001; 49:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/88\">",
"      Garcia-Toro M. Acute manic symptomatology during repetitive transcranial magnetic stimulation in a patient with bipolar depression. Br J Psychiatry 1999; 175:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/89\">",
"      Nedjat S, Folkerts HW. Induction of a reversible state of hypomania by rapid-rate transcranial magnetic stimulation over the left prefrontal lobe. J ECT 1999; 15:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/90\">",
"      Rachid F, Golaz J, Bondolfi G, Bertschy G. Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression. World J Biol Psychiatry 2006; 7:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/91\">",
"      Sakkas P, Mihalopoulou P, Mourtzouhou P, et al. Induction of mania by rTMS: report of two cases. Eur Psychiatry 2003; 18:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/92\">",
"      Chang CH, Chen SJ, Chang CH, Tsai HC. Manic episode following a combined treatment of repetitive transcranial magnetic stimulation and venlafaxine. J Neuropsychiatry Clin Neurosci 2010; 22:E18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/93\">",
"      Gijsman HJ. Mania after transcranial magnetic stimulation in PTSD. Am J Psychiatry 2005; 162:398; author reply 398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/94\">",
"      Huang CC, Su TP, Shan IK. A case report of repetitive transcranial magnetic stimulation-induced mania. Bipolar Disord 2004; 6:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/95\">",
"      Hausmann A, Kramer-Reinstadler K, Lechner-Schoner T, et al. Can bilateral prefrontal repetitive transcranial magnetic stimulation (rTMS) induce mania? A case report. J Clin Psychiatry 2004; 65:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/96\">",
"      Trevino K, McClintock SM, Husain MM. The use of topical lidocaine to reduce pain during repetitive transcranial magnetic stimulation for the treatment of depression. J ECT 2011; 27:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/97\">",
"      Loo C, Sachdev P, Elsayed H, et al. Effects of a 2- to 4-week course of repetitive transcranial magnetic stimulation (rTMS) on neuropsychologic functioning, electroencephalogram, and auditory threshold in depressed patients. Biol Psychiatry 2001; 49:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/98\">",
"      Martis B, Alam D, Dowd SM, et al. Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin Neurophysiol 2003; 114:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/99\">",
"      Hausmann A, Pascual-Leone A, Kemmler G, et al. No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. J Clin Psychiatry 2004; 65:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/100\">",
"      Moreines JL, McClintock SM, Holtzheimer PE. Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review. Brain Stimul 2011; 4:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/101\">",
"      Kozel FA, Nahas Z, deBrux C, et al. How coil-cortex distance relates to age, motor threshold, and antidepressant response to repetitive transcranial magnetic stimulation. J Neuropsychiatry Clin Neurosci 2000; 12:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/102\">",
"      Nahas Z, Teneback CC, Kozel A, et al. Brain effects of TMS delivered over prefrontal cortex in depressed adults: role of stimulation frequency and coil-cortex distance. J Neuropsychiatry Clin Neurosci 2001; 13:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/103\">",
"      Mosimann UP, Marr&eacute; SC, Werlen S, et al. Antidepressant effects of repetitive transcranial magnetic stimulation in the elderly: correlation between effect size and coil-cortex distance. Arch Gen Psychiatry 2002; 59:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/104\">",
"      Jorge RE, Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry 2008; 65:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/105\">",
"      Jorge RE, Robinson RG, Tateno A, et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry 2004; 55:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/106\">",
"      Manes F, Jorge R, Morcuende M, et al. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int Psychogeriatr 2001; 13:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/107\">",
"      Kim DR, Epperson N, Par&eacute; E, et al. An open label pilot study of transcranial magnetic stimulation for pregnant women with major depressive disorder. J Womens Health (Larchmt) 2011; 20:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/108\">",
"      Garcia KS, Flynn P, Pierce KJ, Caudle M. Repetitive transcranial magnetic stimulation treats postpartum depression. Brain Stimul 2010; 3:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/109\">",
"      Nahas Z, Molloy MA, Hughes PL, et al. Repetitive transcranial magnetic stimulation: perspectives for application in the treatment of bipolar and unipolar disorders. Bipolar Disord 1999; 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/110\">",
"      Zhang X, Liu K, Sun J, Zheng Z. Safety and feasibility of repetitive transcranial magnetic stimulation (rTMS) as a treatment for major depression during pregnancy. Arch Womens Ment Health 2010; 13:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/18/16682/abstract/111\">",
"      Klirova M, Novak T, Kopecek M, et al. Repetitive transcranial magnetic stimulation (rTMS) in major depressive episode during pregnancy. Neuro Endocrinol Lett 2008; 29:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14641 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16682=[""].join("\n");
var outline_f16_18_16682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2800570\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31837777\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31837784\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174821082\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174821090\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174821604\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6090175\">",
"      - Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6091275\">",
"      Experimental techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6090183\">",
"      - Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2497412\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14226517\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2497405\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31837791\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259860039\">",
"      Acute transcranial magnetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2613176\">",
"      - Compared with sham treatment (placebo)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2497627\">",
"      Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174821114\">",
"      - Compared with electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259859970\">",
"      - Durability of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14226488\">",
"      - Combined with pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259860078\">",
"      Maintenance transcranial magnetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31837798\">",
"      SAFETY AND ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31837812\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31837820\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31837834\">",
"      Pregnancy and postpartum depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2800570\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/43/12988\" title=\"table 2\">",
"      Screening 13-item questionnaire for rTMS candidates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=related_link\">",
"      Depression in pregnant women: Clinical features and consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20666?source=related_link\">",
"      Postpartum blues and depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/30/6633?source=related_link\">",
"      Unipolar depression in adults: Overview of neuromodulation procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5097?source=related_link\">",
"      Unipolar depression in adults: Treatment with surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4105?source=related_link\">",
"      Unipolar major depression with psychotic features: Acute treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_18_16683="Autosomal dom forms kidn CA";
var content_f16_18_16683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Autosomal dominant forms of kidney cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VHL",
"       </td>",
"       <td>",
"        VHL",
"       </td>",
"       <td>",
"        Clear cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HPRC",
"       </td>",
"       <td>",
"        MET",
"       </td>",
"       <td>",
"        Papillary type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLRCC",
"       </td>",
"       <td>",
"        FH",
"       </td>",
"       <td>",
"        Renal cell carcinoma, HLRCC type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BHD",
"       </td>",
"       <td>",
"        BHD",
"       </td>",
"       <td>",
"        Chromophobe/hybrid oncocytic neoplasm/clear cell carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VHL: von Hippel-Lindau; HPRC: hereditary papillary renal carcinoma; HLRCC: hereditary leiomyomatosis renal cell carcinoma; FH: fumarate hydratase; BHD: Birt-Hogg-Dub&eacute; syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zbar, B, Glenn, G, Merino, M, et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol 2007; 177:461. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16683=[""].join("\n");
var outline_f16_18_16683=null;
var title_f16_18_16684="Moms who deliver at home";
var content_f16_18_16684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of mothers giving birth in home and hospitals, US, 2009",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Home",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hospital",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         White, non-Hispanic",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        81.5",
"       </td>",
"       <td class=\"centered\">",
"        53.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Age 30+",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        51.7",
"       </td>",
"       <td class=\"centered\">",
"        38.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Parity 3+",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        49.8",
"       </td>",
"       <td class=\"centered\">",
"        27.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Foreign born",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        9.5",
"       </td>",
"       <td class=\"centered\">",
"        23.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gestation 37+ weeks",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        94.6",
"       </td>",
"       <td class=\"centered\">",
"        87.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         County &lt;100,000 population",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        33.4",
"       </td>",
"       <td class=\"centered\">",
"        22.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No reported prenatal care",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        5.6",
"       </td>",
"       <td class=\"centered\">",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nonsmoker",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        97.1",
"       </td>",
"       <td class=\"centered\">",
"        90.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         13+ years of education",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        57.9",
"       </td>",
"       <td class=\"centered\">",
"        51.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: National Center for Health Statistics. VitalStats: Birth data 2010 state and county files. Available at:",
"     <a href=\"file://www.cdc.gov/nchs/VitalStats.htm\" target=\"_blank\">",
"      file://www.cdc.gov/nchs/VitalStats.htm",
"     </a>",
"     (Accessed December 8, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16684=[""].join("\n");
var outline_f16_18_16684=null;
var title_f16_18_16685="Glucocorticoid nasal sprays";
var content_f16_18_16685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glucocorticoid nasal sprays",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic available in US?",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dose",
"        <br/>",
"        (per nostril)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual pediatric dose",
"        <br/>",
"        (per nostril)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of preparation",
"        <br/>",
"        (alcohol content*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluticasone propionate",
"       </td>",
"       <td>",
"        Flonase",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Two sprays once daily or one spray twice daily",
"       </td>",
"       <td>",
"        One spray once daily",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray (0.25 percent alcohol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluticasone furoate",
"       </td>",
"       <td>",
"        Veramyst",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Two sprays once daily",
"       </td>",
"       <td>",
"        One spray once daily",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mometasone",
"       </td>",
"       <td>",
"        Nasonex",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Two sprays once daily",
"       </td>",
"       <td>",
"        One spray once daily",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Ciclesonide",
"       </td>",
"       <td>",
"        Omnaris",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Two sprays once daily",
"       </td>",
"       <td>",
"        Two sprays once daily",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zetonna",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        One spray once daily",
"       </td>",
"       <td>",
"        One spray once daily for children &ge;12 years",
"       </td>",
"       <td>",
"        Pressurized aerosol spray (3.4 percent alcohol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Budesonide",
"       </td>",
"       <td>",
"        Rhinocort Aqua",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        One spray once daily",
"       </td>",
"       <td>",
"        One spray once daily",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Trimacinolone",
"       </td>",
"       <td>",
"        Nasacort AQ",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Two sprays once daily",
"       </td>",
"       <td>",
"        One to two sprays",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasacort (CFC free)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Two sprays once daily",
"       </td>",
"       <td>",
"        One spray once daily",
"       </td>",
"       <td>",
"        Pressurized aerosol spray (0.7 percent alcohol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Beclomethasone",
"       </td>",
"       <td>",
"        Beconase AQ",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        One or two sprays twice daily",
"       </td>",
"       <td>",
"        One spray twice daily",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray (0.25 percent alcohol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Qnasl",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Two sprays once daily",
"       </td>",
"       <td>",
"        Two sprays once daily for children &ge;12 years",
"       </td>",
"       <td>",
"        Pressurized aerosol spray (8 percent alcohol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flunisolide",
"       </td>",
"       <td>",
"        Nasarel (brand version no longer available in US)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Two sprays twice daily",
"       </td>",
"       <td>",
"        One spray three times per day or two sprays twice daily",
"       </td>",
"       <td>",
"        Aqueous suspension pump spray (contains propylene glycol, a possible irritant)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Nasal sprays work best when they are administered properly and the medication remains in the nose rather than draining down the back of the throat. Note that the recommended techniques for the aqueous and aerosol sprays are different (explained in the text). If the nose is crusted or contains mucus, it should first be cleaned with a saline nasal spray prior to use of intranasal sprays. Some people find that holding the other nostril closed with a finger improves their ability to draw the spray into the upper nose.",
"    <div class=\"footnotes\">",
"     * Alcohol may contribute to dryness or irritation.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Not available in US. Available in Canada and other countries.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16685=[""].join("\n");
var outline_f16_18_16685=null;
var title_f16_18_16686="NH4 excretion";
var content_f16_18_16686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Formation of urinary NH4+",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 232px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the proximal tubule, glutamine is taken up by the cells and metabolized into NH4+ and alpha-ketoglutarate. Utilization of the latter results in the generation of HCO3-, whereas NH4+ substitutes for H+ on the Na+-H+ exchanger and is then secreted directly into the lumen. The mechanism is different in the collecting tubules; nonpolar, lipid-soluble NH3 diffuses from the interstitial fluid into the lumen, where it combines with secreted H+ to form NH4+. Ammonium is lipid-insoluble and is therefore unable to back-diffuse out of the lumen. Note that each NH4+ ion that is excreted is associated with the generation of a new HC03- ion that is returned to the peritubular capillary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16686=[""].join("\n");
var outline_f16_18_16686=null;
var title_f16_18_16687="Diffuse scleritis in RA";
var content_f16_18_16687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse scleritis in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse scleritis in a patient with rheumatoid arthritis manifested by diffuse injection and scleral thickening, but no nodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_18_16687=[""].join("\n");
var outline_f16_18_16687=null;
